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Summary.
Among the potential non-viral vectors for human gene therapy are polypeptide- 
DNA systems. In this study the factors affecting gene transfer by this method have 
been evaluated. Complexes of plasmid DNA with poly-L-lysine, streptavidin-poly-L- 
lysine, alanine-lysine graft co-polymers and histone HI were prepared by direct 
mixing and examined by spectrofluorimetry and agarose gel electrophoresis. 
Addition of polypeptides to DNA yielded complexes that progressively excluded the 
fluorescent probe ethidium bromide and exhibited marked reductions in 
electrophoretic mobility. For each polymer the cation-to-DNA phosphate ratio 
required to produce DNA condensation was determined. For poly-L-lysine 
homopolymers and histone HI, condensation was induced at peptide cation-to-DNA 
phosphate ratios close to electrostatic equivalence.
Complexes formed between polypeptides and plasmid DNA carrying the lacZ 
reporter gene (pRSVlacZ) were used to transfect B16 melanoma cells in vitro. 
Polylysine(127), (214), (859) and histone HI were effective intra-cellular gene 
delivery agents, while polylysine(13) and alanine-lysine graft co-polymers were 
ineffective. A critical dependence of gene transfer efficiency on the polycation-to- 
DNA ratio was established. Zeta potential measurements confirmed gene transfer 
was charge-mediated with transfecting polypeptide-DNA complexes requiring an 
excess of positive charge. Consistent with the cellular uptake of polypeptide-DNA 
complexes through endocytosis, the expression of the lacZ gene included in the 
transported DNA was shown to be dependent on the presence of the lysosomotropic 
agent chloroquine. Stability experiments showed polypeptide complexed DNA was 
protected from degradation by serum. Other factors which effect gene delivery and 
expression include complex morphology, carrier molecular weight, DNA dose, and 
dosing schedule.
As an alternative strategy, the feasibility of delivering DNA to B16 melanoma 
cells by means of receptor-mediated endocytosis was tested. Molecular conjugate 
vectors which employed concanavalin A for targeting produced a modest but 
significant increase in lacZ expression compared to a control vector. However, a 
more specific system incorporating Na-biotin-(Gly3)-[Nle4,D-Phe7]a-MSH, a ligand 
at the MC 1 receptor expressed on melanoma cells and melanocytes, failed to 
produce increases in delivery efficiency.
For Mum and Dad.
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It is now widely accepted that the basis of many diseases is the development or 
inheritance of abnormalities in the cellular genetic code. This understanding, 
brought about by recent advances made in the sciences of molecular biology and 
human genetics, is likely to revolutionise the approach to treating disease. Although 
many advances have been made in medicine the vast majority of therapies, with the 
exception of surgery and anti-microbial chemotherapy, have been aimed at treating 
the chemical or biochemical consequences of a disease (Friedmann, 1993). 
However, gene therapy is based on the correction of a disease phenotype at the level 
of the responsible defect. Gene therapies were originally proposed for monogeneic 
dysfunctions where the clinical manifestations of a disease could be treated simply 
by replacing the defective gene. However, more recently genes have been inserted 
into eukaryotic cells in order to express pharmacologically active proteins in situ.
1.1. Single gene defects as targets for gene therapy.
The initial target diseases for treatment by gene therapy were those which resulted 
from deficiencies or mutations in a single gene. Perhaps the most extensively 
studied of these is cystic fibrosis (Schreier, 1994). This disease of the exocrine 
glands results from mutations in the cystic fibrosis transmembrane conductance 
regulator gene (Riordan et al, 1989) that encodes a cyclic AMP-regulated chloride 
ion channel (Welsh et al, 1990). The CFTR gene has been transferred in vivo to the 
airways of animal models using a number of delivery systems with the restoration of 
cAMP mediated Cl" efflux (Hyde et al, 1993; Alton et al, 1993). Several of the 
subsequent clinical trials in cystic fibrosis patients have also reported the successful
1
delivery and expression of a functional gene product in the nasal epithelia of subjects 
so indicating the clinical potential of gene therapy for this disease (Zabner et al, 
1994, Caplen et al, 1995). Other single gene defect diseases proposed as targets for 
treatment include -anti-trypsin deficiency (Kay et al, 1992), Gaucher's disease 
(Ohashi et al, 1992) and Lesch-Nyhan syndrome (Mulligan and Berg, 1981).
1.2. Gene therapy for neoplastic disease.
Gene therapy is one of a number of novel biological approaches to the treatment 
of neoplastic disease that are likely to supplement the more traditional therapies of 
surgery, radiotherapy and chemotherapy. Indeed, the first approved gene transfer 
experiment was conducted in patients with advanced malignant melanoma although 
in this study the aim was to track tumour-infiltrating lymphocytes expressing a 
marker gene (Rosenberg et al, 1989). In similar corrective strategies to those 
discussed in section 1.1. experiments have been conducted where mutant genes have 
been replaced with a single functional copy. Using this technique the in vivo 
proliferation of a number of human tumour cell lines was prevented following 
transfection with a wild type p53 gene which encoded a phosphoprotein with tumour 
suppressor activity (Mercer et al, 1991). However, as the tumourigenicity of cells is 
unlikely to result from a single mutation then it may be necessary to target two or 
more genetic defects simultaneously (Vile and Russell, 1994). These corrective 
strategies require highly efficient gene transfer as each individual cell must be 
targeted.
1,2,1, Genetic immunomodulation.
A novel adaptation of gene therapy applied to the treatment of cancer has been the 
vaccination of subjects with tumour cells modified ex vivo with genes encoding 
molecules of the major histocompatability complex. The use of cancer vaccines has
2
been reviewed extensively by Dalgleish, (1994). The principle of this strategy is that 
the presence of expressed molecules on the surface of transfected cells enhances their 
immunogenicity and results in recruitment of immune cells to the tumour mass and 
the killing of cancer cells. This approach has recently been extended to the direct 
modification of tumour cells in situ by in vivo transfer of allogenic MHC genes 
CPlm tzetal, 1993).
There has also been considerable interest in inducing tumours to constitutively 
secrete cytokines such as alpha-interferon and Interleukin 2 in order to increase the 
tumour killing properties of the immune system. Indeed, there have been several 
reports indicating that the insertion of the IL2 cDNA in murine tumours results in the 
generation of an anti-tumour response (Fearon et al, 1990; Gansbacher et al, 1991). 
Conceptually, this technique gives an anti-tumour response by generating cytokine 
concentrations in the tumour local which could otherwise only be achieved by the 
infusion of high doses of recombinant protein. The latter strategy is associated with 
severe systemic side-effects (Foa et al, 1992).
1.2.2. Gene directed enzyme pro-drug therapy.
One of the most promising applications of gene therapy to the treatment of cancer 
is the selective targeting of drugs to tumours using pro-drug therapy (for a review see 
Deonarain et al, 1995). In this technique a foreign gene encoding an enzyme capable 
of converting an inactive pro-drug into a cytotoxic compound is introduced into 
tumour cells. Several strategies for achieving selective delivery, including targeting 
with immunoliposomes or viruses with predetermined tissue specificity, were 
proposed in a review by Gutierrez et al, (1992). However, the method of selection 
preferred by these workers was to restrict the expression of the gene to target cells 
possessing the correct transcriptional control elements (Harris et al, 1994). Using
3
vectors containing the gene for cytosine deaminase under the control of the ERBB2 
promoter sequence selective conversion of 5-fluorocytosine to 5-fluorouracil was 
seen in ERBB2 expression positive pancreatic and breast tumour cell lines; 
significant cell death was observed in ERBB2(+) cells whilst ERBB2{-) cells 
remained viable.
1.2.3. DNA vaccination.
Gene therapy has also been proposed as a strategy for the generation of protective 
immunity against viral infections. In a recent advance the direct injection of plasmid 
DNA encoding the influenza A nucleoprotein into muscle resulted in both gene 
expression and the generation of antigen-specific cytotoxic T-lymphocytes (Wolff et 
al, 1990). The resulting cell mediated immunity, which appeared not to be strain 
specific, protected the animal model against a lethal viral challenge (Ulmer et al,
1993). Therapeutic gene vaccines have also been developed as one of a number of 
gene therapies for HIV infection (for a review see Yu et al, 1994). A trial involving 
the retroviral delivery of the gene encoding HIV-1 gpl60 outer coat protein has now 
advanced to the clinical stage.
1.3. Gene transfer.
Gene transfer to eukaryotic cells may be accomplished either ex vivo or in vivo. In 
the first situation, target cells are removed from the patient, isolated, and expanded in 
culture before being genetically modified. The explanted cells, which now express 
the desired gene, are then returned to the patient. This technique has generally been 
used in the treatment of haematological disorders (e.g. adenine deaminase 
deficiency), where the target cells are directly accessible, or for the modification of 
immune cells prior to tumour vaccination. Under these conditions it is possible to
4
use gene transfer strategies such as electroporation and calcium-phosphate-DNA co- 
precipitation (Graham and Van der Eb, 1978) which are unacceptable in vivo. 
However, this technique requires cell lines from each patient to be established in the 
laboratory which delays treatment and makes the method difficult to apply in 
common clinical practice (Plautz et al, 1993). In contrast, in vivo gene transfer 
involves the delivery of the therapeutic gene directly to the target cells at the level of 
the affected tissues or organs. This approach could expand the practical applications 
for gene therapy and would in essence be similar to current pharmaceutical 
treatments. However, whilst this strategy is conceptually more convenient it places 
significant additional requirements on the gene delivery system.
7.3.1. Properties of the ideal delivery system.
For in vivo gene therapy to succeed as a strategy for treating disease it is widely 
recognised that the therapeutic gene must be reproducibly expressed in the target 
cells at a level sufficient to achieve a therapeutic effect (Dillon, 1993; Mitani and 
Caskey, 1993). Therefore, the delivered gene must be efficiently presented at the site 
of action (i.e. inside the nucleus) which requires transport across multiple sub- 
cellular barriers. These include obtaining access to the target tissue, transit through 
the plasma membrane, transport to the nucleus via the cytoplasm and nuclear entry 
(Michael and Curiel, 1994). It is also important to consider the design of the 
expression module (therapeutic gene+promoter/enhancer elements) which is an 
integral part of the delivery system since it regulates the transcription of the 
therapeutic gene. The choice of promoter has been shown to influence significantly 
the level of gene product expression in vivo (Davis et al, 1993). In addition, several 
other intrinsic characteristics are required by the delivery system to accomplish in 
vivo gene transfer successfully. The requirements for an ideal gene transfer system 
are as follows (Michael and Curiel, 1994; Rolland etal, 1994):
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(i) the delivery of therapeutic genes to the target cell must be efficient and 
reproducible.
(ii) the vector system must be stable in vivo and either by means of selective 
delivery or expression, the system must exhibit specificity for the target site.
(iii) the vector system incorporating the therapeutic gene must be internalised by
the target cell and gain access to the cytoplasm.
(iv) the vector system must allow transfer of DNA from the cell cytoplasm to the
nucleus and express therapeutic gene.
(v) the vector system should be non-toxic and biodegradable (synthetic vectors).
(vi) the vector system must lack immunogenicity and must not be recognised by
the reticuloendothelial system.
(vii) the vector system, as a pharmaceutical formulation, needs to be physically 
and chemically stable.
1.3.2. Current technologies for gene delivery.
A list of the major approaches to delivering genes, with selected references, is 
shown in Table 1.1. The techniques proposed currently for gene transfer are based 
on either viral transduction or physical transfection (Hodgson, 1995). In 
transduction, the therapeutic gene is introduced into the target cell genome following 
viral infection. Alternatively, transfection uses either physical of particulate methods 
to transfer the foreign gene into the cell nucleus.
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Table 1.1. Gene transfer techniques. Significant reviews and early publications 
considering these techniques and their applications are cited.
Strategy Method Reference
Viral
Retroviruses Shimotohno and Temin (1981)
Adenoviruses
Eglitis and French Anderson (1988) 
Berkner (1988); Ali et al, (1994)
Adeno-associated virus Flotte and Carter (1995)
Herpes simplex virus Geller and Breakfield (1990)
Vaccinia virus Sutter and Moss (1992)
Non Viral
Direct Electroporation Andreason and Evans (1988)
Micro-injection Graessmann and Graessmann (1986)
Micro-particle acceleration Johnston (1990)
Particulate Plasmid DNA Wolff et al, (1990); Ulmer etal, (1993)
Calcium phosphate precipitation Graham and Van der Eb (1975)
Liposomes Feigner etal, (1987); Gao and Huang (1991)
Cationic polypeptides Smull and Ludwig (1962); Farber etal, (1975)
Poly amido acid cascade polymers Haensler and Szoka (1993)
7
1.4. Viral Vectors.
Viral methods for gene transfer have their origins in the discovery that a series of 
'tumour viruses' produced their effects by integrating their genetic material into the 
genome of the infected cell (Westphal et al, 1968). Therefore, viral gene transfer 
systems capitalise on the efficient internalisation pathway of the progenitor virus for 
gene delivery. Since the development of retroviral vectors (Shimotohno and Temin, 
1981), delivery systems based on adenovirus (Berkner, 1990), adeno-associated 
virus (Flotte and Carter, 1995), herpes simplex virus (Geller and Breakfield, 1990) 
and vaccinia virus (Sutter and Moss, 1992) have been used for gene transfer. 
Although not part of this study retroviral and adenoviral vectors are considered as 
they are the most commonly used systems for in vivo gene transfer.
1.4.1. Retroviruses.
The majority of approved clinical trials of gene therapy have involved the use of 
retroviral vectors for gene transduction (Davies, 1992). In this context the vectors 
are retroviruses (RNA viruses) in which the genome has been altered so that viral 
proteins are not made in cells infected with the vector. Using this method it is 
possible to achieve a high efficiency of gene transfer with approaching 100% of 
dividing cells being transduced in culture (Mitani and Caskey, 1993). These vectors 
have been used in the experimental treatment of lysosomal storage diseases (Ohashi 
et al, 1992) and in selective cancer therapies (Huber et al, 1991). However, the use 
of retroviral vectors is associated with a number of problems that are inherent in the 
biological properties and life-cycle of the virus.
Primarily, a round of cell division is required shortly after infection for the 
integration of pro-viral DNA into the cell genome (Miller et al, 1990). This serves to 
effectively reduce the transfer efficiency of the technique especially for the 
transduction of cells in situ where the rate of cell division is significantly less than in
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culture. Additionally, the very nature of this integration is of concern for although 
the process confers permanency of expression on transduced cells it has been linked 
to the insertional activation of oncogenes (Donahue et al, 1992). In the latter study, 
three out of the ten monkeys which received retrovirally transduced bone marrow 
progenitor cells developed a T-cell lymphoma. However, it is possible this was an 
isolated case, which resulted from infection of subjects with a retroviral supernatant 
containing a high titre of replication competent retroviruses (Anderson, 1993). It is, 
therefore, necessary that vector-producing cell lines must undergo extensive testing 
for the presence of replication competent retroviruses.
The size of the foreign gene which can be accommodated into retroviral vectors is 
limited as RNA is packaged within the virion. The amount of exogenous DNA 
which recombinant retroviral vectors can package is limited to 6-7 kbp (Eglitis and 
Anderson, 1988). Additionally, these enveloped viruses undergo complement 
mediated inactivation in the presence of serum. As such it is likely that even if 
retroviral vectors can be highly purified their use will remain confined to the ex vivo 
transfer of genes in culture systems where their high efficiency can be utilised.
1.4,2, Adenovirus.
Adenoviruses are a group of non-enveloped DNA-containing viruses with spiked 
icosahedral morphology. Though a large number of adenoviral serotypes exist the 
adenoviral vectors for gene transfer are generally constructed using the non- 
oncogenic types 2 and 5 (Ali et al, 1994). Systems of this type have been used 
successfully for in vivo gene transfer to airway epithelial cells (Rosenfeld et al, 1992) 
and skeletal muscle (Ragot et al, 1993). The construction of adenoviral vectors 
allows the accommodation of up to 7.5 kbp of foreign DNA although manipulation 
of the viral genome has shown this can be increased to 9.3 kbp (Armentano et al, 
1994).
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Adenoviral vectors are radically different from retroviruses as they are capable of 
infecting both quiescent and terminally differentiated cells such as hepatocytes and 
neurones (Jaffe et al, 1992; La Gal La Salle et al, 1993). However as the adenoviral 
genome does not generally undergo integration following infection, foreign genes are 
transiently expressed. Given this situation the repeated administration of adenoviral 
vectors will be required in chronic therapies. Importantly, multiple challenges with 
adenovirus particles have resulted in the development of anti-adenoviral antibodies 
in animals (Kass-Eisler et al, 1994; Yei et al, 1994). Presumably it is this 
mechanism which reduces the efficiency of gene transfer and expression on repeated 
administration of adenovirus vectors (Smith etal, 1993; Yei et al, 1994).
Adenoviral vectors have also been associated with inflammatory immune 
responses. In experiments with primates this toxicity appeared to be dose related 
(Simon et al, 1993); the minimal inflammation that developed on administration of 
viral titres of 107 and 108 p.f.u. increased to more severe perivascular lymphocytic 
and histolytic infiltration at doses of 109 and 1010 p.f.u. Toxicity of this type has also 
been noted in clinical trials of adenoviral systems for the treatment of cystic fibrosis 
where effects have ranged from mild neutrophilia in the nasal cavity (Zabner et al,
1993) to more severe inflammation of the lower respiratory tract (Crystal et al,
1994). In one case inflammation subsequent to the aerosol delivery of adenovirus 
required the hospitalisation of a subject (FDA transcript, 1993).
1.5. Non-viral gene transfer.
As alternatives to viral vectors, non-viral delivery systems are being developed. 
These systems differ from viral delivery systems as they are generally based on 
plasmid DNA which is not ’infective' per se and, therefore, needs to be shuttled into 
the cell by some carrier system (Schreier, 1994); the physicochemical properties of 
plasmid DNA (high molecular weight, high charge density, sensitive to
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hydrodynamic shear and nuclease digestion) generally reduces the efficiency with 
which it can enter into cells (Spooner et al, 1995). Conceptually, this approach has 
several advantages over the viral systems described in section 1.4 as the technical 
difficulties involved in the construction, manufacture and use of possibly pathogenic 
viral constructs is avoided (Feigner and Rhodes, 1991). Additionally, although 
permanency of expression is not generally achieved with non-viral systems this may 
be considered advantageous as it is possible to reverse a treatment that has resulted in 
undesirable side-effects (Wolff et al, 1990).
The non-viral gene transfer systems which are currently available are based on 
either the physical introduction of nucleic acids into the target cells or the use of 
synthetic particles. The first group of methodologies includes electroporation 
(Andreason et al, 1988), micro-injection (Graessmann and Graessmann, 1986) and 
microparticle bombardment (Johnston, 1990). Since these technologies may only be 
used for ex vivo genetic modification they are not discussed in detail. Those non- 
viral systems which are potentially useful for in vivo gene transfer have been based 
on naked DNA or synthetic particles such as liposomes or polypeptide carriers. 
Current research using polypeptide carriers is focused on encapsulating therapeutic 
genes into particle systems which are engineered to imitate viral mechanisms for cell 
entry and intra-cellular trafficking.
1.5.1. Plasmid DNA.
Plasmid DNA is prepared for gene transfer to mammalian cells by inclusion of an 
expression module containing the therapeutic gene and the necessary cis-acting 
elements including promoter and enhancer sequences as well as transcript processing 
signals (Vile and Russell, 1994). This technique has been used successfully to 
produce expression of dystrophin in muscle tissue (Cox et al, 1993) and to generate 
immunity (Wolff et al, 1990). DNA in this form is not expected to integrate into the
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host cell chromosome. Rather, the DNA is intended to reside transiently as an 
episomal element during which time mRNA will be transcribed as a gene product 
(Ledley and Ledley, 1994). The advantages of this method are two-fold; first, large 
gene sequences can be introduced easily into the molecule and secondly plasmid 
DNA is itself weakly immunogenic and therefore can be administered repeatedly 
(Madaio et al, 1984). However, the efficiency of transfection with naked DNA is 
relatively low and it is likely that therapies will be limited to those, such as muscular 
disorders, where the site of administration is directly accessible.
1,5,2. Liposomal gene transfer.
The use of liposomes as vehicles for the delivery of polynucleotides began with 
neutral lipids but the use of this technique was limited by the low encapsulation 
efficiencies of the vectors (Feigner, 1990). Even with the use of large unilamellar 
vesicles only 30-50% of the input polynucleotide could be encapsulated (Szoka and 
Papahadjopoulos, 1978). However, it has been possible to circumvent these 
problems using polycationic liposomes comprised of positively charged lipids 
(Feigner et al, 1987; Behr et al, 1989; Gao and Huang, 1991). Since cationic 
vesicles interact avidly and spontaneously with negatively charged nucleic acids, the 
complete entrapment of DNA molecules is achieved at low liposome-to-nucleic acid 
ratios, thus obviating the difficulties related to the presence of empty liposomes in 
the transfection mixtures (Gershon et al, 1993).
Cationic lipid mediated transfection using small unilamellar vesicles formed with 
N-[l-(2,3,-dioleyloxyamino)propyl]-A,Ar,A-trimethylammonium chloride (DOTMA) 
and dioleoeylphosphatidyl-ethanolamine (DOPE) is now established as an efficient 
method for the delivery of both DNA and RNA to a wide variety of eukaryotic cell 
types (Feigner et al, 1987; Malone et al, 1989). This combination of lipids is now
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available in the proprietary product Lipofectin®. Depending on the cell type, this 
methodology produced from 5- to >100 fold more gene expression than either the 
calcium phosphate or DEAE-dextran transfection techniques (Feigner et al, 1987). 
An alternative strategy is the use of liposomes prepared from DOPE and cationic 
derivatives of cholesterol (Gao and Huang, 1991).
Cationic liposome delivery of nucleic acids into the cell cytosol was initially 
postulated to occur by fusion with the plasma membrane (Feigner et al, 1987; 
Feigner, 1990). This hypothesis was proposed on the basis of in vitro experiments 
showing that vesicles comprised of DOTMA and DOPE, fuse with negatively 
charged lipid membranes and cell surfaces (Duzgunes et al, 1989). However, 
Legendre and Szoka, (1992) have shown that in CV-1 cells (monkey fibroblasts) 
treatment with the lysosomatropic agent chloroquine significantly increased cationic 
liposome-mediated gene transfer. These data suggest endocytosis was also a 
possible, and perhaps major, mechanism for the uptake of DOTMA/DOPE 
liposomes; similar results have also been described for cationic liposome systems 
with differing phospholipid compositions (Feigner et al, 1994). The release of 
systems from the endosomal compartment is believed to result from 
phosphatidylethanolamine-assisted membrane fusion (Feigner et al, 1994).
The utility of cationic liposomes has been further established by in vivo studies 
which have demonstrated cationic lipid mediated gene transfer to the airways (Alton 
et al, 1993; Logan et al, 1995), catheterised blood vessels (Nabel et al, 1992) and 
cells of the systemic circulation (Zhu et al, 1993). In addition, the in vivo toxicity of 
cationic lipid systems in several species appears to be minimal (San et al, 1993). 
However, despite liposomes representing significant progress toward the aim of 
acheiving effective in vivo gene delivery it is not yet clear whether these systems are 
sufficiently efficient to result in the necessary levels of gene expression for
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therapeutic applications. Moreover, problems surrounding the pharmaceutical and 
serum stability of cationic-liposome-DNA complexes exist.
1.5.3. Synthetic or semi-synthetic cationic polymers.
The cationic polymers diethylaminoethyldextran and polybrene (a 5-10 kDa 
straight chain polymer containing quaternary amino groups) were originally used as a 
means of increasing the uptake of virus particles into cells possessing a net negative 
charge (Vogt, 1967; Toyoshima and Vogt, 1969). However, their polycationic nature 
has more recently been used to enhance the delivery of polyanionic polynucleotides 
to mammalian cells. The standard DEAE-dextran protocols have produced 
expression of the gene product in approximately 5-20 % of cells; however, the 
transfections are generally carried out on confluent cells to avoid the significant 
toxicity seen with this protocol (Danielsen et al, 1986). A less common procedure 
for the transformation of cells with DNA is the use of the synthetic polycation 
polybrene (Kawai and Nishizawa, 1984). Most protocols describing the use of 
DEAE-dextran or polybrene require the use of a mild hypertonic lysis step, using 
DMSO or NH4C1, which presumably increases membrane permeability at the level of 
the plasma membrane or the endocytic vesicles (Feigner, 1990); the latter procedures 
are unsuitable for in vivo gene transfer.
1.5.4. Cationic Polypeptides.
The use of cationic polypeptides to increase the uptake of functional 
polynucleotides followed from the work of Smull et al, (1961). In this study either 
histone (calf thymus) or protamine (200-1000 pg/ml) was pre-mixed with polio virus 
RNA, under isotonic conditions at neutral pH, and then applied to HeLa cell 
monolayers. Both histone and protamine produced an increase in infectivity which 
was subsequently calculated to be approximately 100-fold greater than with the
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native nucleic acid (Smull and Ludwig, 1962). Perhaps surprisingly, these workers 
also reported that some other cationic substances, including poly-L-lysine and 
spermine, appeared not to enhance RNA uptake. However, in a later and conflicting 
study, polyomithine, polylysine, and polyarginine appeared to facilitate the entry of 
nucleic acids into Chinese hamster lung cells in culture and uptake into a nuclear 
sub-cellular fraction was demonstrated (Farber et al, 1975). Higher molecular 
weight polymers were generally found to be the more effective than smaller 
polymers. A similar technique employing poly-L-omithine (Mr = 100,000-200,000) 
was optimised for the transient and stable transformation of several cell lines (Bond 
and Wold, 1987). Efficiency of transfection was relatively low with 1 to 2% of the 
recipient cells taking up and expressing the selectable marker gene (thymidine 
kinase). However, in contrast to the vast majority of studies with cationic 
polypeptides and DEAE dextran the authors reported a close correlation between the 
transient and long term transfer efficiencies.
1.6. Studies on the action of cationic polypeptide carriers.
Early evidence from the studies of Smull and Ludwig, (1962) showed that the 
ability of basic polypeptides to increase RNA uptake by eukaryotic cells was only 
observed when nucleic acids were treated with the polypeptide before adsorption to 
cells. This suggested that positively charged proteins mediated their effects on gene 
transfer as a direct result of the interaction with the negatively charged nucleic acids 
(the theoretical basis of this interaction is examined in section 1.6.1.). Further 
support for this hypothesis is provided in several of the studies which have employed 
polycations in gene delivery. Common to these procedures was a critical dependence 
of gene transfer efficiency on the ratio of polypeptide to donor DNA. Furthermore, 
Feigner, (1990) observed that unlike the calcium phosphate co-precipitation 
technique the inclusion of carrier DNA in polypeptide-DNA formulations did not 
improve uptake. These observations infer that an excess of cationic polypeptide is
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required to neutralise the negatively charged DNA polymer in a polypeptide-DNA 
complex so that the complex can interact with a cell surface that is negatively 
charged (Bell, 1978).
1.6.1. Interactions of polycations and nucleic acids.
The specific interaction of nucleic acids with synthetic polycationic polypeptides 
has been the subject of a number of studies motivated in a large part by the desire to 
understand the nature of the action of basic DNA binding proteins in the cell nucleus 
(Leng and Felsenfeld, 1966). The interaction of poly-L-lysine, protamine, arginine- 
rich histone IV and lysine-rich histone lb with DNA was initially investigated using 
equilibrium dialysis (Akinrimisi et al, 1965). Data from this study indicated the 
importance of electrostatic factors in binding. Polylysine binding neutralises charges 
on DNA and produces dehydration as water molecules are excluded from the vicinity 
of the structure (Chang et al, 1973). This process can be prevented in solutions of 
high ionic strength (1.5 M NaCl; Carroll, 1972).
When cationic polypeptides are added to DNA it is apparent that the 
physicochemical properties of the system components are modified. In this regard it 
has been established that the melting temperature of DNA complexed with 
polylysine, polyomithine, polyarginine or lysine rich histones is significantly greater 
than that of naked DNA (Olins et al, 1967; Olins, 1969). Such findings indicate the 
stabilisation of DNA molecule strands on complexation. However, to effect this 
stabilisation a sequence of at least eight or more basic residues is required (Olins et 
al, 1968). The binding of DNA by these cationic polypeptides is also associated with 
structural phase transitions, with polypeptide-DNA complexes exhibiting markedly 
different behaviour to naked DNA on analysis by electrophoretic sedimentation 
(Tsuboi et al, 1966) and ultracentrifugation (Leng and Felsenfeld, 1966; Olins et al, 
1967). Additionally, these studies suggest that at lysine/phosphate ratios less than
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unity the binding of DNA and polylysine is co-operative. That is binding is non- 
random, such that when 0.5 equivalents of lysine are added per equivalent of 
nucleotide phosphate, half of the DNA and all the polylysine appear in a complexed 
state (Shapiro et al, 1969). From the analysis of systems formed between DNA and 
lysine rich histone (Olins and Olins, 1971) or polylysine (Olins and Olins, 1971; 
Laemmli, 1975) it is clear that the complexation event is associated with the 
formation of ordered structures with a compact configuration. In some cases the 
structures in these systems were toroidal (donuts). Circular dichroism studies 
published by Carroll, (1972) suggest the method used for the preparation of such 
systems may influence their physical characteristics.
1.7. Physicochemical characterisation of particulate systems.
Since the activity of particulate gene delivery systems is likely to be intrinsically 
linked to their physicochemical properties then the characterisation of these colloids 
is likely to become important in both the development and quality control of gene- 
pharmaceuticals. The colloid characteristics which are likely to be most influential 
are particle size and surface charge.
1.7.1. Electrical properties of colloids.
Surfaces of particles dispersed in a solvent become charged as a result of the 
adsorption of ions or ionisation of surface groups. These effects generate an 
electrical double layer around the particle in which the potential is highest near the 
surface and decays with the distance into the continuous phase (Fig. 1.1.). The 
charge on the surface of a particle is partially neutralised by co-ions in the stem layer. 
Each particle exposed to an electric field will move toward the appropriate pole and 
will carry with it an ionic environment which extends a small distance into the 
solvent. The potential at the surface of this layer (surface of hydrodynamic shear) is
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termed the zeta potential (Q and is a practical measure of the potential on the colloid 




Figure 1.1. Representation of the conditions at a positive colloid surface, with a 
layer of adsorbed ions in the Stem plane. The potential at the particle surface is 
shown (\|/0). As the particle moves the effective surface is defined as the surface of 
shear at which the zeta potential (Q is measured. Charge decays as a function of the 
distance (X) from the particle surface (adapted from Martin et al, 1970).
1.7.1.1. Measurement o f surf ace charge.
The zeta potential on particles can be measured by a variety of techniques. 
However, the direct microscopic observation of particle movement under an applied 
electric field is tedious, error prone and is unsuitable for systems containing particles 
with sub-micron sizes (Washington, 1992). Therefore, this technique has largely 
been replaced by light scattering methods in which the velocity distribution of 
particles is measured from the Doppler shift of scattered light from moving particles. 
An extensive description of this technique is provided by Hunter, (1981). The zeta 
potential can then be determined using the Smoluchowski equation (Fig. 1.2.) which 




Figure 1.2. Smoluchowski equation for large particles in weak electrolytes. £ = zeta 
potential, j l l c  the electrophoretic velocity, rj the viscosity, D the dielectric constant of 
the suspending medium, and 8q the permittivity of free space.
1.7.2. Particle sizing techniques-general considerations.
A wide range of techniques have been applied to the study of particle size in 
pharmaceutical systems and these are reviewed extensively by Washington, (1992). 
However, the sub-micron size distribution of gene delivery systems makes photon 
correlation spectroscopy (PCS) and electron microscopy the most suitable methods 
for their characterisation. Scanning probe microscopy may also be a useful tool for 
the analysis of systems, though there is no published work available at present.
1.7.2.1. Photon correlation spectroscopy.
PCS is a light scattering technique that can be used in analysing particles from 10 
nm up to a few micrometers in size. In this methodology, the fluctuations in 
scattered light intensity resulting from the Brownian diffusion of particles through a 
focused laser beam are used to calculate the diffusion coefficient of the particles. 
Small particles diffuse relatively rapidly which results in the fluctuations in 
scattering light being rapid. Conversely, the fluctuations in scattered light produced 
by large particles is relatively much slower. Data is collected by autocorrelation and 
a number of complex mathematical convolutions are then applied in order to 




Transmission electron microscopy is useful for the size analysis of sub micron 
particles but has a number of disadvantages (Washington, 1990). It is of limited use 
in the quantitative study of disperse systems, as obtaining numerical data on a total 
population of particles is both tedious and time consuming. However, the technique 
is more applicable in determining the gross morphological changes which take place 
within formulations. A further disadvantage of electron microscopy is the 
considerable sample preparation required. In the majority of published protocols, 
viral and liposomal particles are stained with heavy metals such as uranium or 
tungsten to increase sensitivity (Rolland, etal, 1994, March etal, 1995).
1.8. Targeting of gene expression.
The rationale behind the concept of gene targeting is to achieve a desired response 
from the expression of a gene product in selected cells without undesired actions at 
non-target sites. To this aim, two separate methodologies have been proposed for 
restricting the expression of genes to specific cell types. The first approach, 
transcriptional targeting, exploits observations that certain cells differentially and 
specifically express selected genes (e.g. gut epithelial cells/carcino-embryonic 
antigen; Schrewe et al, 1988). Expression of these genes is regulated by cell or 
tissue specific promoters. Therefore, by placing therapeutic genes under the control 
of such promoters it has been possible to restrict expression to a particular tissue 
(Vile and Hart, 1993). The specificity of gene expression can also be increased 
through the use of locus control regions (LCRs). These regulatory gene clusters 
direct the expression of transgenes in a copy dependent and integration site 
independent manner in different tissues. Cell specificity of LCRs was first 
demonstrated by Van Assendelft et al, (1989). In these experiments, expression of 
the P-globin gene under the control of a p-globin minilocus was only observed in
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erythroid cells. LCRs for T-cell specific gene expression have also been found 
(Greaves et al, 1989). This approach allows the use of non-specific strategies (such 
as amphotropic retroviruses or liposomes) for gene delivery.
The second approach, transductional targeting, involves the selective introduction 
of genes into target cells. In such strategies the vector system targets expression by 
restricting delivery of the foreign gene to the target cells. The vector systems 
employed for cell specific gene transfer have included modified retrovirus particles 
(Etienne-Julan et al, 1992), liposomes (Soriano, et al, 1983) or polycationic 
macromolecules (Wu and Wu, 1987).
1.8.1, Receptor-mediated gene delivery.
Receptor-mediated (selective) endocytosis is a natural process which cells use to 
take up macromolecules such as hormones (epidermal growth factor), low density 
lipoprotein, and. plasma transport proteins (trans-cobalamin, transferrin). The 
process initially requires the binding of the ligand to its specific cell surface receptor. 
Once the macromolecules are bound, ligands and receptors tend to cluster into 
specialised invaginated membrane regions (coated pits). One component of these 
coated pits is the protein clathrin (Pearse, 1976) which together with associated 
proteins mediates vesicle formation. Internalisation of the macromolecule then 
occurs as the clathrin-coated membrane is pinched off as a coated vesicle. After loss 
of their clathrin coat, vesicles then fuse with and become part of the acidic 
endosomal compartment. Ligand and receptors can have different fates which 
include recycling to the cell membrane or degradation in lysosomal compartments. 
However, the pathways for ligand and receptor processing are highly specific as 
indicated by the following examples; transferrin (receptor recycled, ligand recycled; 
Hanover and Dickson, 1985), low density lipoprotein (receptor recycled, ligand
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degraded; Basu et al, 1981), epidermal growth factor, (receptor degraded, ligand 
degraded; Stoschek and Carpenter, 1984) and immunoglobulin A (receptor 
transported, ligand transported; Mostor et al, 1984). The internalisation rates of LDL 
and transferrin are rapid as a result of the clustering of receptors. Other receptor- 
ligand complexes do not internalise as rapidly but internalise through membrane 
turnover.
The majority of non-viral vectors systems considered for cell specific gene 
transfer have consisted of receptor ligands linked to a polycationic DNA binding 
moiety (Findeis et al, 1993). In these vector based strategies the ligand domain 
permits interaction with cell surface receptors that are constituents of the cellular 
internalisation pathways (Batra et al, 1994) whilst the polycationic polymer 
condenses DNA to give a particulate system (Wagner et al, 1991). In this way, the 
cellular entry of DNA is subject to the endocytic process described above.
1.8.2. Ligands for targeting polycation-DNA complexes.
The polypeptide based conjugate vectors which have been developed to deliver 
DNA via the receptor-mediated endocytosis pathway are listed in Table 1.2. 
However, only those based on asialorosomucoid and cell-selective antibodies are 
genuine targeting systems as they interact with binding sites expressed on a restricted 
population of cells. The possibility of targeting with other receptor ligands, such as 
transferrin, is based on observations which show the overexpression of receptors in 
certain disease states (eg. transferrin in breast cancer; Faulk et al, 1980). However, 
transferrin receptors are expressed by most cells. Transferrin and asialorosomucoid 
have been studied widely for the in vitro and in vivo targeting of polycation 
complexes. Their use is described in detail in section 1.8.2.1. and 1.8.2.2.
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Table 1.2. Proposed strategies for the targeting of polycation-DNA complexes.
Ligand Receptor Reference
Asialorosomucoid galactose specific Wu etal, (1987); Cristiano eta l,(1993)
Galactose galactose specific Perales et al, (1994); Chen et al, (1994)
Transferrin transferrin Wagner et al, (1990)
Lactose membrane lectins Midoux et al, (1993)
Insulin insulin Rosenkranz etal, (1992)
Lectins glycolipids/glycoproteins Batra et al, (1994)
Antibodies cell surface epitopes Chen et al, (1994); Rojanaskul et al, (1994)
Folic acid folate receptor Gottschalk et al, (1994)
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1.8.2.1. Asialorosomucoid.
The first method described for the cell specific delivery of DNA consisted of 
complexing DNA to asialorosomucoid (AsOR) using poly-L-lysine (Wu and Wu,
1987). In these experiments two AsOR-polylysine conjugate molecules were 
adsorbed per pSV2CAT plasmid, which produced a system with approximately 10 
ligand molecules per plasmid. These complexes were taken up selectively in the 
human hepatoma cell line HepG2, which expresses the asialoglycoprotein receptor; 
this receptor binds and internalises galactose-terminal (asialo-)glycoproteins. 
Furthermore, Wu and Wu (1988a), showed that if an excess of ASOR was included 
in the transfection medium with the targeted polylysine-pSV2 CAT complex it was 
possible to competitively inhibit the expression of chloramphenicol acetyl 
transferase.
These systems have also been shown to be capable of delivering DNA in vivo 
(1988b). Following intravenous administration, free AsOR and the AsOR- 
polylysine-pSV2CAT complexes were taken up preferentially by the liver, 
presumably by an asialoglycoprotein receptor-mediated process. In studies with a 
similar system, southern blot analysis in combination with cell isolation techniques, 
revealed >80% of the DNA-carrier complex internalised by the liver was 
endocytosed by hepatocytes (Chowdury et al, 1993). Therefore, a large proportion of 
the delivery systems avoided uptake by the phagocytic Kuppffer cells. Gene 
expression in vivo using systems of this type was transient with peak expression of 
chloramphenicol acetyl transferase seen after 96 hours (Wu and Wu, 1988b).
. However, the therapeutic potential of DNA vectors based on this technology may be 
limited as on repetitive administration of these systems to mice, antibodies against 




Wagner et al, (1990) have developed a polycation-plasmid DNA delivery system 
which achieves cellular internalisation through transferrin. The 80 kDa glycoprotein 
transferrin mediates the uptake of iron into eukaryotic cells through a dimeric 
transmembrane receptor. The attraction of this pathway for delivery of DNA is that 
the native ligand is rapidly taken into cells; in erythroblasts as many as 104 
transferrin molecules are taken up each minute by the >105 receptors on each cell 
(Huebers and Finch, 1987). However, this strategy is not likely to achieve selective 
uptake as receptors for this endogenous ligand are also expressed on proliferating 
tissues (e.g. bone marrow, intestinal epithelium, epidermis) and some non­
proliferating cells (hepatocytes, tissue macrophages, pituitary cells, pancreas islet 
cells) (Wagner et al, 1994a). The value of the transferrin system may be as a generic 
delivery system, provided that escape from the endosome can be achieved.
Bimstiel and colleagues have used delivery systems of this type for transferrin- 
dependent receptor-mediated delivery and expression of marker genes in several cell 
lines in culture (Zenke et al, 1990; Cotten et al, 1990). Importantly, these workers 
also demonstrated that the size of the DNA constructs which can be delivered by 
these systems was in excess of that which could be incorporated into the genome of 
viral particles. Using this technology, Cotten et al, (1992) efficiently transferred a 
48-kilobase cosmid into HeLa cells; subsequent expression of the luciferase reporter 
gene encoded in 48 kbp cosmid was equivalent to that seen on delivery of this gene 
in an 8 kbp plasmid. More recently transferrin-polylysine-DNA modified with 
adenovirus particles have been used for the genetic modification of cells in situ (Gao 
et al, 1993). In these studies transient expression of p-galactosidase was seen in the 
airway epithelial cells of cotten rats for up to 7 days.
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1.9. Targeting of bioactive materials using a-melanocyte stimulating hormone 
(a-MSH)
Mammalian a-MSH (Ac-Ser1-Tyr2-Ser3-Met4-Glu5-His6-Phe7-Arg8-Trp9-Gly10- 
Lysn -Pro12-Val13-NH2) is one of a group of structurally related melanocortins that 
derive from the same precursor molecule, pro-opiomelanocortin (POMC). The 
sequence of this tridecapeptide was first published in 1957 (Harris and Lemer). In 
melanocytes and melanoma cells the biological actions of the melanocortins are 
mediated through the G-protein coupled MCI receptor (for a review see Eberle,
1988). Significantly, with regard to the use of these melanotropic peptide hormones 
as targeting moieties, it has now been established that internalisation of the receptor- 
ligand complex proceeds almost immediately after the binding to the receptor. It is 
believed that, once in the cell, the hormone is then processed through the 
endosomal/lysosomal trafficking pathway with degradation of the complex in the 
lysosome (Adams, 1993).
Several published studies have attempted to employ MSH peptides for the 
selective delivery of imaging agents, cytotoxic drugs or toxins to melanoma cells. In 
a recent study Bard et al, (1990) used a chelating derivative of a-MSH, bisMSH- 
DTPA (diethylenamine pentaacetic acid) labelled with 1HIn for the in vivo imaging 
of malignant melanoma. In this study, tumour associated radioactivity was 
significantly higher than in other tissues. Conjugates of a-MSH containing 
melphalan have also been shown to specifically bind to the MSH receptor in a human 
melanoma cell line. Although the cytotoxicity of these conjugates was less than the 
free drug alone, it was cell specific, and the effect could be inhibited by excess a- 
MSH (Morandini et al, 1994).
The binding activity of a-MSH has been increased by modifying the native amino 
acid sequence. Sawyer et al, (1980) synthesised [Nle4,D-Phe7]a-MSH, which has 
proved to be a highly potent analog of a-MSH exhibiting prolonged activity. The
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binding affinity of this peptide at the MCI receptor in cultured B16 melanoma cells 
was subsequently shown to be approximately 10-fold greater than the native peptide 
(Sahm et al, 1994), The more potent and prolonged activity of this peptide is 
suggested to be due to higher affinity binding to the receptor and a higher stability 
towards degradation and oxidation. [Nle4,D-Phe7]a-MSH analogues should therefore 
be better suited to the targeting of drugs than the native peptide.
1.10. Lectins for targeting.
Lectins are a group of diverse proteinaceous substances which are characterised 
by their ability to recognise specific glycoconjugates (glycoproteins/glycolipids) on 
the surface of cells (Liener et al, 1986). This property of lectins has been used to 
determine phenotypic variants in tissues on the basis of the differential expression of 
surface carbohydrates (Shimamoto et al, 1987). In addition to specific binding it is 
also apparent that lectins can mediate endocytosis (Roche et al, 1983; Roche et al, 
1990). Lectins have been employed to selectively direct the delivery of toxins 
(Gilliland et al, 1978), chemotherapeutic agents (Lin et al, 1981), and polypeptide 
gene delivery systems (Batra et al, 1994).
In the first study a disulphide linked conjugate of concanvalin A (Con A) and 
fragment A from diptheria toxin was synthesised. The conjugate inhibited protein 
synthesis in HeLa, CHO or SV3T3 cells in culture, being 100- to 1000-fold more 
active than the free toxin. This activity was inhibited by ConA and a- 
methylmannoside. Of more relevance to this project is the possibility of using lectins 
to target polycation gene delivery systems. Batra et al, (1994) showed that the 
efficiency of gene transfer to Lewis lung carcinoma cells in culture could be 
increased by employing molecular conjugates containing concanavalin A. Other 
lectins including wheat germ agglutinin and soybean agglutinin were tested but failed 
to faciliate gene delivery indicating a degree of specificity.
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1.11. Enhancement of gene transfer efficiency using adenovirus and synthetic 
peptides.
Approaches to increasing the low levels of gene transfer seen in many cell types 
with ligand-polycation-DNA complexes have focused on the use of mechanisms to 
enhance the release of particles from the endosome/lysosome compartments. Escape 
from the endosome has been shown in several studies to be the limiting step in gene 
expression (Zenke et al, 1990; Cristiano et al, 1993). The initial strategy employed 
was the use of the lysosomotropic agent chloroquine which increases the pH of 
intracellular vesicles and therby inhibits nuclease action (Luthmann and Magnusson, 
1983) though the enhancement of gene expression may depend on the osmotic 
disruption of the endosome. However, the toxicity of chloroquine and related 
compounds, at the concentrations required to effect endosmolysis, would limit the 
use of this technique in living organisms (Cotten et al, 1990). More recently, this 
group has used inactivated adenovirus particles to augment delivery of transferrin- 
polycation complexes both in vitro and in vivo (Curiel et al, 1991; Wagner et al, 
1992a; Gao et al, 1993); this technique has been reviewed comprehensively by 
Curiel, (1994). The co-intemalisation of virus particles and complexes serves to 
release the DNA-delivery system from the endosomes by virus mediated disruption 
of the vesicle membrane. This technique has been reported to result in expression of 
a reporter gene by 100% of cells in culture (Wagner et al, 1992a).
More recently this technology has been developed by the replacement of virus 
particles with fusogenic peptides derived from the influenza virus haemagglutinin 
protein (HA) (Wagner et al, 1992b; Midoux et al, 1993). HA produces membrane 
disruption in the low pH environment of the endosome. Importantly for targeting, 
this strategy avoids the non-specific binding of viral coat proteins. Cell surface 
receptors for adenovirus are endogenous on many cell types and promiscuously 
expressed (Stratford-Perricaudet et al, 1992).
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1.12. Origin and aims of this study.
Several techniques are available to deliver foreign genes to eukaryotic cells in 
vitro. However, many of these methods are unsuitable for in vivo gene therapy as 
they compromise cell viability or cannot be targeted to a specific cell type. 
Polycationic polypeptides have previously been investigated as potential carrier 
systems for the transfer of plasmid DNA to eukaryotic cells and more recently 
systems modified with cell surface receptor ligands have demonstrated selective gene 
transfer to cells in vitro and in vivo. Conceptually, model systems of this type 
represent replication deficient, membrane-free, synthetic viruses that can encapsulate 
large sequences of DNA (Wagner et al, 1992a).
The initial aim of this project is to use a cell specific recognition system to 
achieve a level of selective delivery to melanoma cells in vitro; our model being the 
binding of a-MSH and analogs to melanocortin receptors. Previous attempts to 
target genes to these cells have been through the less specific technique of 
transferrinfection (Plank et al, 1994; Wagner et al, 1994b). A general method using 
the lectin concanavalin A will also be tested. Molecular conjugate vectors are to be 
formed by linking ligands to DNA through poly-L-lysine modified with the 60 kDa 
biotin-binding protein streptavidin. This technology provides a universal method for 
the attachment of biotinylated compounds. Histone HI and alanine-lysine graft co­
polymers are to be investigated as alternative carriers to poly-L-lysine.
In developing cationic polypeptide gene delivery systems it is thought important 
to systematically investigate the formulation factors such as polypeptide-to-nucleic 
acid ratio and carrier molecular weight which have previously been suggested to 
affect delivery efficiency. Moreover, it is recognised these factors are intrinsically 
linked to the physicochemical properties of complexes. From measurements of DNA 
condensation, complex morphology and electrostatic charge it is hoped to gain
29
further understanding of the mechanisms underlying polycation-mediated gene 
transfer. The in vitro stability of polycation-DNA complexes are also to be assessed.
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Chapter 2
Complexation of Deoxyribonucleic acid using cationic polypeptides.
It is now widely recognised that cationic polypeptides interact spontaneously with 
negatively charged nucleic acids resulting in the formation of particulate systems 
(Feigner, 1990). These complexes have recently been used to facilitate gene transfer 
to eukaryotic cells. The work detailed in this chapter describes the formulation of 
polycation-DNA complexes to be used in subsequent gene transfer experiments. 
Systems formulated using poly-L-lysine, histone HI and a series of alanine 
substituted polylysine derivatives are described. Formation of complexes between 
these cationic polypeptides and DNA was investigated using qualitative and 
quantitative assays based on the exclusion of the fluorescent probe ethidium 
bromide.
2.1. Deoxyribonucleic Acid (DNA).
Linear double stranded calf thymus DNA was purchased as the sodium salt 
(Sigma). Prior to use DNA was dissolved in TE buffer (pH 8.0) and stored at -20°C. 
The majority of DNA fragments were in the range 564-21,224 base pairs. Size 
analysis was performed by agarose gel electrophoresis (section 2.1.6.).
Gene transfer was monitored using a 7.8 kbp plasmid construct, pRSVlacZ, in 
which the Eschericia coli p-galactosidase reporter gene is under the control of the 
rous sarcoma virus long terminal promoter/enhancer sequence. To facilitate 
selection this plasmid also encoded ampicillin resistance. pRSVlacZ was obtained 
from Dr. D. Ogllvie (Zeneca Pharmaceuticals, Alderley Edge, Chesire, U.K.). 
Plasmid DNA was propagated in E.coli XLl-Blue (Stratagene), isolated by the
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alkaline lysis technique (Bimboim and Doly, 1979) and purified by anion exchange 
chromatography (see section 2.1.4.). E.coli XLl-Blue shows a phenotypic resistance 
to tetracycline (Bullock et al, 1987). Plasmid containing bacteria were grown in LB 
medium supplemented with ampicillin (50 pg/ml) and tetracycline (12.5 fig/ml).
2.1.1. Preparation of competent E.coli XLl-Blue cells.
E.coli cells were transformed using a variation of the heat shock technique 
described by Cohen et al, (1972). Competent cells were prepared as follows: An 
overnight culture of E.coli XLl-Blue cells was diluted 1:10 and grown to an OD600 
of 0.2-0.3 in 40 ml LB medium. Cells were then chilled on ice and centrifuged at 
4000g for 10 minutes at 4°C. The medium was removed and the cells resuspended 
in 5 ml ice cold 0.1M CaCl2. The cell suspension was stored on ice for 30 minutes 
before the cells were re-centrifiiged and suspended in 1.0 ml of 0.1M CaCl2. 
Competent cells were stored overnight at 4°C before use.
2.1.2. Measurement of bacterial growth in liquid media.
The number of cells present in culture was estimated by spectrophotometric 
measurement at 600 nm (Milton Roy Spectronic 601). At low density, cell 
concentration is directly proportional to optical density (in the range OD = 0.03-0.3), 
where optical density is defined according to the Beer-Lambert law. An OD of 1.0 at 
600 nm corresponds to approximately 1 xlO9 cells/ml.
2.1.3. Transformation of E.coli XL-1 Blue cells by heat shock.
Three hundred microlitres of the competent cell suspension was transferred to a 
thin walled glass tube. pRSVlacZ DNA (3 pg) was added to the cells and the 
contents of the tube mixed. The cells were heat shocked by placing the tube in a 
water bath, pre-heated to 50°C, for 45 seconds and then chilled on ice for 2 minutes.
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Following heat shock, cells were allowed to recover in 1 ml SOC medium at 37°C 
with shaking for 1 hour (to allow expression of plasmid-coded antibiotic resistance). 
Transformed cells were selected by spreading onto LB agar plates containing 
ampicillin (50 pg/ml) and tetracycline (12.5 pg/ml). In a control transformation, 
antibiotic resistance was confirmed as plasmid mediated by subjecting cells to heat 
shock in the absence of the recombinant DNA.
2.1.4. Large scale isolation and purification of plasmid DNA.
Bacterial suspension was transferred to four 50 ml tubes and centrifuged at 4,000 
rpm for 15 minutes. The supernatant was then carefully decanted from each tube, so 
as not to disturb the pellet. This step was repeated for the remainder of the 500 ml 
culture. The composition of all buffers used in this procedure is described in 
appendix 1. Each pellet was resuspended in 2.5 ml buffer PI, using a sterile Pasteur 
pipette, before being pooled in an ultra-centrifuge tube. Ten millilitres of buffer P2 
was added and the tube contents mixed by gently inverting five times. After four 
minutes 10 ml of buffer P3 was added to the cell lysate. The tube was placed on ice 
for 30 minutes and then centrifuged at 25,000 rpm at 4°C for 45 minutes in a 
Beckman Ti45 rotor. The supernatant was removed promptly and applied onto a 
single-use modified silica anion exchange purification column (Qiagen). Prior to use 
the column was pre-equilibrated with 10.0 ml of buffer QBT. The column was then 
washed twice with 30 ml of buffer QC. Plasmid DNA was eluted using 15 ml of 
buffer QBT and precipitated by the addition of 10.5 ml of isopropanol. The tube 
contents were gently mixed and centrifuged at 4°C for 45 minutes at 25,000 rpm. 
Pelleted DNA was washed with 15 ml of ice-cold 70 % ethanol and repelleted by 
centrifugation. Following aspiration of the supernatant, residual ethanol was 
removed from the pellet by air drying at room temperature for 10 minutes. Plasmid 
DNA was resuspended in TE buffer (pH 8.0) and stored for up to 3 months at -20°C. 
Each isolation yielded approximately 500 pg of purified plasmid DNA.
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2.1.5. Spectrophotometric determination of nucleic acid concentration.
The quantity and purity of DNA was determined using triplicate 
spectrophotometric readings at 260 nm and 280 nm (Milton Roy Spectronic 601). 
Measurements were made against a blank sample of TE buffer (pH 8.0). An OD of 
1.0 at 260 nm corresponds to a solution of 50 pg/ml for double stranded DNA 
(Sambrook et al, 1989). The purity of the DNA solution was determined by 
measurement of the ratio of absorbances at 260 nm and 280 nm. Protein 
contamination of DNA solutions would reduce this ratio to below 1.8. All plasmid 
DNA samples used in transfection and complexation experiments had an A260:A280 
ratio greater than 1.8.
2.1.6. Preparation of a horizontal agarose gel.
Agarose gels were cast and run in Bio-Rad DNA sub-cells. Ultrapure agarose 
(Bio-Rad) was dissolved in TAE buffer at 100°C to give a gel of the appropriate 
concentration. The solution was allowed to cool to 60°C, made up to weight with 
water, and ethidium bromide added to 0.5 pg/ml. The gel was poured and allowed to 
set at room temperature for 45 minutes. Once set, gels were submersed in TAE 
buffer. DNA samples were mixed with 0.2 volumes of 5X DNA loading buffer and 
electrophoresis carried out at 70 V until the tracking dye reached the end of the gel. 
DNA bands were visualised on a UV light box. Photographs were taken using 
Polaroid 55 film in a Polaroid camera. Negatives were prepared by washing in an 
18% w/v solution of sodium sulphite and then rinsing with water.
2.1.7. Digestion of DNA with restriction endonucleases.
DNA restrictions were performed in accordance with manufacturer's instructions. 
For complete plasmid digestion, reaction mixtures were allowed to incubate at 37°C 
for 60 minutes. Partial digests are described in section 2.1.8.
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2.1.8. Partial digestion ofpRSVlacZ with Xbal.
To 1 pg of plasmid DNA were added 5 pi of 5X reaction buffer (Sigma), 2.5 pi 
BSA solution (2 mg/ml) and 1 pi Xbal (Sigma 20 units/pl). The total volume was 
made up to 50 pi with sterile water and the reaction mixture mixed by pipetting and 
incubated at 4°C. At 5 minute time intervals reactions were stopped by the addition 
of 7 pi DNA loading/reaction stop buffer. Samples were stored on ice until needed. 
After the final samples had been removed, all samples were run on a 1.0% agarose 
gel.
2.1.9. Scanning densitometry.
Gel photographs (negative) were scanned using a Bio-Rad scanning densitometer 
model GS-570. Analysis of the digitised images was performed using Molecular 
Analyst software package. Quantification of bands was determined using Volume 
Analysis software (Bio-Rad).
2.2. Cationic polymers.
Cationic polymers used in this study are described below and the physical 
characteristics summarised in Table 2.1. and 2.2. Polymer solutions were prepared 
under clean laboratory conditions. Hepes buffered saline (HBS: 20 mM Hepes/150 
mM NaCl, pH 7.4) or Milliq water was filter sterilised using a 0.2 pm nitrocellulose 
filter (Sartorious).
2.2.1. Poly-L-lysine.
Poly-L-lysine Hydrobromide samples [average degree of polymerisation 
(determined by light scattering) = 13, 214 and 859] and Poly-L-lysine Hydrochloride 
(DPn=127) were obtained from Sigma. All polymers were polydisperse. Prior to use 
polymers were dissolved in HBS or Milliq water to give a 5.0 mg/ml solution and 
stored at 4°C. Polymers were stored in rubber capped glass vials (Chromacol).
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Table 2.1. Physical characteristics of poly-L-lysine polymers. Data were supplied by 
the manufacturer.





Poly-L-lysine*HBr 13 1684 2736 N/A
Poly-L-lysine*HCl 127 16300 21000 1.25
Poly-L-lysine*HBr 219 28000 45800 1.1
Poly-L-lysine*HBr 859 110100 179600 1.1
N/A=Not available.
2.2.2. Histone HI.
Calf thymus histone HI (21 kDa) was supplied as 1 mg of lyophilised solid 
(Calbiochem). The solid was reconstituted with HBS to give a 1 mg/ml solution and 
stored in 100 pi aliquots at -70°C in 1.5 ml microcentrifuge tubes. Aliquots of 
histone HI were not re-frozen once defrosted.
2.2.3. Alanine-lysine graft co-polymers.
Alanine-lysine graft co-polymers (AK 100, AK200, and AK500) were a gift from 
Professor Ferenc Hudecz (Eotyos University, Budapest, Hungary). The physical 
properties of these graft co-polymers are described in Table 2.2 and their chemical 
structure illustrated in Figure 2.1. Polymers were supplied as a 100 mg/ml solution 
in water and diluted with HBS to give a 2 mg/ml solution. Polymers were stored at - 
20°C in 0.5 ml microcentrifuge tubes.
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Table 2.2. Physical characteristics of alanine-lysine graft co-polymers.




AK100 66 28200 4.2: 1.0 426.8
AK200 280 89700 2.7: 1.0 320.2













Figure 2.1. Chemical structure of alanine-lysine graft co-polymers. The a-amino 
group of these polymers provides the cationic charge for interaction with DNA. 
Monomer units varied in the number of alanine residues grafted to the each lysine 
residue.
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2.3. Calculation of Polymer-to-DNA charge ratio.
Complexation of pRSVlacZ and chromosomal DNA were determined as a 
function of both the mass of cationic polypeptide added and the positive to negative 
charge ratio.
^  , x Total number Positive charges (mols)Charge Ratio (+ / -) = --------------------------------- -—  ------ -
Total number Negative charges (mols)
2.3.1. DNA.
The calculation of negative charge provided by DNA was determined on the basis 
that each nucleotide in the DNA sequence is associated with a single negative 
charge. A mean value of 330 was calculated for the molecular weight of a 
monophosphorylated nucleotide from data given by Sambrook et al, (1989) for 
dAMP, dCMP, dGMP and dTMP.
2.3.2. Poly-L-lysine homopolymers.
Positive charge provided by synthetic poly-L-lysine homopolymers was calculated 
using the molecular weight and DPn determined by the manufacturer. Compensation 
was made where polymers were supplied in salt form.
2.3.3. Alanine-lysine graft co-polymers.
Using the alanineilysine ratio described in Table 2.2. the effective molecular 
weight of each monomer unit, with which one charge is associated, was calculated. 
From this value the charge provided by a polymer molecule was then calculated. 
Complete ionisation of a-amino terminal groups was assumed.
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2.3.4. Histone HI.
Calculation of charge provided by histone HI was based on the presence of basic 
lysine and arginine residues in the polypeptide sequence. Amino-acid analysis of 
calf thymus histone HI was performed by Bradbury et al, (1975a).
2.4. Formation of polycation-DNA complexes
Polycation-DNA complexes were prepared by mixing dilute solutions of the 
polypeptide with DNA. Stock solutions of polylysine polymers were diluted to a 
concentration of 78 pg/ml (free polylysine). For experiments using histone HI and 
alanine-lysine graft co-polymers, working concentrations of 200 pg/ml were 
produced. All dilutions were prepared in HBS. DNA solutions were prepared by 
diluting 6 |ig pRSVlacZ or calf thymus DNA to 250 pi (24 fig/ml) in a sterile 1.5ml 
microcentrifuge tube. Varying masses of polypeptide were then added to individual 
microcentrifuge tubes and diluted to a total volume of 250 pi. The mass range of 
polypeptide used in complexation reactions is described in Table 2.3. Each 
polypeptide solution (250 pi) was then added dropwise to 250 pi of DNA solution 
(24 pg/ml) while vortex mixing. Complexation was allowed to proceed at ambient 
temperature for 30 minutes before analysis by gel electrophoresis or 
spectrofluorimetry.
Table 2.3. Mass and charge range of polypeptides used in complexation reactions.
Polymer pLL (13) pLL (127) pLL (214) pLL (859)
Mass Range (pg) 0-14.4 0-6.0 0-6.0 0-4.8
Charge Range(mols) 0 -l.lx l0 '7 0-4.7xl0‘8 0-4.7 x 10*8 0-3.7x10'8
Polymer AK100 AK200 AK500 Histone HI
Mass Range (pg) 0-15.6 0-13.8 0-12.6 0-2.3
Charge Range (mols) 0-3.7xl0'8 0-4.3xl0'8 0-3.7xl0"8 0-3.3xl0'8
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2.5. Ethidium bromide as a fluorescent probe.
Ethidium bromide acts as a fluorescent probe following intercalation between 
DNA base pairs. Ultraviolet radiation at 254 nm is absorbed by DNA and 
transmitted to the dye with energy re-emitted at 590 nm in the red-orange region of 
the visible spectrum (Sambrook et al, 1989). The fluorescent yield of the dye on 
intercalation is greater than for the dye in free solution. This effective change in 
intensity allows nucleic acid to be distinguished against background in agarose gels 
and also allows quantification of DNA using spectrofluorimetry.
2.5.1, Analysis of DNA complexation by fluorescence spectrophotometry.
Quantitative analysis of complexation was determined using a method based on 
that described by Gershon et al, (1993). Polymer-DNA complexes containing 6pg 
pRSVlacZ in 0.5 ml were formed as described in section 2.4. Following incubation 
at room temperature for 30 minutes, 500 pi of complex suspension was added to 2.5 
ml 150 mM NaCl. Immediately prior to analysis, 3 pi ethidium bromide (0.5 mg/ml) 
was added to the various DNA-polymer mixtures (1:5 molar ratio of probe to 
nucleotides). Each sample was then mixed by vortexing and fluorescence monitored 
(A,ex = 260 nm, A,em = 600 nm; 1 cm light path cell) using a Shimadzu RF-540 
spectrofluorophotometer, with 5 nm excitation and emission slits. Complexation of 
DNA produces a reduction in fluorescence as intercalation of ethidium bromide 
between DNA base pairs is prevented. The degree of complexation was measured as 
a decrease in fluorescence relative to the control, which contained 6 pg uncomplexed 
plasmid DNA. Fluorescence of the control sample was normalised to 100%.
2.5.2. Gel mobility shift assay.
Gel mobility shift assays complemented quantitative spectrofluorometric methods 
for determining complexation of plasmid DNA. Complexes containing increasing
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quantities of polypeptide were prepared as in section 2.4. Immediately after 
formation, 40 pi of each complex suspension was removed and 10 pi of 5X loading 
buffer added. A 10 pi aliquot from each preparation, containing 100 ng plasmid 
DNA, was then resolved by electrophoresis through a 1% agarose gel at a constant 
voltage (80V) for 75 minutes. Gels contained ethidium bromide (0.5 pg/ml) for 
visualisation of DNA. Following electrophoresis, gels were viewed and 
photographed as described in section 2.1.6.
RESULTS
2.6. Analysis of DNA for use in transfection.
Following isolation and purification, plasmid pRSVlacZ was analysed by gel 
electrophoresis to determine the suitability for use in transfection experiments. A 
representative gel is shown in Figure 2.2. Plasmid-DNA prepared by alkaline lysis 
(Fig. 2.2.; Lane 5) were routinely shown to be free from contamination with RNA or 
chromosomal DNA. Bands were identified by partial digestion using Xbal (Fig. 2.2.; 
Lane 2 and 3). During electrophoresis DNA migrates from the origin of the gel 
toward the anode (Bottom of gel). From the bottom of the gel, bands corresponded 
to supercoiled, nicked open-circle, and linear forms of plasmid DNA respectively. 
Digestion of pRSVlacZ using 20 units of restriction enzyme at 37°C for 30 minutes 
(Fig 2.2.; Lane 4) showed a single band of 7.8 kilobases. Band densities were 
determined by scanning densitometry volume analysis (as described in section 2.1.9.) 
with appropriate corrections for supercoiled DNA which appears underrepresented 
on visual examination; the conformation of supercoiled DNA reduces ethidium 
bromide intercalation by 30% (Koch et al, 1993). Samples used in transfection 
experiments routinely contained greater than 85% supercoiled DNA.
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1 2 3 4 5 6
Mol.wt. 
(base pairs)
2 3 1 3 0
9 4 1 6
6 5 5 7
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2 3 2 2
2 0 2 7
Figure 2.2. Agarose gel electrophoresis of pRSVlacZ. Lane 1 and 6, HindHl-cut A, 
DNA; Lane 2, pRSVlacZ (Xbal, 10 minutes, 4°C); Lane 3, pRSVlacZ (Xbal, 20 
minutes, 4°C); Lane 4, pRSVlacZ (Xbal, 60 minutes, 37°C); Lane 5, pRSVlacZ 
(undigested).
2.7. Complexation of plasmid DNA using poly-L-lysine.
Figure 2.3. demonstrates the influence of polymer chain length on the 
complexation of pRSVlacZ-DNA by a series of polylysine polymers. In these 
experiments increasing quantities of polymer (described in Table 2.3.) were mixed
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with 6 |ig DNA. For pLL(127), pLL(214) and pLL(859) fluorescence intensity was 
reduced on the addition of cationic polypeptides in a dose dependent manner. The 
number of molecules required to be added to DNA in order to produce fluorescence 
quenching was inversely related to the DPn (Fig. 2.3.a). Therefore, to effect 
fluorescence quenching with pLL(127) 6.8 times the number of pLL(859) molecules 
was required. The specific polypeptide-to-DNA mass ratio at which fluorescence 
intensity was reduced to background levels (Fig. 2.3.b; Polymer:DNA = 0.4:1) 
corresponded to a charge ratio of 1.1 (Fig. 2.3.c). However pLL(13), the smallest 
polymer tested, appeared to behave anomalously as maximum fluorescence 
quenching was achieved only on the addition of a two fold mass excess of polymer. 
The quench curve produced with this polymer was consequently shallower than those 
seen for pLL(127), pLL(214) and pLL(859). An effective polymer:DNA charge ratio 
(+/-) at the point of complexation was 5.1. In addition, fluorescence intensity was 
only reduced to a minimum of 20.6% of the control level.
2.7.1. Gel electrophoresis of Poly-lAysine-DNA complexes.
The mobility shift assay performed on complexes formed between pLL(214) and 
pRSVlacZ-DNA is shown in Figure 2.4.a. Based on charge neutralisation, as shown 
by the reduction of the electrophoretic mobility of DNA, the interaction of poly-L- 
lysine^ 14) and DNA could be detected at a mass ratio of 0.1:1 (Fig. 2.4.a). In this 
sample, both unretarded free DNA, which migrated through the gel at the same rate 
as pRSVlacZ, and complexed DNA which was retained at the gel origin could be 
detected. At mass ratios of 0.3:1 and greater, free DNA could not be detected in the 
gel. Poly-L-lysine labelled with fluorescein-isothiocyanate (Sigma) was used to form 
complexes with pRSVlacZ for use in uptake studies. Using pLL-FTTC(219) 
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Figure 2.3. Complexation of DNA using poly-L-lysine. pRSVlacZ-DNA was mixed 
with increasing quantities of (•) pLL(13), (■) pLL(127), (D)pLL 214 and (A)  
pLL(859). Data is expressed in terms of the molar quantity of polymer added to DNA 
(Plate A), polymer:DNA mass ratio (Plate B) and charge ratio (Plate C). Data 
presented is compiled from representative experiments.
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ApLL:DNA Ratio
M ass 0:1 0.1:1 0.2:1 0.3:1 0.4:1 0.5:1 0.6:1 0.8:1
C harge (+/-) 0 0 .2 6  0.51 0 .78  1 .03 1 .29  1 .55 2 .07
B
pLL-FITC:DNA Ratio
M ass 0:1 0.1:1 0.2:1 0.3:1 0.4:1 0.5:1 0.8:1 1.0:1
Figure 2.4. Agarose gel electrophoresis analysis of poly-L-lysine-DNA complexes. 
pRSVlacZ was incubated with increasing amounts of pLL (Plate A) or pLL-FITC 
(Plate B) and incubated at room temperature for 30 minutes. 0:1 represents 
pRSVlacZ only; bands represent from bottom to top of gel, plasmid DNA in 
supercoiled and open circle conformations.
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2.7.2. Influence of DNA conformation and the presence of buffer salts on 
complexation.
Measurements made on complexes formed with an equal mass of calf thymus 
DNA or closed-circular-supercoiled DNA (6 pg) and increasing quantities of 
pLL(214) showed similar fluorescence patterns (Fig. 2.5.). In each case background 
levels of fluorescence intensity were reached at a polymer:DNA. mass ratio of 0.4:1 
which corresponds to a charge ratio of 1.1. Complexes prepared for transfection 
experiments were usually prepared in HBS. However, to assess if the presence of 
buffer salts affected the complexation process, systems were prepared in double 
distilled de-ionised water. Under these conditions the mass of polymer required to 
induce fluorescence quenching was the same as in the presence of buffer salts 
(PolymenDNA; 0.4:1) indicating that at the concentrations routinely used in complex 
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Figure 2.5. Effects of DNA conformation and buffer salts on complexation. 
Complexes were formed between pLL(214) and 6 pg calf thymus-DNA (■) or 
pRSVlacZ-DNA (•)  in HBS. Effect of buffer salts was assessed by forming 
complexes between pLL(214) and pRSVlacZ in water (A).
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2.8. Complexation of DNA using novel cationic polypeptides.
Fluorescence quenching was achieved with alanine substituted poly-L-lysine 
polymers, of 66 (AK100), 280 (AK200) and 650 (AK500) monomer residues, at 
polymer-to-DNA mass ratios of 2.3, 1.7 and 1.5 respectively (Fig. 2.6.a). The 
fluorescence quench curve for pLL(214) is also shown. For each of the alanine- 
lysine heteropolymers the amount of charge required to produce fluorescence 
quenching was found to be greater than for pLL(214). AK100 and AK200 showed 
similar fluorescence quench curves with no further quenching observed above a 
charge ratio of 1.8. In contrast, complete quenching was produced by pLL(214) at a 
charge ratio of 1.1 (Fig. 2.6.b).
2.9. Analysis of Histone Hl-DNA complexes.
Complexation of plasmid-DNA by histone HI was examined by both 
spectroflourimetry (Fig. 2.7.) and gel mobility shift assay (Fig. 2.8.). In order to 
achieve fluorescence quenching with HI, a 1.7 fold mass excess of polypeptide was 
required to be added to DNA. Fluorescence exhibited at this polypeptide-to-DNA 
mass ratio was 14.5% of the control value and was not reduced by further increasing 
the mass excess of polypeptide. In contrast, condensation of DNA using pLL(214) 
reduced fluorescence intensity to 3% of the control value. The charge ratio at which 
fluorescence quenching occurred was 1.1 and 1.4 for pLL(214) and HI respectively 
(Fig. 2.7.b). Agarose gel electrophoresis (Fig. 2.8.) showed that as the proportion of 
histone HI in the samples increased there was a decrease in the electrophoretic 
mobility of DNA. The movement of Hl-DNA complexes formed at a mass ratio of 
0.4:1 was retarded, compared to free pRSVlacZ-DNA, but moved freely in the gel 
and was not retained at the origin. This is in contrast to the complexation of DNA by 
poly-L-lysine where plasmid molecules existed in either the free or complexed state. 
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Figure 2.6. Complexation of pRSVlacZ-DNA using alanine-lysine graft co­
polymers. Effect of polymer-to-DNA ratio on fluorescence intensity in terms of mass 
(Plate A) and charge (Plate B) for poly-L-lysine (214) and a series of alanine-lysine 
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Figure 2.7. Complexation of pRSVlacZ-DNA using histone HI. Effect of 
Polypeptide-to-DNA to ratio on fluorescence quenching in terms of mass and charge. 
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Figure 2.8. Agarose gel electrophoresis of histone Hl-pRSVlacZ-DNA complexes. 




The co-operative interaction of linear DNA and the cationic homopolypeptides 
polylysine and polyarginnine has previously been described using circular dichroism 
(Olins et al, 1967) and ultracentrifugation (Leng and Felsenfeid, 1966). However, 
data were not available which detailed the quantity of polymer required to 
completely complex plasmid-DNA under the conditions to be used for in vitro 
transfection experiments. Analysis of the interaction between plasmid-DNA and 
cationic polypeptides in these initial studies was therefore motivated by the desire to 
formulate complexes in a reproducible manner. A basic requirement prior to the 
development of gene delivery systems of this type was the isolation of plasmid-DNA 
of high purity.
2.10.1. Preparation of plasmid-DNA for transfection.
Plasmid-DNA used throughout this study was purified by anion-exchange 
chromatography following isolation by alkaline-lysis and was shown to be free from 
RNA and contaminating protein. This is important as a critical parameter in the 
formation of reproducible complexes was thought to be the accurate quantification of 
DNA. The presence of RNA in plasmid DNA samples would result in the over­
estimation of DNA concentration. RNA as a nucleic acid is also capable of 
interacting with cationic polypeptides and would compete for polypeptide binding.
In addition to purity, observations by Lehmann and Oomen, (1985) indicated that 
the topology of DNA molecules affects the level of transcription. This study showed 
the level of chloramphenicol acetyl transferase expression was markedly higher when 
supercoiled DNA's rather than linear DNA's were transfected into monkey CV-1 
cells. Subsequently, Weintraub et al, (1986) demonstrated supercoiled DNA to be a 
more effective template for transcriptions. The influence of plasmid conformation
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on gene expression was found to be most pronounced in plasmids, such as pRSVlacZ 
which contain enhancer sequences; the supercoiling of DNA increasing the 
efficiency with which bound transcription factors were used. Therefore, 
maximisation of expression requires delivery of DNA in the supercoiled form. DNA 
samples used in this study routinely contained greater than 85% of DNA molecules 
in this conformation.
Purification of plasmid-DNA by anion-exchange column chromatography was 
also found to be more convenient than the traditional method of caesium chloride 
gradient centrifugation which requires the labelling of DNA with ethidium bromide. 
However, Wicks et al, (1995) have shown this method does not remove 
lipopolysacchride (LPS) which has been shown to reduce transfection efficiency 
(Cotten et al, 1994). A chromatographic method for removing LPS contamination 
has recently been reported (Horn et al, 1995).
2.10.2. Complexation of plasmid-DNA using poly-L-lysine.
Analysis of plasmid-DNA complexation using poly-L-lysine of differing degrees 
of polymerisation demonstrated similar behaviour for polymers of 127, 214 and 859 
monomer units. The exclusion of ethidium bromide from poly-L-lysine complexes 
was independent of the number of polymer molecules in the reaction system. 
However, for each of the polymers tested complete complexation was achieved at a 
polypeptide-to-DNA mass ratio of 0.4:1 which equated to a theoretical charge ratio 
of 1.1. Preparation of complexes in either HBS or water did not affect this process. 
These data are in accordance with the general theory on DNA complexation which 
has shown that at a given degree of charge neutralisation, DNA molecules collapse 
into packed forms in a highly co-operative process (Manning, 1981). The 
electrostatic interaction of polylysine and DNA has previously been demonstrated to 
induce this phenomenon with complexation and subsequent condensation of DNA
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being significantly affected by the ratio between the two polymers (Carrol, 1972). 
The extensive ultracentrifugation of systems formed between calf thymus DNA and 
pLL(lOO), at lysine:phosphate ratios >1.0, showed DNA was completely 
incorporated into a fraction with a sedimentation profile different to that of naked 
DNA (Leng and Felsenfield, 1966). This suggests a transition between a solution 
state and a colloidal system on complexation. The fluorescence quenching of 
ethidium bromide observed on incubation with complexes formed at charge ratios 
>1.1 is therefore indicative of the exclusion of fluorescent probe from collapsed 
DNA structures. Gershon et al, (1993) demonstrated that a similar positive charge 
density (Liposome:DNA;(+/-) = 1.2) was required to achieve DNA condensation 
using cationic liposomes (DOTMA/PE, 1:1). The overall positive charge density 
remained identical when pLL(90) was used to provide partial charge neutralisation in 
these systems. These data show good correlation with the work of Tsuboi et al, 
(1966) who found the binding of the homopolymer polylysine to DNA to have 1 to 1 
stoichiometry (one basic residue per nucleotide).
Complexes formed between pLL(13) and plasmid-DNA, however, require higher 
lysineiphosphate ratios to induce condensation. This perhaps suggests that small 
chain length polymers are ineffective at binding or condensing DNA. Complete 
exclusion of ethidium bromide was only achieved by increasing the concentration of 
pLL(13) and effectively shifting the equilibrium between bound and free polylysine. 
The form of these complexes also appears different since at high polypeptide-to- 
DNA ratios the fluorescence intensity of complexes was only reduced to 20.6% of 
the control level. This is in contrast to the background levels achieved using 
polylysines of longer chain length. Commercially produced pLL(13) was, however, 
polymeric and presumably included a significant number of short chain oligomers. 
Pure oligmers should be synthesised to determine what is the minimum chain length 
for DNA condensation.
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2.10.3. Complexation of DNA using novel cationic polypeptides.
Poly-L-lysine substituted with alanine oligopeptides retained the capability for 
DNA binding. In this series of molecules, polylysine was derivatised with alanine 
through the butylamino side chain such that the a-amino group of the alanine residue 
provided the positive charge. However, for each of the alanine-lysine graft co­
polymers the amount of charge required to produce fluorescence quenching was 
found to be greater than for pLL(214) which binds DNA with 1 to 1 stoichiometry 
(Tsuboi et al, 1966, Olins et al, 1967). The observation that fluorescence quenching 
occurred at a graft co-polymer:DNA charge ratio greater than unity suggests each a- 
amino group does not interact with the negative charge associated with each 
nucleotide. This may result from the steric effect produced by displacing the positive 
charge away from the polymer backbone. Moreover, as the condensation of plasmid- 
DNA by AK500 was achieved at charge ratios lower than those described for AK100 
and AK200 it is apparent that longer chain polymers of this type bind DNA more 
effectively.
2.10.4. Complexation of DNA using Histone HI.
Early investigations by Olins and Olins, (1971) showed that following 
complexation of DNA by histone HI, at a sodium chloride concentration of 150 mM, 
toroid structures were reproducibly formed. These structures were similar to those 
described for both polylysine (Laemmli, 1975) and transferrin-derivatised polylysine 
(Wagner et al, 1991). However, histone HI differs from the polymers investigated 
earlier in this study as at least part of the molecule forms a globular structure in 
aqueous solution (Bradbury et al, 1975b). The retarding of nucleic acids within the 
gel at a polypeptide:DNA mass ratios of 0.4:1, rather than the formation of 
aggregates, is consistent with the observations by Johnson et al, (1995) who 
described the preparation of 'slow' complexes. In these systems, histone HI is
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reversibly bound to DNA. However, this type of complexation, is unusual in 
systems where salt concentrations are greater than 100 mM (Singer and Singer, 
1978). That this mechanism was seen under the condition used in this experiment is 
perhaps a reflection of the conformation of the pRSVlacZ-DNA molecules or the 
presence of impurities. At mass ratios greater than 0.8:1 the addition of histone HI 
to pRSVlacZ also resulted in 'fast' co-operative complexation where DNA was 
localised in the well of the gel. Clark and Thomas (1986) also describe the formation 
of complexes by co-operative complexation at high H1:DNA ratios(>1.0% w/w) 
although in these experiments DNA was in a linear conformation.
2.10.5. Complexation of DNA: Comparison of gel mobility shift and ethidium 
bromide exclusion assays.
As described previously the neutralisation of the anionic charges of DNA by the 
protonated amino groups of cationic carrier polypeptides produces a change in the 
electrophoretic mobility of plasmid-DNA. In the gel mobility shift assay this results 
in a reduction in free DNA and a corresponding increase in complexed DNA which 
remains at the gel origin. In contrast to the gel mobility shift assay the ethidium 
bromide exclusion assay is carried out on the bulk sample. In this test, the ability of 
ethidium bromide to bind DNA in the presence of increasing quantities of polymer is 
measured spectrofluorometrically. Ethidium bromide has been shown to intercalate 
into DNA in a manner similar to the acridines (Waring, 1965) and this produces a 
change in fluorescent yield. The mechanism by which DNA binding of ethidium is 
inhibited is not fully understood; the cationic polymer may prevent intercalation by 
blocking the sites of insertion, altering the flexibility or conformation of DNA, or by 
preventing electrostatic interaction between the ethidium cation and nucleotide 
phosphates (Olins, 1969).
Comparison of data obtained from the two assays for the complexation of plasmid 
DNA by poly-L-lysine(214) indicated some inconsistencies. Notably, the apparent
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end point for the gel mobility shift assay was achieved with the addition of a mass of 
polymer which did not produce complete fluorescence quenching in the ethidium 
exclusion test (total retention of DNA at the gel origin was defined as the end point 
of the gel mobility shift assay). However, as discussed previously, the ethidium 
bromide assay showed condensation at charge ratios which were in agreement with 
generally held theories on DNA collapse. It is therefore possible that this assay may 
be a more accurate reflection of the subtle changes resulting in DNA condensation.
2.11. Summary.
In summary, complexation of both plasmid and chromosomal DNA by poly-L- 
lysine was demonstrated using both spectrofluorimetry and gel mobility shift assays. 
Poly-L-lysine appeared to bind and condense DNA in accordance with the general 
theories of DNA complexation. The quantity of cationic polypeptide required to 
complex DNA completely, in terms of both mass and charge, was also determined 
for alanine-lysine heteropolymers and histone HI. Cationic-polypeptide-DNA 
complexes formulated using these data were tested in gene delivery studies which are 




Since the first description of receptor mediated gene delivery several methods 
have been described for conjugating cell surface ligands to DNA-polylysine 
complexes. The direct coupling of asialoorosomucoid to poly-L-lysine by way of a 
covalent chemical bond has been achieved using the bifunctional cross-linking 
reagent N-succinimidyl 3-(2-pyridyldithio)propionate (Wu and Wu, 1987) and the 
water soluble carbodiimide l-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(Cristiano et al, 1993). The use of SPDP was also the preferred method for covalent 
linking of transferrin (Wagner et al, 1990) and IgG monoclonal antibodies to poly-L- 
lysine (Rojanasakul et al, 1994). An alternative method exploits the specific binding 
of biotinylated ligands by streptavidin or anti-biotin antibodies (Batra et al, 1994). 
This strategy requires construction of DNA-complexes using poly-L-lysine 
derivatised with an appropriate biotin binding protein. Targetable vectors can then 
be formed by addition of biotinylated receptor ligands which are bound to complexes 
through a high affinity non-covalent interaction. The application of (strept)avidin- 
biotin technology in forming targeted complexes was prompted by the exceptional 
affinity (10'15M_1) of biotin/avidin binding. Systems of this type allow alteration of 
the ligand moiety of the construct, which changes the specificity of the vector, 
without the requirement for several complicated synthesis reactions. The work 
presented here describes the conjugation of streptavidin to poly-L-lysine.
3.1. Peptide bond formation by carbodiimide reagents.
Carbodiimides are a group of condensing reagents that facilitate the formation of a 
peptide bond between free amino and carboxyl groups. Practically, this is a one-step
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procedure which may be performed at room temperature with subsequent high yields 
(Sheehan and Hess, 1955). In addition to their use in peptide synthesis, carbodiimide 
reagents have found various applications in the coupling of small molecule drugs and 
peptides to carrier polymers and proteins in macromolecular drug delivery systems; 
e.g. bovine serum albumin linked to a-melanocyte stimulating hormone (McGuire et 
al, 1965) and methotrexate bound to poly-L-lysine (Ryser and Shen, 1978). Directly 
relevant to this study was the use of the water soluble carbodiimide EDC to prepare 
hydrazide derivatives of streptavidin for glycoconjugate labelling (Bayer et al, 1987). 
The use of water-soluble carbodiimides for such purposes enables separation of the 
product from unreacted reagents and reaction by-products by gel filtration and 
dialysis (Bauminger and Wilchek, 1980).
A general scheme for the linking of poly-L-lysine and streptavidin using a 
carbodiimide reagent is presented in Figure 3.1. The postulated mechanism for this 
reaction involves the protonation of the carbodiimide reagent (I) which is 
subsequently susceptible to attack from the acid anion (II). Rearrangement to an o- 
acylisurea intermediate (HI) produces a species which can react with an amine (IV) to 
give the desired peptide (V) and a urea (VI) or rearrange to an acylurea (VII). As 
acyl ureas are mainly produced at elevated temperatures peptide bond formation can 
be increased by performing the reaction at around 0°C (Bauminger and Wilchek, 
1980).
3.2. Physical characteristics of proteins.
Bovine serum albumin (BSA) was used as a model protein in this study as the use 
of streptavidin in initial conjugation reactions was prohibitively expensive. These 
globular proteins are similar in size (BSA = 66 kDa; streptavidin = 60 kDa). The 
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Figure 3.1. Peptide bond formation between streptavidin and poly-L-lysine using 
carbodiimide reagents. For EDC R1=CH3CH2, R2=CH2CH2CH2NH+(CH3)2C1‘. 
STR=streptavidin.
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3.3. Synthesis of bovine serum albumin-poly-L-lysine conjugates.
Conjugation of bovine serum albumin and poly-L-lysine (219) was performed 
using l-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC). The optimum 
quantity of EDC required for efficient coupling was determined by reacting 
equimolar quantities of BSA and poly-L-lysine hydrobromide using an increasing 
quantity of EDC. A 0.5 ml aliquot of BSA solution (16 mg/ml) was added to a small 
glass reaction vial containing 5 mg of poly-L-lysine hydrobromide. After thorough 
mixing, aliquots of freshly prepared EDC solution (25 mg/ml) were added to the 
solution and the volume adjusted to 2.0 ml with 50 mM Hepes (pH 7.4). The 
composition of the reaction mixtures is described in Table 3.1. Following incubation 
at 4°C for 24 hours the reaction mixtures were separated by ion exchange 
chromatography (see section 3.4.). Eluate was monitored by flow UV 
spectrophotometry at 280 nm. Peak areas were then calculated by integration and the 
proportion of unreacted and conjugated BSA was expressed as a percentage of the 
BSA standard peak area.
Table 3.1. Composition of reaction mixtures containing BSA and poly-L-lysine.
Reactant Stock Solution 
Concentration
Reaction M ixture
- A B C D E F
BSA 16mg/ml 0.5ml 0.5ml 0.5ml 0.5ml 0.5ml 0.5ml
pLL (219) - - 5 mg 5mg 5 mg 5mg 5 mg
EDC 25mg/ml - - 0.3ml 0.4ml 0.5ml 0.6ml
Hepes 50mM(pH 7.4) 2.0ml 2.0ml 1.7ml 1.6ml 1.5ml 1.4ml
Molar Ratio 
(BSA : pLL : EDC)
1:0:0 1:1:0 1:1:357 1:1:477 1:1:596 1:1:715
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3.4. Isolation of reaction products using ion exchange chromatography.
Isolation of proteins modified with poly-L-lysine was carried out by small scale 
preparative ion-exchange chromatography. A step gradient buffer system was 
developed based on the continuous gradient described by Wagner et al, (1990) for 
the isolation of transferrin-polylysine. Separation of the reaction products was based 
on the differential elution of proteins and poly-L-lysine under low and high salt 
conditions.
SP Sepharose HP ion exchange media (strong cation, Pharmacia) was packed into 
a 1.0 cm x 20 cm glass column (Pharmacia) to give a settled volume of 2.0 cm3. 
Initially, buffer A was used as the eluent. The reaction mixture was then applied to 
the column through a syringe loading sample injector connected to a 2.0 ml 
calibrated loop. The eluate was monitored by flow UV spectrophotometry at 280 
nm. A schematic diagram of the chromatography system is provided in Figure 3.2. 
The first peak was eluted in buffer A [50 mM Hepes/IM NaCl (pH 7.9)] and 
collected in a 4.0 ml glass vial. A second peak was then eluted using buffer B [50 
mM Hepes/2M NaCl (pH 7.9)].
3.5. Synthesis of streptavidin-poly-L-lysine conjugates.
Recombinant streptavidin (Sigma) was coupled to poly-L-lysine (Mr = 28000) 
according to the general method described in section 3.3. Sixty-seven nanomoles of 
streptavidin (4.0 mg) were reacted with an equimolar quantity of poly-L-lysine (3.1 
mg; free base) in 1380 pi of 20 mM Hepes (pH 7.4) using a 600 fold molar excess of 
EDC. After incubation for 24 hours at 4°C, the reaction was terminated by 
fractionation on an ion exchange column (see section 3.4.). Fractions were collected 
in sterile 4 ml glass vials. Poly-L-lysine-streptavidin adducts were prepared under 
clean laboratory conditions to minimise microbiological contamination.
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Buffer A: 50mM Hepes/IM NaCl (pH 7.9) 
Buffer B: 50mM Hepes/2M NaCl (pH 7.9) 
Filtered (0.2 pm), degassed 
Gilson Minipuls 2, 1.0 ml/min flow rate 
Rheodyne 7132 
C 10/20 (Pharmacia)
Gilson Model 116 
BBC Servogor 120 
Milton Roy CI-4100
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3.6. Dialysis of fractions isolated by ion exchange chromatography.
Following separation by cationic exchange chromatography, the fractions isolated 
in 1M NaCl/50 mM Hepes (pH 7.9) and 2M NaCl/50mM Hepes (pH 7.9) were 
placed in dialysis tubing (10 mm flat width) with an exclusion limit of 12,000 to 
14,000 daltons (Spectrum Medical Industries, Los Angeles, CA, USA). Plastic 
closures were used to secure the ends of the tubes. Dialysis was carried out at 4°C 
for 24 hours against 1000 ml of 150 mM NaCl/50 mM Hepes (pH 7.4) in a conical 
flask with constant stirring. The buffer was changed once during dialysis. Prior to 
use, the dialysis tubing was cut to an appropriate length and boiled for 10 minutes in 
a 2 mM solution of EDTA then washed thoroughly in double distilled water. This 
washing procedure was repeated before the tubing was placed in a 100 ml Duran® 
bottle, submersed in double distilled water and autoclaved for 15 minutes at 121°C.
3.7. Analysis of conjugate composition.
Composition of conjugates and calculation of total yield was established by 
quantitative assay of samples following dialysis. Standard curves are presented in 
appendix 3.
3,7,1. Quantification of streptavidin content of conjugates.
Streptavidin content of conjugates was determined by UV spectrophotometry at 
280 nm. Poly-L-lysine does not absorb UV radiation at this wavelength. Values 
were corrected by subtracting the corresponding UV absorbance of HBS at 280 nm. 
A standard curve was prepared using streptavidin of the specific batch used in the 
synthetic reaction. A representative curve is presented in section A3.1.
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3.7.2. Ninhydrin assay for primary amines.
Poly-L-lysine content of fractions was determined spectrophotometrically 
according to the ninhydrin method modified from Blackburn, (1968). Samples (75- 
300 pi) were transferred into 16 x 150 mm test tubes and made up to 1.0 ml total 
volume with 50 mM Hepes/150mM sodium chloride (pH 7.4). Then, 1.0 ml of 
ninhydrin reagent solution (ninhydrin 20g/l-1, hydrinantin 3g/l"1, lithium acetate 1M, 
dimethylsulphoxide 75% w/v) was added and the samples vortexed. The tubes were 
capped and placed in a heating block (Techne DB-2A) pre-adjusted to 100°C. After 
exactly ten minutes, the tubes were removed and placed on ice. A 1.0 ml aliquot was 
removed and diluted to 5.0 ml with water. The absorbance of each solution was 
measured against the reaction blank, prepared from buffer, at 570 nm using a Milton 
Roy 601 spectrophotometer. A standard curve was prepared using poly-L-lysine (see 
section A3.2.). Triplicate assays were conducted for each sample and the mean value 
used for calculation of polymer concentration. At the concentrations present in the 
conjugate samples, streptavidin produced negligible responses.
3.8. Electrophoresis of fractions isolated by ion exchange chromatography to 
confirm their identity.
Following ion exchange chromatography, purified fractions were analysed by 
SDS/PAGE, PAGE and affinity blotting to determine their constituents. 
Electrophoresis was carried out in the Mini-Protean® system (Bio-Rad) using de­
naturing and native 15% polyacrylamide gels prepared according to the formulations 
in Table 3.2.
Sample preparation for SDS-PAGE was by boiling one volume of eluate with 0.2 
volumes of sample buffer for 10 minutes. Electrophoresis was carried out at 200V 
until the tracking dye, or appropriate prestained marker, reached the bottom of the
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gel. Native gels were prepared for PAGE in a similar manner, although sodium 
dodecyl sulphate was removed from both the gel formulation and sample buffer. 
Samples prepared for PAGE were not boiled.
3.8.1. Visualisation of proteins.
After electrophoresis, gels were removed from the glass plates and proteins were 
either stained directly or transferred to nitrocellulose for subsequent reaction with 
biotin-DAPA-peroxidase (Sigma).
Directly stained gels were soaked, with gentle agitation in 0.1 % w/v Coomassie 
Brilliant Blue R-250 in 50 % methanol/10% acetic acid for 60 minutes. Gels were 
then destained in 10% methanol/20 % acetic acid until the background stain was 
removed. Gels were dried onto filter paper using a Model 583 slab dryer (Bio-Rad). 
A drying temperature of 70°C and a 60 minute cycle was used for mini-gels.
3.8.2. Affinity blotting of biotin binding proteins.
Following separation by electrophoresis, proteins were transferred onto 
nitrocellulose membranes (0.45 pm pore size, Bio-Rad) according to the western 
blotting method modified from Towbin et al, (1979). Transfer was carried out using 
a Mini-Trans blot cell (Bio-Rad), (25 mM Tris, 192 mM glycine and 20 % v/v 
methanol, pH 8.3), at 100V for one hour.
Transferred streptavidin was detected using a biotin-DAPA-peroxidase conjugate, 
prepared from Type VI horseradish peroxidase (Sigma). Blots were first washed for 
one hour with gentle agitation in TBS containing 0.15% v/v Tween 20. This blocked 
unbound sites on the nitrocellulose membrane. Following this blots were then rinsed 
thoroughly in TBS and soaked, with gentle agitation, in TBS/0.15% Tween 20 
containing 2 pg/ml biotin-DAPA-Peroxidase for 3 hours at room temperature. This
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solution was removed, and the blots washed again with TBS. Blots were visualised 
with freshly prepared developing solutions. Immediately before developing the blot, 
0.5 ml of 3% w/v 4-chloro-l-napthol in methanol and 50 pi of 6% w/v hydrogen 
peroxide was added to 50 ml of 10 mM Tris (pH 7.4). The blot was exposed to the 
developing solution (4-chloro-l-napthol 30 pg/ml, hydrogen peroxide 60 pg/ml, 10 
mM Tris, pH 7.4) for 30 minutes. This solution was warmed slightly to speed the 
reaction. Colour development was allowed to proceed for 30 minutes before the 
reaction was stopped, to avoid high background, by washing with distilled water.
Table 3.2. Composition of running gel and stacking gel for SDS-PAGE.
Constituent Running Gel (15%) Stacking Gel (5%) Sample buffer
Stock 1 10.0 ml 1.7 ml -
SDS 10% w/v 0.2 ml 0.1 ml 5 ml
1.5M Tris pH 8.8 5.0 ml - -
0.5M Tris pH 6.8 - 1.25 ml 2.5 ml
Distilled Water 4.6 ml 6.8 ml 5 ml
AMPS 10% w/v 0.2 ml 0.1 ml -
TEMED 10 pi 10 pi -
2-mercaptoethanol - - 0.25 ml
Bromophenol Blue 
5% w/v - - 0.2ml
Glycerol - - 2.5 ml
Stock 1: 30% w/v acrylamide and 0.8 % w/v N,N'-methylene-bis-acrylamide 
(Bis) Final acrylamide concentration = 15% in the running gel and 5% in the 
stacking gel.
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3.9. Formation of streptavidin-poIy-L-Iysine-DNA complexes.
Complexes of various streptavidin-polylysine:DNA ratios were formed by adding 
a solution containing 0-4.2 pg of the polypeptide (77 pg/ml; calculated as free 
polylysine) to a solution containing 6 pg DNA (24 pg/ml). The complexation 
reaction was otherwise as described in section 2.4.
3,9.1. Analysis of DNA complexation.
Throughout this study two batches of streptavidin-polylysine conjugates (Bn 001 
and Bn 002) were prepared using the synthetic method described in section 3.5. The 
composition of conjugates was analysed as described in section 3.7. In addition, to 
ensure reproducibility, the ability of differing batches of Str-pLL to complex DNA 
was compared by spectrofluorimetry (see section 2.5.1.).
RESULTS.
3.10. The effect of EDC concentration on the conjugation of BSA to polylysine.
Data illustrating the influence of EDC concentration on the conjugation of BSA 
and poly-L-lysine are described in Table 3.3. Varying the relative concentration of 
EDC (BSA:pLL:X) gave an increase in BSA eluted in buffer B, from 9.6 % (at 1:1:0) 
to 83.8 % (at 1:1:715). This was accompanied by a decrease in BSA eluted in buffer 
A. The curves illustrating the relationship between conjugation of BSA and EDC 
concentration were linear at lower concentrations, with deviation from linearity at 
higher concentrations (Fig. 3.3). Mixing of BSA and poly-L-lysine in the absence of 
the coupling reagent resulted in the elution of 9.6% of BSA in buffer B suggesting a 
non-covalent interaction between the reactants. The mean yield of BSA eluted in
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buffer A and buffer B was 96.4% of the standard peak area, indicating a minimal loss 
of protein during product isolation.
Table 3.3. Conjugation of BSA and poly-L-lysine (219). Equimolar quantities of 
BSA and polylysine were coupled using increasing quantities of EDC in 50 mM 
Hepes (pH 7.4). Reaction mixtures were separated by ion exchange chromatography 
as described in section 3.4. The quantity of BSA eluted in each buffer is expressed 




Percentage of BSA 
input eluted in Buffer A 
Mean (Min ; Max)
Percentage of BSA 
input eluted in Buffer B 
Mean (Min ; Max)
Percentage of BSA input 
eluted in Buffer A and B 
Mean (Min ; Max)
n
1:1:0 89.1 (83.7 ; 96.4) 9.6 (4.9; 17.0) 98.8 (94.3 ; 100.7) 3
1:1:238 54.2 (52.9; 55.5) 37.9 (37.4; 38.4) 92.1 (90.3 ; 93.9) 2
1:1:357 39.3 (35.4; 44.5) 60.2 (58.1 ; 62.2) 99.5 (93.5 ; 106.7) 3
1:1:477 24.8 (24.2; 25.3) 71.6 (68.0; 75.7) 96.4 (93.3 ; 96.0) 3
1:1:596 17.5 (14.9; 23.3) 76.8 (71.8; 81.2) 94.3 (86.7 ; 104.5) 3
1:1:715 13.6(12.1 ; 16.2) 83.8 (80.3 ; 89.3) 97.4 (92.4; 101.7) 3
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Figure 3.3. Conjugation of BSA and poly-L-lysine (219). BSA and pLL were 
coupled using increasing quantities of EDC (Molar ratio BSA:pLL:EDC=l:l:X). The 
reaction mixtures were separated using ion exchange chromatography. The 
proportion of BSA eluted in buffer A (Panel A) and buffer B (Panel B) was 
calculated as a percentage of the BSA standard peak area. The mean (■), minimum 
(•)  and maximum (A) values are shown for each EDC concentration.
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3.11. Isolation of streptavidin-poly-L-lysine conjugates by cation exchange 
chromatography.
Streptavidin-poly-L-lysine was separated from the reaction mixture using the 
chromatography system described in section 3.4. A representative chromatogram for 
the separation is shown in Figure 3.4. Peak A was eluted in 1M NaCl/50 mM Hepes 
(pH 7.9). A second peak (B), which was believed to contain the product, was then 
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Figure 3.4. Purification of streptavidin-poly-L-lysine(219) conjugates. Separation of 
reaction mixtures was by cation-exchange chromatography.
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3.11.1, Identification of peak constituents.
Following separation peak fractions were analysed by qualitative ninhydrin assay, 
gel electrophoresis and affinity blotting to identify the fraction containing the 
streptavidin modified polylysine conjugate. Initial qualitative ninhydrin tests 
indicated the presence of polyamines in fraction B; a positive colour reaction was 
observed after 5 minutes. Fraction A was negative for primary amines. In each case 
the volume of the samples analysed were adjusted to compensate for variation in the 
streptavidin content. Fraction's A and B both contained streptavidin as indicated by 
A280 values.
To examine the coupling of streptavidin and poly-L-lysine, ion exchange fractions 
were analysed by SDS-PAGE. The electrophoretic pattern of proteins eluted in 
buffer A and B were identical, showing a major doublet band at a mass less than 18.5 
kDa and a minor band at 32 kDa (Fig. 3.5.). A positive reaction to biotin-DAPA- 
peroxidase was also exhibited by these bands on affinity blotting. The multiple 
bands are likely result from the method used to isolate the streptavidin (Bayer et al, 
1986). To determine if the apparent migration pattern indicated chemical instability 
of the conjugate, or resulted from the disruption of protein secondary structure, 
samples were also analysed by PAGE. However, as the undenatutred form of this 
protein stained poorly with coomassie blue reagent, detection was carried out using 
biotin-conjugated-peroxidase after electro-transfer onto nitrocellulose membranes. A 
representative result obtained for the streptavidin-polylysine conjugate is shown in 
Figure 3.6. In this non-denaturing system, streptavidin migrated as a single band and 
gave a specific reaction to biotin-DAPA-peroxidase. Streptavidin was detected in 
fraction A but was not seen in fraction B. This result indicates the absence of free 
streptavidin in the reaction product. The positively charged streptavidin-polylysine 




Figure 3.5. SDS-PAGE analysis of ion-exchange fractions. Protein was detected by 
coomassie blue staining. Lane 1, Molecular weight standards; Lane 2, Fraction A; 
Lane 3, Fraction B.
Streptavidn a  B
8mq 4ng
Figure 3.6. Affinity blot analysis of fractions purified by ion-exchange 
chromatography. Aliquots of fractions A and B containing streptavidin (1.2 pg) 
were analysed using PAGE and electro-eluted onto nitrocellulose membranes as 
described in section 3.8.2. Streptavidin was detected using biotin-DAPA-peroxidase. 
Control lanes of unreacted streptavidin were also included.
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3.11.2. Quantitative analysis of conjugate composition.
During this study two batches of conjugates containing poly-L-lysine modified 
with streptavidin were prepared. Results from quantitative analysis of these batches 
following dialysis is shown in Table 3.4. The yield of conjugate and the level of 
streptavidin substitution of polylysine was similar for each batch. These data were 
used in calculating the polycation concentration for complexation studies












001 67 68 39 (57.4%) 17.3 (25.8 %) 1:0.44
002 67 68 33 (47.8%) 14.0 (20.9 %) 1:0.43
3.12. Complexation of DNA using streptavidin modified polylysine.
Figure 3.7. shows the mobility shift assay performed on complexes formed 
between streptavidin modified polylysine and pRSVlacZ-DNA. Movement of 
plasmid-DNA was initially retarded at a DNA-to-polypeptide mass ratio of 0.14:1 
with the amount of unbound plasmid decreasing with increasing polymer 
concentration. Complete association of plasmid DNA into complexes was seen at 
the mass ratio of 0.37:1. Further analysis of DNA condensation was carried out 
using the ethidium bromide exclusion assay described in section 2.5.1. Following 
appropriate dilution's the exclusion of ethidium bromide produced by each batch of 
conjugate was similar; a reduction of fluorescence intensity to background levels 
being achieved at a polypeptide-to-DNA mass ratio of 0.43:1 which corresponds to a 
charge ratio (+/-) of 1.1. In the calculation of charge ratios, corrections were not 
made for the streptavidin, which would be negatively charged at pH 7.4, as it was 
considered that only positively charged poly-L-lysine molecules would be involved 
with DNA condensation.
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M a s s  R a tio  0:1 0.14:1 0.23:1 0.37:1 0.43:1 0.53:1 0.63:1 0.70:1
  -.........
Figure 3.7. Analysis of pRSVlacZ complexed with increasing amounts of 
streptavidin-polylysine. Complexes were prepared as described in section 3.8 and 
resolved through a 1% agarose gel. 0:1 represents pRSVlacZ only; bands represent 







Figure 3.8. Effect of formulation in terms of polymer:DNA mass ratio on 
fluorescence intensity for the quantitative assessment of batch variation. After 
appropriate dilution of stock solutions complexes were formed between pRSVlacZ 
and batch 001 (■) and batch 002 (•) of streptavidin-poly-L-lysine adducts.
74
3.13. Discussion.
3.13.1. Conjugation of bovine serum albumin and streptavidin to poly-L-lysine 
using l-ethyl-3-(3-dimethylaminopropyl)carbodiimide.
The conjugation of the 60 kDa biotin binding protein streptavidin to a cationic 
polypeptide (polylysine) was achieved using a simple one step procedure employing 
EDC to create an amide bond between carboxylic acid residues on the protein and an 
amine group on the polymer. This reaction has been used previously for the coupling 
of asialorosomucoid to polylysine with separation of the products and reactants 
achieved by FPLC (Cristiano et al, 1993). In this study cation-exchange 
chromatography followed by dialysis was used to isolate the conjugates.
Bovine serum albumin (BSA) appeared to provide a good model compound for 
initial conjugation reactions as a result of similarities in size and charge to 
streptavidin. Therefore, the optimal conditions for the preparation of streptavidin 
modified polylysine were determined from experiments with BSA. The preparation 
of a streptavidin modified polylysine conjugate was first documented by Wagner et 
al, (1992a). However, this strategy requires the modification of polylysine to give a 
reactive group which is then coupled with 3-(2-pyridyldithio)propionate-modified 
streptavidin. The protein and polycation are linked through a reducible disulphide 
bridge. In contrast to the above method, using EDC to couple streptavidin and 
polylysine would yield a stable amide bond between the reactants and does not 
require the purification of intermediates.
The pH chosen for the reaction of protein and polypeptide was a compromise 
since the EDC link to acid residues is promoted by hydrogen ions whilst lysine 
residues are more reactive at elevated pH where amine groups are predominantly 
unprotonated. Reactions were, therefore, carried out at pH 7.4. Experiments to
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determine the optimum quantity of EDC for coupling of BSA to poly-L-lysine gave 
the expected results; conjugation efficiency was directly related to the concentration 
of EDC in the reaction mixture (BSA and pLL constant). An apparent complexation 
of poly-L-lysine and BSA was also observed without EDC (9.6 % of BSA input 
eluted in buffer B). This was thought to result from an ionic interaction between the 
polypeptides; the possibility of which is indicated by the relative pi values for BSA 
(4.0) and poly-L-lysine (11.5). The curvilinear relationship between conjugation 
efficiency and EDC concentration suggested coupling was limited by level of 
reactants. However, as the structure of poly-L-lysine provides a large molar excess 
of reactive sites then the plateau in conjugation efficiency was therefore more likely 
to be related to formation of active intermediates with carboxyl groups of BSA. It 
was unlikely that all these residues will be accessible due to the globular nature of 
the protein.
Using this data a 600 fold molar excess of EDC was selected for the reaction of 
streptavidin and polylysine. In preliminary experiments these reaction conditions 
had yielded a high level of conjugation between BSA and polylysine with 76% of 
BSA conjugated to poly-L-lysine. However, as these conditions resulted in only 47% 
of applied streptavidin being coupled to poly-L-lysine then the ideality of BSA as a 
model protein was questioned. The analysis of protein sequence data for BSA and 
streptavidin (Seqnet, SERC, Daresbury, UK.) showed the former to possess a greater 
number of acidic residues available for linking to polylysine (99 versus 52). If a 
similar proportion of these residues are accessible in each protein then it is likely that 
the number of reactive sites on streptavidin was limiting. The yield of streptavidin in 
the modified conjugate was calculated from the weight of starting reactants and at 
25.8% of input for Batch 001 was significantly lower than that described by Wagner 
et al, (1992a) for a similar conjugate (56% of input) prepared using N-succinimidyl 
3-(2-pyridyldithio)propionate.
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3.13,2. Separation of reaction products by ion exchange chromatography.
Separation of the reactants and products was successfully achieved using cation 
exchange chromatography. The excess of uncoupled streptavidin was eluted first 
using 1M NaCl/50mM Hepes (pH 7.9); streptavidin-poly-L-lysine adducts were 
retained on the column due to their high positive charge density and were only eluted 
on changing the buffer to 2M NaCl/50mM Hepes (pH 7.9). This second peak gave a 
positive colour reaction for amines with ninhydrin.
Initial attempts to validate the isolation process by analysis of fractions by SDS- 
PAGE failed to detect any difference in the rate of migration of protein eluted in 
buffers A or B. This raised the possibility that following isolation the conjugate was 
unstable resulting in separation of streptavidin from the cationic DNA binding 
moiety. However, non-covalent interactions between protein sub-units are known to 
be sensitive to denaturing conditions. Indeed, Sheldon et al, (1992) have described 
the dissociation of sub-units from a monoclonal antibody-streptavidin conjugate 
during separation by SDS-PAGE. In this system, protein sub-units subsequently 
migrated at an Mr of 15 kDa. SDS-PAGE was unsuitable for analysis of coupling as 
the detergent component off the system promoted dissociation of the non-covalently 
bound protein sub-units. Conjugate stability was, therefore, confirmed by analysis of 
samples on a native polyacrylamide gel and transfer of protein to a nitrocellulose 
membrane. In this case a reactive streptavidin band was detected in the sample from 
the first peak but was not present in the product fraction. The streptavidin-polylysine 
adducts, which have a high positive charge density, are unable to enter the gel. 
These results are consistent with the isolation of the product under high salt 
conditions [2M NaCl/50 mM Hepes (pH 7.9)] with unreacted streptavidin eluted in 
1M NaCl/50 mM Hepes (pH 7.9).
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3.13.3. DNA complexation by streptavidin-poly-L-lysine.
As expected from the work described by Wagner et al, (1991), poly-L-lysine 
retained the ability to complex and condense DNA following derivatisation with a 
large protein molecule. Gel mobility shift assays indicated a decrease in free plasmid 
DNA as a function of increasing polypeptide concentration. Indeed, comparison of 
the fluorescence quenching profiles produced by the native and derivatised cationic 
polymer showed condensation was induced at the same polypeptide-to-DNA mass 
ratio (calculated as polylysine). Furthermore, the streptavidin modified polylysine 
adducts from each batch of conjugate appeared to complex DNA in a similar manner. 
It was therefore likely that complexes would behave similarly in the in vitro 
transfection experiments.
3.14. Summary.
The carbodiimide method of conjugation gave a streptavidin-modified polylysine 
conjugate that retained the ability to bind and condense DNA. This conjugation 
method proved to be reproducible between batches. However, the reaction was 
inefficient in comparison to the method described by Wagner et al, (1992a) although 
it conferred two distinct advantages; the procedure was less complex requiring a 
single chromatographic separation and the linkage formed was non-reducible making 
it more applicable for use in biological systems. Ion exchange chromatography was 
suitable for isolation of the reaction product, which was free from unconjugated 
streptavidin. This product was used for receptor-mediated gene delivery studies and 
to examine the formulation requirements for this process.
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Chapter 4
Transfection of B16 murine melanoma cells.
Prior to the construction of poly-L-lysine-DNA-ligand complexes for gene 
targeting studies it was necessary to determine the ability of the carrier system to 
transfer DNA in vitro. The studies presented here aim to determine the factors which 
influence gene transfer using streptavidin-poly-L-lysine-DNA formulations; changes 
in complex composition, dose, dosing schedule, and external factors such as the time 
course of expression, presence of serum and conjugate stability are examined. To 
determine the optimal conditions for delivery using polycation systems the addition 
of agents that affect the survival of transfected DNA in the intracellular environment 
was also assessed. Finally, histone HI was tested as an alternative carrier protein.
4.1. Cell Culture.
Minimum Essential Medium with Earle's salts, RPMI-1640 medium, MEM 
vitamin solution, MEM non-essential amino acids, and penicillin/streptomycin were 
obtained from Gibco (Paisley). Fetal calf serum was purchased from ICN/Flow 
(High Wycombe). Water was freshly double distilled, deionised and autoclaved at 
121°C for 15 minutes. Tissue culture flasks were from Falcon and 6 well plates from 
Nunc.
4.1.1. Cell line maintenance and subculture.
B16 mouse melanoma cells were donated by L.R. Kelland (Institute of Cancer 
Research, Sutton). Cells were maintained in a LEEC anhydric incubator at 37°C in a 
humidified atmosphere under standard conditions of 95% air/5% C 02. In order to 
maintain a pH of 7.2-7.4, the medium was routinely changed the day before the cells
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reached confluence. Subculture was undertaken with confluent cells by washing the 
cell monolayer twice with PBS and then incubating with a sufficient volume of 
0.02% w/v EDTA/PBS for 10 minutes. Detached cells were then diluted to 10 ml 
with culture medium and each 175 cm2 flask inoculated with 2 x 106 cells. For 
transfection experiments, cells were grown in MEM medium containing 10% fetal 
calf serum (FCS), 2 mM L-glutamine, 1% MEM non-essential amino acids, 50 IU/ml 
penicillin, and 50 mg/ml streptomycin. Cells used in receptor binding experiments 
were grown in RPMI-1640 medium (see section 6.4.). The same routine was used to 
maintain cultures for this assay.
4.2. Analysis of p-galactosidase expression.
Gene transfer efficiency was determined in vitro using plasmid DNA which 
encoded the E.coli lacZ gene for p-galactosidase under the control of the Rous 
sarcoma virus long terminal repeat sequence. Use of reporter gene technology to 
monitor delivery efficiency obviated the difficult and time consuming need for direct 
assays of mRNA. The use of the lacZ gene allowed several assays to be performed. 
Total enzyme activity was determined in cell extracts using a spectrophotometric 
method based on the conversion of o-nitrophenol-p-D-galactopyranoside (ONPG) to 
the chromophore o-nitrophenol (Miller, 1972). This assay was performed on cell 
extracts and standardised by determining the total soluble protein content of each 
well. Distribution of expression within cell populations was determined either 
histochemicaily, using 5-bromo-4-chloro-3-indolyl-p-D-galactopyranoside (X-gal) 
using the method described by MacGregor et al, (1991), or quantitatively by flow 
cytometry (Nolan et al, 1988).
4.2.1. Preparation of cell extracts.
The medium was removed from the culture and the cells washed three times with 
5 ml of PBS. A 1.0 ml aliquot of PBS was then added to the plate and the cells
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removed by gentle scraping with a cell scraper and transferred to a 1.5 ml 
microcentrifuge tube. When multiple extracts were prepared, the cell scraper was 
washed in 70% ethanol, rinsed in water and blotted dry between samples. Cells were 
collected by centrifugation and resuspended in 250 pi of 0.1 M sodium phosphate 
buffer (pH 7.4). The cells were then resuspended and subjected to three freeze thaw 
cycles (freeze in a dry ice-ethanol bath and thaw at 37°C). The sample was 
centrifuged for 5 minutes at 5,000 rpm and the supernatant carefully removed to a 
clean microcentrifuge tube. Extracts were analysed immediately.
4,2,2. Quantitative assay of $-galactosidase activity in cell extracts.
Cell extract supernatant (5-100 pi) was adjusted to 300 pi total volume using 
double distilled water. An equal volume of 2X ONPG assay buffer (1.35 mg/ml o- 
nitrophenylgalactopyranoside, 2 mM MgCl2, 100 mM 2-mercaptoethanol, 200 mM 
sodium phosphate, pH 7.3) was then added to the cell extract solution, mixed, and 
incubated in a water bath at 37°C. Prior to mixing, all solutions were pre­
equilibrated at 37°C for 10 minutes. A blank reaction, which contained no cell 
extract, was also prepared. After exactly 30 minutes the reaction was terminated by 
the addition of 1.0 ml 1M sodium carbonate. Reaction mixtures were then 
transferred to disposable microcuvettes and the absorbance of the solution measured 
at 420 nm. A standard curve for this assay was prepared using purified E.coli (3- 
galactosidase (Promega) and is presented in section A3.3. Total enzyme activity in 
cell extracts was expressed as milliunits or converted to relative activity by dividing 
the amount of p-galactosidase (milliunits) recovered per well by the amount of 
protein (milligrams) remaining in each well at the end of the period allowed for gene 
expression. In this thesis, total activity data is presented when the toxicity of test 
conditions reduced cell viability.
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4.2.3. Quantification o f soluble protein in cell extracts.
The soluble protein content of cell extracts was determined using DC assay 
reagent (Bio-Rad). This assay is based on the method of Lowry et al, (1951). For 
assaying protein, 25-100 pi of cell extract supernatant was added to 100 mM sodium 
phosphate buffer, pH 7.4 to give 100 pi total volume. The assay was then performed 
in accordance with manufacturer's instructions. Absorbances were measured at 750 
nm. Standard curves were prepared using bovine serum albumin. A representative 
curve is presented in section A3.4.
4.2.4. In situ cytochemical staining for $-galactosidase activity.
B16 melanoma cells transfected with the P-galactosidase reporter gene were 
detected, in situ, using a method modified from MacGregor et al, (1991). Forty eight 
hours after transfection the growth medium was removed from the adherent cell 
monolayers. The cells were then washed twice with PBS and over-layered with 
fixative solution (1% glutaraldehyde, 1 mM magnesium chloride, 100 mM sodium 
phosphate) for five minutes at 4°C. The fixative solution was removed by two 
washes with PBS. A 2% w/v solution of X-gal in dimethylformamide was diluted to 
2 mg/ml in 3.3 mM potassium ferrocyanide, 3.3 mM potassium ferricyanide, 1 mM 
magnesium chloride, 150 mM sodium chloride and incubated with the cells for four 
hours in a humidified atmosphere at 37°C. All solutions were prepared in glass. 
After staining, cells were washed three times with PBS and then examined under a 
light microscope. Cells expressing the lacZ gene hydrolyse the chromogenic 
substrate X-gal to give the dye bromochloroindole. A positive reaction is seen as a 
blue colour against an unstained background.
4.2.5. Analysis o f $-galactosidase expression by flow cytometry.
The proportion of the total cell population which expressed p-galactosidase 
following transfection with pRSVlacZ was determined by FACS analysis using the
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method described by Nolan et al, (1988). A 200 mM stock solution of the 
fluorescent probe fluorescein-di-(3-D-galactopyranoside (FDG) was prepared by 
dissolving 1.5 mg of the pale yellow solid in 11.4 pi of DMSO:water (1:1 v/v). Since 
the mixing of DMSO and water is exothermic it was necessary to cool the mixture 
before dissolving FDG. The 2 mM working solution of FDG was prepared by 
adding 11 pi of 200 mM FDG to 1090 pi water and was stored in 300 pi aliquots at 
-20°C. Staining medium (SM:10 mM Hepes, 4% v/v FCS: pH 7.4) was prepared 
immediately before use using 2x SM salts and fetal calf serum.
4.2.5.1. Cell preparation and FDG staining.
Medium was removed from the confluent culture and the cells were washed twice 
with 2.0 ml PBS. Adherent cells were removed using 0.02% w/w EDTA/PBS, 
transferred to a 1.5 ml microcentrifuge tube and collected by centrifugation at 10,000 
rpm for 10 minutes. The cell pellet was resuspended in 250 pi SM and a 50 pi 
aliquot of the cell suspension transferred to a 4 ml FACS tube (Falcon). The tube 
containing the cell suspension was then placed in a water bath for 10 minutes at 37°C 
before 50 pi of prewarmed 2 mM FDG was added. The suspension was mixed 
rapidly by vortexing and returned to the 37°C water bath for exactly 60 seconds. 
FDG is passively taken up into the cells during this brief hypotonic shock. Loading 
was stopped by the addition of 1900 pi of ice cold isotonic SM and the tube placed 
on ice for 60 minutes to allow FDG hydrolysis. SM was transferred using automatic 
pipette tips chilled at -20°C. Immediately prior to FACS analysis 10 pi propidium 
iodide (20 mg/ml) was added to each sample. Analysis was performed with live 
gating as described in section 4.10. Compensation was made for cell 
autofluorescence by incubating untransfected cells with 50 pi of water during the 
loading step. Endogenous p-galactosidase activity of B16 cells was measured by 
incubating untransfected cells with FDG.
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4.3. Transfection of B16 melanoma cells.
For gene transfer experiments, cells were removed from adherent cultures using 
the method described in section 4.1.1. and plated at a density of 1 x 105 cells per well 
of a six well plate (35 mm diameter). The cells were then allowed to grow at 37°C 
for 16-18 hours to achieve 40-50% confluence before the medium was replaced with 
1.5 ml of pre-warmed MEM+10% FCS. After 60 minutes, 0.5 ml HBS (pH 7.4) 
containing the test substance was added dropwise to each well and the mixture 
swirled gently to give an even distribution. The cells were then incubated at 37°C in 
5% C02 for four hours. At the end of this period the transfection medium was 
aspirated and cells were washed twice with ice-cold MEM+10% FCS. Cells were 
then incubated under the standard cell culture conditions for 48 hours in 2.0 ml of 
complete medium before p-galactosidase activity was quantified.
4.3.1. Transfection o f B16 cells using streptavidin-poly-Lrlysine-DNA complexes.
Unless otherwise stated B16 melanoma cells were transfected using streptavidin- 
poly-L-lysine complexes prepared at a polypeptide-to-DNA mass ratio of 0.63:1 
using the method described in section 3.8. It has previously been established that at 
this mass ratio the movement of plasmid DNA was completely retarded (section
3.12.). In all cases the volume of buffer in which the delivery system was 
administered was adjusted to 0.5 ml.
4.4. Influence of chloroquine on gene transfer.
Transfections were performed in the presence or absence of 100 pM chloroquine 
using streptavidin-poly-L-lysine-DNA complexes containing 6 pg pRSVlacZ. To 
test the influence of the cationic carrier polymer, cells were also incubated with an 
equivalent mass of free pRSVlacZ. Chloroquine (Sigma) was prepared as a 100 mM 
solution in water, sterilised by passing through a 0.2 pm filter, and stored at -20°C. 
Immediately before use, this solution was diluted to 10 mM with HBS (pH 7.4) and a
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20 |il aliquot added into the medium. The plate was then swirled and complexes or 
plasmid DNA added to the cells. Cells were then treated as in section 4.3.1.
4.4,1. Dose response effect of chloroquine on gene transfer.
The experimental procedure in this case was as described in section 4.4. except 
that the concentration of chloroquine was varied. Immediately prior to introducing 
streptavidin-poly-L-lysine complexes, aliquots of the diluted chloroquine solution 
were added into the medium to give concentrations of 25, 50, 75, 100 and 150 pM. 
Cells were then treated as described in section 4.3.1.
4.5. Influence of polypeptide concentration on transfection efficiency.
The transfection procedure was as described in section 4.3. Complexes 
containing a fixed mass of pRSVlacZ (6 pg) and 0, 0.8, 1.4, 2.2, 2.6, 3.2, 3.8, 4.2, 
and 5.6 pg streptavidin-poly-L-lysine (calculated as free polylysine) were formed in a 
final volume of 0.5 ml HBS. Transfections were carried out in the presence of 100 
pM chloroquine.
4.6. Effect of serum and time of harvesting on transfection efficiency.
In these experiments, cells were transfected using a method modified from that 
described in section 4.3.1. Cells were grown overnight in complete medium as 
previously described. One hour before transfection the complete medium was 
removed and the cell monolayer washed twice with either MEM+10% FCS or serum 
free MEM. The cells were then incubated with 1.5 ml of the appropriate medium for 
60 minutes before the test substance was added. Transfections were performed in the 
absence or presence of serum (final concentration = 7.5% v/v) for the duration of the 
incubation period. Transfections were carried out in the presence of 100 pM 
chloroquine. Following a 4 hour exposure to DNA cells were treated as described in 
section 4.3.1. Cells were harvested 24,48 and 72 hours after transfection.
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4.7. Optimal DNA dose for transfection.
Cells were transfected using a protocol modified from that described in section
4.3.1. One hour before addition of complexes, growth medium was aspirated from 
each well and replaced with 1.38 ml of pre-warmed MEM+10% FCS. Cells were 
then incubated with 0, 125, 250, 375, 500, and 625 pi aliquots of the complex 
suspension which corresponded to doses of 0, 1.5, 3.0, 4.5, 6.0, and 7.5 pg 
pRSVlacZ respectively. The volume of medium was then adjusted to 2.0 ml with 
HBS (pH 7.4). Cells were then treated as described in section 4.3.1.
4.8. DNA stability in serum.
Streptavidin-poly-L-lysine-DNA complexes were prepared as described in section
3.8. Six micrograms of free DNA in 500 pi HBS, or complexes containing an 
equivalent mass of pRSVlacZ, were incubated for 4 hours at 37°C with 1.5 ml of 
MEM or MEM+10% FCS. The influence of nuclease activity on DNA stability was 
assessed by substituting the complete growth medium with MEM+10% FCS which 
had been heat treated at 56°C or 90°C for 30 minutes. After incubation of the DNA, 
a 40 pi aliquot was removed from each sample and mixed with 10 pi gel loading 
buffer. Thirty two microlitres of this mixture were analysed on a 1% agarose gel.
4.8.1. Availability ofcomplexed DNA to enzymatic degradation.
Bovine pancreatic DNase I (Sigma) was dissolved at a concentration of 0.25 
units/pl in 0.15 M NaCl/50% glycerol and stored at -20°C according to the method 
described by Sambrook et al, (1989). Samples containing 6 pg of pRSVlacZ or 
streptavidin-polylysine-DNA complexes were prepared in 500 pi HBS. To each 
sample 5 pi 1M MgS04 was added to give a final concentration of 10 mM Mg++. 
Each mixture was then divided into two samples and 4 units DNase I was added to 
one of the two samples. The mixtures were incubated for 10 minutes at 4°C. Then a
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40 |il sample was removed and mixed with 10 pi gel loading buffer before 10 pi 
aliquots were analysed on a 1% agarose gel.
4.9. Association of polypeptide-DNA complexes with B16 melanoma cells.
Analysis of the kinetics of association of a positively charged polypeptide-DNA 
complex with B16 melanoma cells was analysed using flow cytometry. Fluorescein 
labelled poly-L-lysine(219)-pRSVlacZ complexes were prepared at a DNA-to- 
polypeptide mass ratio of 0.6:1 as described in section 2.7.2. Cells were then 
incubated with these positively charged complexes for 30, 60, 120, 180 and 240 
minutes at 37°C in the presence of 100 pM chloroquine. At the appropriate time 
point, adherent cells were washed twice with 1.0 ml of PBS and then removed using 
0.02% w/v EDTA. Cells were transferred to a 1.5 ml microcentrifuge tube, collected 
by centrifugation, washed and resuspended in 1.0 ml of PBS. Cell fluorescence 
intensity, relative to control cells, was measured at each time point as described in 
section 4.10. Comparison of the association of complexes with cells over time was 
made by comparing the mean fluorescence intensity after correction for changes in 
background fluorescence.
4.10. Flow cytometry.
Flow cytometry was used in the analysis of uptake of fluorescein labelled 
polymer-DNA complexes (section 4.9.) and in quantitative analysis of transfection 
efficiency (section 4.2.5.). In each case, quantitative fluorescence analysis of cell 
populations was performed using Becton Dickinson FacsVantage at an emission 
wavelength of 530 (± 15) nm following excitation at 488 nm using an argon ion 
laser. A minimum of 104 cellular events were analysed for each sample.
4.11. Use of Histone HI as a cationic carrier polypeptide.
Histone HI-pRSVlacZ complexes were formed at polypeptide-to-DNA mass 
ratios between 0.63 and 2.3:1 and incubated with B16 melanoma cells according to
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the transfection protocol described in section 4.3. Transfection efficiency of histone 
HI was also compared with the optimised streptavidin-poly-L-lysine formulation on 
the same cell population. After 48 hours p-galactosidase activity was monitored in 
cell extracts using ONPG and expression measured at the cellular level using flow 
cytometry.
RESULTS
4.12. Requirement for chloroquine during transfection.
Cotten et al, (1990) have been successful in transfecting cells from the K-562 
erythroleukemia line using plasmid DNA complexed with transferrin-polylysine. 
However, in order to achieve expression of the p-galactosidase reporter gene in more 
than a few cells of the population, the presence of chloroquine was required during 
the transfection period. Similar results were also obtained in the transfection of B16 
melanoma cells with streptavidin-poly-L-lysine-DNA complexes (polypeptide:DNA 
(pg/pg)=0.63:1). When the complex alone was used to transfect cells, analysis 
indicated less than 2 milliunits of p-galactosidase activity per mg of soluble protein 
in each extract (Fig. 4.1.). Additionally, X-gal staining showed few or no positively 
stained blue cells (Fig. 4.2.b). Following the inclusion of chloroquine in the 
transfection medium, to a final concentration of 100 pM, a significant increase in P- 
galactosidase activity was demonstrated with analysis of cell extracts showing 416.6 
± 72.5 milliunits of enzyme activity per mg of soluble protein. A corresponding 
increase in the number of cells stained blue was observed with approximately 10% of 
cells expressing the enzyme (Fig. 4.2.c). In the absence of chloroquine gene transfer 
was 200 fold less efficient. However, transfection of cells with naked plasmid DNA 
in the presence of chloroquine did not produce significant levels of expression. 
Levels of endogenous p-galactosidase activity in this cell line were low and not 
increased by chloroquine treatment.
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chloroquine -tdioroqiine -tcHoroqiine
Figure. 4.1. Influence of chloroquine on transfection efficiency. B16 melanoma 
cells were transfected with plasmid DNA or streptavidin-poly-L-lysine-pRSVlacZ 
complexes in the presence or absence of 100 pM chloroquine. p-galactosidase 





Figure. 4.2. In situ analysis of P-galactosidase activity in B16 murine melanoma 
cells after incubation with complexes, (x 200) (a) Control, (b) Complex only, (c) 
Complex with 100 pM chloroquine. Cells expressing p-galactosidase are stained 
blue.
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4.13. Dose response effect of chloroquine on transfection efficiency.
The concentration of chloroquine used in experiment 4.4. (100 pM) was that 
detailed in the literature for transfection of HepG2 human hepatoma cells (Monsigny 
et al, 1994). The data shown in Figure 4.3.a illustrates the relationship between 
chloroquine dose, p-galactosidase activity and protein synthesis in B16 melanoma 
cells following simultaneous addition of 6 pg of complexed pRSVlacZ-DNA. An 
increase in relative p-galactosidase activity was seen at chloroquine concentrations of 
25 pM and greater. As the concentration of chloroquine in the transfection medium 
increased an inhibition of protein synthesis was also produced leading to a 
corresponding reduction in total cell number per well and in the protein content of 
cell extracts. Analysis of total enzyme activity (Fig. 4.3.b) confirmed the optimal 
dose as 100 pM and showed the increase in relative enzyme activity was not simply a 
result of the reduction in the level of cell viability. At concentrations above 100 pM 
both relative and total p-galactosidase activity decreased, although little change in 
the total protein content of each well was observed.
4.14. Influence of complex polypeptide composition on transfection efficiency.
Various ratios of streptavidin-poly-L-lysine and pRSVlacZ were tested to 
determine the optimum formulation for gene transfer. Moreover, using the gel 
mobility shift assay shown in Figure 3.7. transfection efficiency could be related to 
the extent of DNA complexation. Maximum gene expression was achieved when 
3.8 pg of streptavidin-poly-L-lysine was complexed with 6 pg pRSVlacZ (Fig. 4.4); 
at this ratio DNA was completely complexed (Polypeptide:DNA;(+/-) = 1.6). 
Transfection of cells with the 0.23:1 formulation, where DNA was significantly but 
not completely complexed, failed to increase expression above endogenous levels. 
Theoretical calculations showed that these complexes exhibited a net negative charge 
(Polypeptide:DNA;(+/-) = 0.6). Levels of p-galactosidase activity above those of the 




o  £  1200
0 °-
«  ?  1000
1  I  800
-200
TO
7 > 3  600




0 25 50 75 100 125 150









0 25 50 100 12575 150
Chloroquine concentration (ij. M)
Figure. 4.3. Influence of chloroquine on the efficiency of transfection. Cells were 
transfected in the absence and presence of 25, 50, 75, 100 and 150 pM chloroquine. 
The effect of chloroquine on relative P-galactosidase activity and cell protein levels 
is described in Panel A. Total p-galactosidase activity/well is shown in Panel B. The 
results are the mean values from two replicate transfection plates. Bars indicate 
range.
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which corresponded to a charge ratio of 1.1 (+/-). At mass ratios greater than 0.63:1, 
the optimum, increasing the proportion of polypeptide within the formulation 
resulted in a decrease in p-galactosidase activity. However, this decrease in relative 
activity was not accompanied by a reduction in protein synthesis.
0:1 0.14:1 023:1 0.37:1 0.43:1 0.53:1 0.63:1 0.70:1 0.93:1
Figure 4.4. Influence of Polypeptide:DNA ratio on gene transfer. Complexes 
formed between pRSVlacZ and increasing quantities of streptavidin-poly-L-lysine 
were incubated with B16 melanoma cells at 37°C for four hours in the presence of 
100 pM chloroquine. P-galactosidase activity was determined after 48 hours. Charge 
ratio of complexes was calculated as described in section 2.3. Each point represents 
the mean ± SEM for three replicate plates.
4.15. Effect of time of harvest and influence of serum on transfection efficiency.
Relative P-galactosidase activity was found to peak after 24 hours in the presence 
or absence of serum (Fig. 4.5.a). However, in the absence of serum a two fold higher
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level of enzyme expression was seen at this time point. Over the following 48 hours 
a decrease in expression was evident with the equalisation of the activity observed in 
the samples transfected in the presence or absence of serum. The pattern of 
expression realised from these data conflicted with the general observation that 
transient expression of gene products reaches a maximum after 48 to 72 hours. 
However, if the data are not adjusted for the quantity of total protein in each sample, 
an indirect measure of cell number, then enzyme activity is lowest after 24 hours but 
increases over the remainder of the experimental period. After 72 hours the 
experiment had to be stopped as the cells had reached confluence.
4.16. Stability of polypeptide-DNA complexes in the transfection medium.
Assessment of carrier mediated protection was determined following incubation 
of plasmid DNA or streptavidin-poly-L-lysine-DNA complexes in transfection 
medium. Analysis of stability was performed using agarose gel electrophoresis and a 
representative gel is presented in Figure 4.6. The incubation of plasmid-pRSVlacZ 
in cell growth medium containing either native serum or serum heat denatured at 56° 
C for 30 minutes, resulted in rapid degradation. In both cases (Lane 4 and 5) 
degradation was essentially complete at the end of the four hour incubation period 
with only a small quantity of linearised DNA present in Lane 4. However, plasmid 
DNA incubated in the absence of serum (Lane 3) or serum heat denatured at 90°C for 
30 minutes (Lane 6) showed migration patterns similar to control DNA (Lane 2). 
Complexed DNA, incubated for four hours in MEM (Lane 7) or in MEM+10% FCS 
(Lane 8), was retained at the top of the gel indicating that the DNA remained bound 
to the conjugate under the simulated transfection conditions. A detailed examination 
of DNA mobility, following incubation of the complex in the presence of serum, 
failed to detect the low molecular weight species characteristic of degradation (Lane 
8).
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Figure. 4.5. Effect of serum and time of harvest on transfection efficiency. 
Transfections were performed with 6 pg pRSVlacZ in the presence or absence of 
serum. Cells were harvested 24, 48 and 72 hours later and assayed for p- 
galactosidase activity. The data are presented as relative (Panel A) and total p- 
galactosidase expression (Panel B). Each point represents the mean ± SEM for three 
replicate plates.
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4.17. Availability of complexed DNA to enzymatic digestion.
The susceptibility of complexed plasmid DNA to enzymatic digestion was 
assessed by exposure to bovine pancreatic deoxyribonuclease I. The presence of 
Mg++, a co-factor for the enzyme, was required for activity. Figure 4.7. shows that 
over a 10 minute incubation period plasmid DNA was rapidly degraded by DNase at 
a concentration of 8 units/ml. Preliminary experiments showed that if the incubation 
time was increased to 120 minutes then DNA could not be detected within the gel; 
the extent of degradation being sufficiently great to prevent detection with ethidium 
bromide. As expected DNA complexed with streptavidin-poly-L-lysine at a 
polypeptide to DNA ratio of 0.63:1 was retained at the gel origin (Lane 5 and 6). 
After incubation with DNase (Lane 6) the complexed DNA retained a pattern of 
electrophoretic migration identical to that of the control (Lane 5). These findings 
confirm that pRSVlacZ is rapidly degraded in the presence of nucleases and that 
DNA within the polymer complex is unavailable for digestion.
4.18. Optimisation of the dosing schedule.
In initial experiments, cells were incubated with free or complexed DNA for four 
hours before the test substance was removed and the transfection medium replaced. 
The effect of changing the length of incubation on p-galactosidase activity is 
illustrated in Figure 4.8. After incubation of cells with the optimised complex for 60 
minutes, a small increase in enzyme activity above background levels was detected. 
After this time point relative p-galactosidase activity continued to increase 
throughout the six hour experimental period. Total p-galactosidase activity per well 
is optimal after 4 hours with a small decrease in enzyme expression produced on 
extending the incubation period to six hours. The rise in relative activity after 4 
hours is, therefore, a reflection of the increased cytotoxicity produced by prolonged 
exposure to chloroquine rather than higher gene expression. Toxicity was evident 
from a significant decrease in the protein content of samples (p<0.05, t test unpaired).
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Figure. 4.6. Stability of pRSVlacZ and DNA-polypeptide complexes incubated in 
transfection medium. Free DNA and complexes were incubated at 37°C for four 
hours under the conditions described below, analysed on a 1% agarose gel and 
visualised using ethidium bromide.
Lane 1, X DNA EcoRVHind IE; Lane 2, pRSVlacZ; Lane 3, pRSVlacZ (MEM); 
Lane 4, pRSVlacZ (MEM+10% FCS); Lane 5, pRSVlacZ (MEM+10% FCS-heat 
treated at 56°C); Lane 6, pRSVlacZ (MEM+10% FCS-heat treated at 90°C); Lane 7, 
Streptavidin-poly-L-lysine-pRSVlacZ complex (MEM); Lane 8, Streptavidin-poly-L- 
lysine-pRSVlacZ complex (MEM+10% FCS).
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Figure 4.7. Availability of complexed DNA to enzymatic digestion. pRSVlacZ DNA 
or pRSVlacZ DNA complexed with streptavidin-poly-L-lysine was incubated with 
bovine pancreatic DNase I as described in section 4.8.1. and analysed on a 1% 
agarose gel.
Lane 1, EcoRVHindHl X DNA; Lane 2, Empty; Lane 3, pRSVlacZ; Lane 4, 
pRSVlacZ+DNase; Lane 5, Streptavidin-poly-L-lysine-pRSVlacZ complex; Lane 6, 
Streptavidin-poly-L-lysine-pRSVlacZ complex+DNase.
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Figure. 4.8. Gene transfer as a function of time. Cells were transfected with 6 pg 
pRSVlacZ DNA complexed with the optimal ratio of streptavidin-poly-L-lysine. 
After incubation in the presence of 100 pM chloroquine for 60, 120, 180, 240 and 
360 minutes, cells were washed twice with ice-cold fresh medium and incubated for 
a total of 48 hours, p-galactosidase activity was then determined. Results shown are 
the mean value from two replicate transfection plates.
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4.19. Optimisation of DNA dose.
Transfection efficiency in B16 melanoma cells is dependent on the dose of DNA 
administered to the cells. Figure 4.9. shows that as the amount of DNA added to the 
cells is increased from 1.5 jig to 6 jig a 2.5-fold increase in relative P-galactosidase 
activity was produced. However, higher dose levels produced an apparent inhibitory 
effect with a 2-fold reduction in P-galactosidase activity when the dose was increased 
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Figure 4.9. Dependence of P-galactosidase activity on DNA dose. Using the 
optimised streptavidin-poly-L-lysine-DNA formulation (described in section 4.14.). 
B16 melanoma cells were incubated with 0-7.5 pg of pRSVlacZ for 4 hours in the 
presence of 100 pM chloroquine. After 48 hours cell extracts were analysed for P~ 
galactosidase activity. Data represent the mean ± SEM for three replicate plates.
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4.20. Cell association of polycation-DNA complexes.
To assess the kinetics of cationic complex uptake, flow cytometry was used to 
follow the association of a fluorescein labelled poly-L-lysine-pRSVlacZ complex 
with B16 melanoma cells. The interaction of these complexes with cells over the 
four hour experimental period is evidenced by the shift in the fluorescence 
histograms to the right (Fig. 4.10.). An increase in relative fluorescence intensity 
(mean fluorescence intensity corrected for background), was also observed (Fig.
4.11.). Between one and three hours this increase was linear. A small rise in 
background fluorescence was also seen to over this period. Importantly, the change 
in relative fluorescence over the incubation period follows a profile similar to that 
described for the increase in total p-galactosidase expression over time. This 
analysis is indicative of a dependence of gene expression on the kinetics of gene 






Figure 4.10. Complex association monitored by flow cytometry. Cells treated with a 
fluorescein labelled poly-L-lysine-DNA complex were analysed after 30 (■•■•), 60 (—), 











30 60 90 120 150 180 210 240
Time (minutes)
Figure 4.11. Uptake of complexes and gene expression as a function of time. 
Relative fluorescence intensity (•) and total p-galactosidase activity (■) were 
monitored following incubation of cells with FITC-poly-L-lysine-DNA complexes.
4.21. Transfection of B16 melanoma cells using Histone Hl-DNA complexes.
Experiments to determine the optimum histone Hl-to-DNA mass ratio for gene 
transfer to B16 cells were performed in the presence of 100 pM chloroquine (Fig.
4.12.). Under these conditions, the highest levels of p-galactosidase expression were 
seen following transfection with the 1.5:1 formulation. Similar to streptavidin- 
polylysine mediated delivery, gene expression was not seen until a critical 
polypeptide:DNA ratio was achieved. In addition, a significant decrease in 
transfection efficiency was observed with systems containing an excess of 
polypeptide; a three fold reduction in relative P-galactosidase expression was 
produced on increasing the mass ratio from 1.5:1 to 2.3:1. The transfection
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efficiency of optimised histone HI and streptavidin-polylysine complexes were also 
compared in this experiment. Histone-Hl complexes prepared at a polypeptide-to- 
DNA ratios of 1.2:1 and 1.5:1 produced levels of relative P-galactosidase activity in 
cell extracts which were significantly greater than with the optimal streptavidin- 
polylysine formulation (p < 0.05, t test unpaired). Indeed, the 1.5:1 histone HI 
complex formulation, produced two-times the activity seen with the optimised 
streptavidin-poly-L-lysine formulation. A similar difference was also apparent on 
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Figure 4.12. Influence of histone Hl-to-DNA ratio in terms of mass and charge on 
gene transfer. The optimal streptavidin-poly-L-lysine:DNA formulation was also 
tested. Complexes were incubated with B16 melanoma cells for 4 hours in the 
presence of 100 pM chloroquine. Data represents the mean ± SEM for three 
replicate plates.
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4.22. Analysis of P-galactosidase expression by flow cytometry.
Flow cytometry was used to discriminate between LacZ+ and LacZ' cells 
following transfection of cells using pRSVlacZ-DNA. Control cells incubated with 
FDG (Fig. 4.13.b) showed a small increase in relative fluorescence above that 
described for an unstained cell population (Fig. 4.13.a). This staining was associated 
with a low level of endogenous P-galactosidase activity. Cells transfected with 
pRSVlacZ developed a fluorescence distribution pattern distinct from that of the 
controls. In Figure 4.13.C , a major peak with fluorescence intensity higher than the 
autofluorescent control and a second peak with stronger fluorescence were observed. 
As the major histogram peak exhibited a fluorescence pattern similar to that seen for 
the controls, and both LacZ+ and LacZ" cells were detected on staining pRSVlacZ 
transfected cultures with X-gal, then it was thought likely that cells in this peak 
represented a negative population. The shift in the negative peak probably resulted 
from free fluorescein leaking from highly expressing cells into lacZ" cells during the 
initial hypotonic shock (M. Roederer, personal communication). Therefore, in 
determining the proportion cells expressing P-galactosidase, fixed markers applied to 
the autofluorescent control could not be used on transfected cell populations. Rather, 
a marker (Ml) was placed manually to include all cells in the second (+ve) peak and 
exclude negative cells (-ve).
4.23. Comparative analysis of transfection efficiencies by flow cytometry.
The results of studies to quantitate the ability of optimised streptavidin-polylysine 
and histone HI complexes to deliver plasmid DNA are presented in Table 4.1; the 
relative proportion of cells which were lacZ+ were compared to those that were lacZ\ 
Transfection of cells with a streptavidin-polylysine system generated p-galactosidase 
expression in 16.4 ± 0.4 % of the total cell population. However, by delivering the 
6.0 pg dose of pRSVlacZ in Histone HI complexes it was possible to increase the 
















Figure 4.13. Detection of B16 melanoma cells expressing p-galactosidase using flow 
cytometry. Cells were transfected using streptavidin-poly-L-lysine in the presence of 
100 pM chloroquine. (a) Control cells (b) Control cells; FDG stained (c) pRSVlacZ 
transfected cells.
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Formulation Events Cells Positive(±SD) % Positive(±SD) n
Streptavidin-polylysine 10000 1612 ±44 16.1 ±0.4 3
Histone HI 10000 2637 ± 93 26.4 ± 0.92 3
Table 4.1. Expression of P-galactosidase in B16 cells following transfection using 
Streptavidin-polylysine and histone HI. The proportion of the cell population 




4.24.1. Gene transfer using streptavidin-polylysine: The influence of chloroquine.
When streptavidin-poly-L-lysine complexes were incubated with B16 melanoma 
cells without chloroquine, appreciable expression did not occur. This was 
demonstrated by the lack of cells staining positive following treatment with X-gal 
and the low levels of total P-galactosidase activity found in cell extracts. To 
determine whether expression was limited by the degradation or trapping of DNA 
within the endosomal/lysosomal trafficking pathway, cells were incubated with 100 
pM chloroquine during transfections. Under these conditions significant levels of P- 
galactosidase expression could be achieved with a 200-fold enhancement of 
expression over the activity produced by the DNA complex alone. These results are 
in general agreement with the work of Cotten et al, (1990) who described the effect 
in the K-562 erythroleukemia cell line and Midoux et al, (1993) who used 
chloroquine to enhance gene transfer in HepG2 human hepatoma cells. However, 
chloroquine treatment of alveolar macrophages transfected with polylysine-IgG- 
DNA complexes produced a more modest (1.6-fold) increase in gene expression 
(Rojanaskul et al, 1994). An absolute analysis of the data from the later study was 
not possible as the authors used a non-standard assay procedure and the levels of 
transfection within the total population were not described.
Improvements in gene transfer efficiency are, however, only produced with 
relatively high concentrations of chloroquine (Zenke et al, 1990). Gene transfer 
efficiency in B16 melanoma cells is seen to increase at chloroquine concentrations 
greater than 25 pM with maximum levels of P-galactosidase produced at a 
concentration of 100 pM. The requirement for such high concentrations of 
chloroquine is inconsistent with the traditional mechanism by which chloroquine is 
thought to enhance gene expression. The weakly basic molecule was thought to 
increase the survival of transferred DNA by increasing the pH of the lysosomes and
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inhibiting the activity of nucleases. However, inhibition is produced at sub-toxic 
chloroquine concentrations (»10pM; Dean et al, 1984) which are much lower than 
those required to increase gene expression. An alternative hypothesis, postulated by 
Zatloukal et al, (1992), is that on accumulation in the endosome chloroquine acts 
osmotically, vacuolarising and finally disrupting the endosome with release of 
complexes into the cytosol. This hypothesis was confirmed in K-562 cells, where the 
absence of Na+,K+-ATPase regulation of endosomal acidification allows 
accumulation of exceptionally high levels of the drug. In mammalian cells the Na+- 
K+ transporters are responsible for the maintenance of the pH gradient and as a 
consequence of their absence the pH of the endosomal compartment reaches 
unusually low values (Sipe et al, 1991). Consequently, virtually 100% of the cells 
express the reporter gene following transfection. This contrasts with the 7-10% of 
B16 melanoma cells expressing p-galactosidase following a similar treatment. The 
disadvantage of the chloroquine procedure was the appearance of dose related cell 
toxicity at concentrations greater than 25 (iM; this being the concentration above 
which gene transfer was augmented. Cytotoxicity was particularly evident on the 
prolonged exposure of cells to high concentrations of the drug. Therefore, increasing 
the time of the incubation period did not serve to improve the efficiency of gene 
transfer.
The influence of chloroquine on gene expression provides an insight into the 
mechanism of cationic-polypeptide polynucleotide delivery. Indeed, the dependence 
of expression on the lysosomotropic agent chloroquine suggests that DNA 
complexed with polycations is delivered to the nucleus via the endosome-lysosome 
trafficking pathway. Moreover, the incorporation of complexes into endosomal 
compartments is consistent with complexes entering cells via a process of 
endocytosis rather than directly through the plasma membrane. A similar uptake 
mechanism has been proposed for cationic liposomes (Legendre and Szoka, 1992).
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4.24.2. Complex composition influences the uptake o f DNA.
Since underivatised polymers have been used successfully for the delivery of 
plasmid DNA, then it may be assumed that some mechanism exists for the binding of 
these complexes to the cell surface and internalisation of DNA. Examining (3- 
galactosidase expression as a function of the polypeptide content of complexes gave 
an indication of this mechanism. Increasing the streptavidin-poly-L-lysine content of 
formulations only produced competent delivery systems at polymer-to-DNA mass 
ratios greater than 0.37:1. Taking into account that a streptavidin-poly-L-lysine(219) 
molecule possesses 218 remaining cationic charges, and that pRSVlacZ is a plasmid 
of 7.8 kb, electroneutrality in complexes formed between str-pLL and pRSVlacZ is 
obtained when a plasmid molecule is covered by 82 str-pLL molecules. Therefore, 
by increasing the polypeptide-to-DNA ratio from 0.37:1 (Polypeptide:DNA; 
(mol/mol) = 75:1) to 0.43:1 (Polypeptide:DNA;(mol/mol) = 90:1) a change in the 
charge density from net negative (Polypeptide:DNA;(+/-) = 0.9) to net positive 
(Polypeptide:DNA;(+/-) = 1.1) is produced. These data suggest plasmid uptake is 
dependant on the charge of a complex. By further increasing the polypeptide to 
DNA mass ratio to 0.63:1 an optimum level of p-galactosidase expression was 
achieved. Perhaps surprisingly, the decrease above this optimum appeared unrelated 
to toxicity. Therefore, it is proposed that the reduction in P-galactosidase expression 
reflects a change in delivery efficiency that is perhaps associated with changes in 
complex conformation.
4.24.3. Optimisation o f DNA dose.
Using the optimised streptavidin-polylysine-DNA formulation described above, 
the effect of DNA dose on transient gene expression was evaluated. The highest 
levels of P-galactosidase activity were achieved following delivery of 6 pg DNA, 
although significant levels of expression were seen with a 1.5 pg dose of pRSVlacZ. 
DNA levels above the optimum appeared to be inhibitory although activity was not
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completely abolished. If the studies by Feigner et al, (1987), using cationic 
liposomes, relate to this situation then it would appear that the quantity of DNA 
required to generate an optimal signal varies with the cell type. Therefore, it will 
probably be necessary to optimise the system for the transfection of individual cell 
lines. It is also noteworthy that optimal doses reported in the literature for in vitro 
transfection with systems based on cationic polypeptides have varied between 2 |ig 
(Zenke et al, 1990) and 20 pg of DNA (Midoux et al, 1993)
4.24.4. Stability o f cationic-polypeptide-DNA complexes.
The conditions to which DNAs are exposed in transfection experiments are 
generally hostile with substantial nuclease activity evident in serum and some 
intracellular compartments (e.g. lysosomes). Indeed, Feigner et al, (1987) showed 
that the transfection of mouse L cells with a DOTMA liposomal type delivery system 
was inhibited by serum containing medium. Serum stability is, therefore, likely to 
significantly influence the success of any attempt to use non-viral systems for gene 
transfer in vitro and in vivo. Studies with streptavidin-polylysine complexes have 
indicated that after 24 hours relative activity was significantly lower when 
transfections were performed in complete growth medium. This suggested potential 
instability of complexes with subsequent degradation of a fraction of the DNA dose. 
However, comparing Fig. 4.5.a and Fig. 4.5.b shows that corrections for the protein 
content of samples effectively raise the relative values of enzyme activity for the 
transfections performed without serum. If total activity is examined then the 
presence of serum appears to have a positive effect on the levels of expression. It is 
likely this paradox reflects the complexity of the model system in which the 
influence of serum on cell viability cannot be separated from any potential effect on 
the delivery system.
The stability of polypeptide-DNA complexes was, therefore, evaluated under 
conditions which simulated the extracellular environment encountered during in vitro
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transfections. These studies confirmed earlier published data which showed 
oligodeoxynucleotides and double stranded DNAs to be readily degraded in culture 
medium containing serum (Wickstrom, 1986; Chiou et al, 1994). It is noteworthy 
that degradation is only arrested following heat treatment at 90°C and not following 
incubation at 56°C for the 30 minutes; the latter are the standard conditions used to 
prepare 'heat inactivated' serum. These results also appear to reflect the in vivo 
situation where DNA is degraded in a similar manner although the kinetics of the 
process appear to be more rapid (Kawabata et al, 1995). The level of 
deoxyribonuclease activity in human and calf serum has been shown to be similar 
(Cox and Gokcen, 1976). Following complexation with streptavidin-poly-L-lysine, 
DNA was protected for the duration of the transfection period. Additionally, the 
stability of complexed DNA in presence of deoxyribonuclease demonstrates that in 
this state nucleic acid is no longer available for enzymatic degradation. It is 
therefore apparent that DNA stability is, at least in part, caused by the 
conformational change induced by polylysine containing conjugates.
4.24.5. Time course o f gene expression.
In vitro gene expression mediated by cationic polypeptide-DNA complexes was 
transient with the maximum level of relative activity observed after 24 hours. This 
closely parallels the expression pattern noted by Gao et al, (1993) following 
transfection of cotten rat airway epithelial cells with human transferrin-polylysine- 
DNA complexes. However, analysis of changes in total P-galactosidase activity with 
time gave a different pattern of expression to that described above for relative 
activity. Here, an increase in activity was observed over the 72 hour experimental 
period. These differences in expression patterns were thought to reflect the 
multiplication of non-transfected cells which effectively reduces the levels of relative 
activity over time. The transient expression of gene products in this system is not 
entirely unexpected as the DNA delivered in these experiments does not contain any
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mechanism to enable long term gene transfer. However, using a cationic-polypeptide 
system Cotten et al, (1993) showed that the incorporation of a replicative episome 
into plasmid vectors could successfully be used to produce gene expression for 
several weeks in vitro. It is also possible to prolong gene expression following gene 
transfer to hepatocytes in vivo by surgical intervention (Wilson et al, 1992). The 
mechanism proposed for these events was the stabilisation of internalised DNA by 
partitioning into nuclear or cytoplasmic compartments. However, these results were 
in conflict with the general literature which suggests that if episomes are to persist in 
eukaryotic cells they must integrate into chromosomal DNA. These techniques may 
remove the necessity for repetitive dosing in correcting genetic defects. However, 
the permanent modification of cells may be ethically unacceptable.
4.24.6, Kinetic analysis o f DNA delivery.
In assessing the capability of polymeric systems to deliver nucleic acids to 
mammalian cell lines, the kinetics of the process are of great interest. The 
association of complexes with B16 melanoma cells was followed with systems 
formulated with fluorescein labelled polylysine. Under the specific conditions 
described in section 4.9., the relative fluorescence of cell populations incubated with 
these complexes increased over the first three hours of the incubation period and then 
remained relatively constant. These data suggest that the cell association of charged 
polycation complexes occurs gradually and is relatively slow. Importantly, the 
relationship between p-galactosidase expression and incubation time showed a 
similar dependence on time. Therefore, in measuring these changes in relative 
fluorescence it is probable that the internalisation of the complexes, and associated 
DNA, was being monitored.
4.24.7. Histone H I as a cationic polypeptide carrier.
Histones were examined as an alternative carrier system for both non-specific and 
receptor-mediated gene delivery as in low ionic strength solvents complexes with
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DNA exist as soluble particles (Olins and Olins, 1971). Histone Hl-DNA 
complexes exhibit similar morphology to those prepared with the synthetic 
homopolymer poly-L-lysine (Laemmli, 1975). Complexes constructed from a fixed 
mass of supercoiled plasmid DNA and increasing quantities of histone HI showed a 
similar spectrum of transfection activity to streptavidin-polylysine in the presence of 
100 fiM chloroquine. However, if the optimum formulation of each of these delivery 
systems is compared then histone HI produces significantly higher levels of (3- 
galactosidase in cell extracts. Importantly, this increase reflects a greater proportion 
of the cell population expressing the enzyme rather than an increase in the level of 
gene product synthesised by each transfected cell.
A number of reasons may be postulated for the superiority of histone HI in 
transforming B 16 melanoma cells; changes in complex structure, nuclear localisation 
of histone based systems, and the efficiency of DNA release from the delivery 
vehicle. It is likely that changes in structure will significantly influence the uptake of 
complexes in cell systems. However as stated previously, electronmicrographs of 
complexes prepared with histone HI and polylysine revealed structures of similar 
morphology. As the experimental conditions were similar to those for the 
preparation of streptavidin-polylysine then complexes of similar dimensions would 
be expected with this system. Perhaps of more importance is the targeted trafficking 
of the carrier polypeptide to the nucleus. The co-introduction of the non-histone high 
mobility group protein-one (HMG-1) and DNA in lipososmes has dramatically 
increased DNA accumulation in the nucleus (Kaneda et al, 1989). When BSA was 
used instead of HMG-1, DNA was located mainly in the cytoplasm. It is also 
possible that complexes containing histone HI undergo facilitated transport into the 
nucleus. Indeed, the complete 21 kDa protein (Bonner, 1975), and proteolytic 
fragments of the C-terminus domain (Dingwall and Allan, 1984), accumulate in 
nuclei by an energy dependent process following interaction with cytoplasmic
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binding factors (Breeuwer and Goldfarb, 1990). However, in discussing this 
mechanism we should consider that the channels in the nuclear pore complex, 
through which transport occurs are approximately 100 A in diameter and may 
prevent the entry of large complexes (reviewed by Peters, 1986). A third factor, 
which is not discussed in the literature, is the relative efficiency of DNA release from 
the delivery system. From data presented by Rosenkranz et al, (1992) it appears that 
DNA remains bound to the carrier polycation in the nucleus. Therefore, in this 
study, DNA is perhaps more readily released from histone HI than polylysine 
Indeed, Olins et al, (1969) have shown that significantly more energy is required to 
induce changes in polylysine-DNA complexes than in systems prepared with lysine 
rich histone fractions. In addition, mechanisms are known to exist which regulate 
the interactions between histone HI molecules (Ogata et al, 1980). These systems 
play an important part in the formation of higher order structures in the 
polynucleosome strands (solenoids). Therefore, it is possible that these endogenous 
regulatory systems are able to release DNA from histone HI more readily than from 
polylysine.
4.25. Summary.
In summary, factors which have been shown to determine the efficiency of gene 
transfer can be divided into those directly related to the formulation (cationic carrier, 
complex composition, stability, dosing schedule, DNA dose) and external influences 
(rate of internalisation and lysosomal degradation).
The polypeptide composition of formulations has a significant influence on gene 
transfer; uptake of DNA is only achieved at a specific polypeptide-to-DNA ratio and 
then reaches an optimum on addition of increasing quantities of streptavidin- 
polylysine. Using this data, formulations can be prepared for gene targeting which 
minimise uptake by non-specific effects. However, successful transfer and
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expression of the P-galactosidase reporter gene also requires the presence of 
chloroquine. These facts support the hypothesis that the mechanism of uptake is 
related to charge. However, no firm conclusions can be drawn as to the influence of 
charge in this system since these data were inferred from theoretical calculations. 
These results provided the basis for the more detailed investigations presented in 
chapter 5. The function of the cationic carrier polymer in producing an effective 
delivery system also appears to extend to the protection of complexed DNA.
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Chapter 5
Influence of cationic polypeptides on gene transfer.
It is apparent from data presented in this study and the published literature, that 
polycationic agents are effective in facilitating the entry of plasmid-DNA into cells in 
culture and in vivo. The majority of these studies have used polymers coupled to 
ligands which bind cell surface receptors. However, it is possible to envisage 
therapeutic situations, for example where the disease is compartmentalised (e.g. 
cystic fibrosis) or where unique receptors are not present on cells, when non-specific 
methods of gene transfer may be applicable. To this end, the formulation factors 
which may influence the efficiency of non-specific gene transfer have been 
investigated. Complexes were prepared from a range of structurally diverse 
polymers and their ability to transfer DNA assessed in relation to changes in 
structure, molecular weight and charge. In order to conclusively establish if non­
specific gene transfer was related to charge, as suggested by experiments with 
streptavidin-polylysine (section 4.14.), electrophoretic light scattering was used to 
measure the zeta potentials of model polypeptide-DNA complexes. Physical 
characteristics of complexes were also examined by electron microscopy.
5.1. Influence of polypeptide-to-DNA ratio on the transfection efficiency of 
complexes prepared using poly-L-lysine.
Complexes containing 6 fig pRSVlacZ and increasing masses of poly-L-lysine 
(13), (127), (214) and (859) were formed in a final volume of 0.5 ml HBS using the 
method described in section 2.4. In general, systems with polypeptide-to-DNA mass 
ratios between 0.1:1 and 1.0:1 were used in transfections. However, for poly-L- 
lysine(13) mass ratios of up to 3.0:1 were tested. Transfections were carried out in 
the presence of 100 pM chloroquine.
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5.2. Influence of polymer chain length on transfection efficiency.
The ability of polymers to deliver plasmid DNA was assessed using the test 
system described in section 4.2. Transfections were performed in triplicate in the 
presence of 100 pM chloroquine using poly-L-lysine(13), (127), (214) and (859). 
Formulations were prepared using the optimal polypeptide-to-DNA mass ratios 
determined in section 5.1. (3-galactosidase activity was measured after 48 hours.
5.3. Alanine-lysine graft co-polymers as an alternative to polylysine carriers.
Complexes of DNA and the alanine-lysine graft co-polymers described in section
2.2.3. were prepared at polypeptide-to-DNA mass ratios between 1.2:1 and 2.9:1. 
Transfections were performed in the presence of 100 pM chloroquine as described in 
section 4.2. and (3-galactosidase activity determined in cell extracts 48 hours later.
5.4. Stability of polylysine-DNA complexes of variable polymer compositions.
Poly-L-lysine(214)-DNA complexes of polypeptide-to-DNA mass ratios 0:1, 
0.2:1, 0.4:1, 0.5:1, and 0.8:1 were prepared in 0.5 ml total volume of HBS. Each 
mixture was then divided into two samples and DNase I added according to the 
protocol described in section 4.8.1. Complexes were analysed on a 1% agarose gel.
5.5. Measurement of zeta potentials.
Zeta potentials of complexes formed between poly-L-lysine(214) and pRSVlacZ, 
at polypeptide-to-DNA mass ratios between 0.2:1 and 5.0:1, were determined using 
an electrophoretic light scattering technique (Brookhaven Instruments, Zetaplus). 
Formulations were prepared in both HBS and water. Application of a constant 
current across a cell containing the colloidal system results in the movement of 
charged particles toward the appropriate electrode. The velocity distribution of 
particles is then calculated from analysis of the Doppler shift of light scattered by the 
particles against an imposed reference beam (250 Hz). Scattered light was measured 
at an angle 15° from the incident. All glass and plasticware used in the preparation
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of complexes and measurement of zeta potentials was washed three times with 
Milliq-grade water (prefiltered; 0.1 pm nylon membrane) to reduce particulate 
contamination. Water and HBS used in the dilution of polylysine and DNA solutions 
was also filtered before use. Complexes were formed as described in section 2.4. 
and incubated at room temperature for 30 minutes. A 1.6 ml volume of sample 
solution was then transferred to a freshly cleaned 3.0 ml disposable cuvette. Before 
five repeat measurements were made the cuvette was allowed to equilibrate in the 
instrument for five minutes to achieve a constant temperature of 25°C. The 250 Hz 
reference point was established between each reading.
5.6. Characterisation of poIylysine-DNA complexes by electron microscopy.
The physical characteristics of polylysine(214)-DNA complexes formed at 
different polypeptide-to-DNA mass ratios were monitored by electron microscopy 
according to the method modified from Ennever et al, (1985). Complexes were 
prepared in water at polypeptide-to-DNA mass ratios of 0.4:1 (the optimum for 
transfection), 1.0:1 and 5.0:1. Immediately after preparation, DNA complexes (12 
pg/ml) were applied to 200 mesh copper grids supported on a pioloform film. 
Samples were allowed to adsorb onto the grid over approximately two minutes, 
blotted and stained with 1% uranyl acetate (1 minute). The grids were then rinsed by 
floating on double distilled water (1 minute) to remove excess stain. Specimens 
were examined on a JEOL-1200EX II transmission electron microscope operating at 
80kV.
Results.
5.7. Transfection activity of poly-L-lysine molecules with differing chain lengths.
In order to examine the relationship between transfection efficiency and polymer 
chain length, it was first necessary to determine the optimal complex formulation for 
each of the poly-L-lysine molecules to be tested. To this end, cells were incubated 
with complexes of variable polymer content according to the method described in
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section 4.2. Levels of relative P-galactosidase activity were then measured after 48 
hours and plotted as a function of the polymer-to-DNA mass ratio (Fig. 5.1.). For 
both poly-L-lysine(214) and (859) maximum gene expression was produced 
following transfection of cells with complexes prepared at a mass ratio of 0.4:1. 
However, with poly-L-lysine(127) the optimum occurred at the higher mass ratio of 
0.5:1. This was true whether the transfection efficiency was expressed as relative p- 
galactosidase activity or total activity per well. Several formulations based on poly- 
L-lysine(13) and the alanine-lysine graft co-polymers were also tested, but these 
systems failed to increase P-galactosidase expression above endogenous levels (Fig.
5.2.). The optimised formulation for each competent polypeptide carrier was then 
used in a subsequent experiment to assess the influence of polymer chain length on 
gene transfer efficiency (Fig. 5.3.). Following delivery of 6 pg pRSVlacZ, gene 
expression facilitated by poly-L-lysine(127) complexes was two times greater than 
that produced with either poly-L-lysine(214) or (859). No significant difference 
(p<0.05, t test unpaired) in P-galactosidase activity was found in cell extracts 
following transfection of cells using poly-L-lysine(214) or (859). In this experiment, 
the rank order of polymer delivery efficiency was the same as that described in the 
optimisation study.
5.8. Stability of complexes of variable polylysine content.
A representative electrophoretic gel of poly-L-lysine(214)-DNA complexes 
incubated with DNase is shown in Figure 5.4. As expected, DNA complexed with 
poly-L-lysine at mass ratios of 0.4:1 and greater was retained at the gel origin. After 
incubation with DNase these complexes showed a high degree of stability. However, 
for complexes where DNA incorporation was not complete (Polypeptide:DNA = 
0.2:1) free DNA was degraded as indicated by the presence of small fragments which 
migrated rapidly through the gel. The reduction in the intensity of the band at the gel 
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Figure 5.1. Influence of polymer-to-DNA mass ratio on gene transfer for complexes 
formed using poly-L-lysine of 13 (•), 127 (■), 214 (□) and 859 (▲) monomer 
residues. Single determinations were made in the presence of 100 pM chloroquine.
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Figure 5.2. Influence of polymer-to-DNA mass ratio on gene transfer for complexes 
formed using AK100 (•), AK200 (■), AK500 (▲), and poly-L-lysine (□). Single 
determiantions were made in the presence of 100 pM chloroquine.
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Figure 5.3. Relative levels of gene expression following transfer of pRSVlacZ to 
B16 melanoma cells using poly-L-lysine polymers of 13, 127, 214 and 859 monomer 
residues. The optimised complex formulations are described in section 5.7. Data 
represents the mean ± SEM for three replicate plates.
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Figure 5.4. Enzymatic digestion of polylysine(214)-DNA complexes of variable 
polypeptide composition. Complexes containing an increasing mass of poly-L-lysine 
and the corresponding DNase digest (D) were analysed on a 1% agarose gel. 
E=empty, M=EcoR 1 /HindUl XDNA lane marker.
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5.9. Zeta potential measurements.
The zeta potentials of poly-L-lysine-DNA complexes are described as a function 
of the polymer-to-DNA ratio in Figure 5.5. In preliminary experiments, 
measurements were made in HBS; this isotonic medium was also used in the 
preparation of systems for transfection. However, the high conductivity developed in 
this salt buffer («17,000 pS) resulted in a broadening of the power spectrum output 
and prevented accurate calculation of zeta potentials. All further experiments were, 
therefore, carried out in 12 pM TE buffer (pH 8.0) which eliminated peak 
broadening and gave sharp responses of the type shown in Figure 5.6. This medium 
did not affect the process of complexation (see section 2.7.2.). Under the given 
conditions, zeta potentials between -44 and +33 mV were obtained on modifying the 
polymer-to-DNA mass ratio from 0.2:1 to 5.0:1. However, charge inversion 
occurred rapidly between the mass ratios of 0.2:1 and 0.4:1 and from interpolation of 
this plot an 'isoelectric point' at a mass ratio of 0.35:1 was determined. Further 
increasing the polymer-to-DNA mass ratio produced complexes with higher zeta 
potentials. However, the relationship between zeta potential and mass ratio was not 
linear and at ratios of greater than 1.0:1 the charge measured on particles was 
relatively constant. The measured and theoretical charges of complexes are 
compared in Figure. 5.5.b. At the estimated point of charge neutralisation 
(Polymer:DNA;(+/-) = 1.0) the zeta potential of polymer-DNA complexes (+3mV) 
was close to zero.
5.10. Electron microscopy studies.
The shape of the poly-L-lysine (214)-DNA complexes formed at a polypeptide-to- 
DNA mass ratio of 0.4:1 are shown in Figure 5.7. Electron microscopy revealed a 
profound condensation of plasmid DNA which in most cases produced, distinct, 
roughly spherical particles (Fig. 5.7.a-c). At higher magnifications the polydisperse 
nature of the particle size distribution is apparent (Fig. 5.7.b) with condensates
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between 10 and 200 nm being observed. However, the particles remained mostly 
discreet. Further increases in magnification (Fig. 5.7.c) failed to show any distinct 
sub-structure to the complexes.
Examination of complexes formed at higher polypeptide-to-DNA mass ratios 
indicated distinct differences in morphology. Condensates formed at a mass ratio of 
0.4:1 were generally discreet and were generally less than 100 nm in diameter (Fig.
5.8.a). However, on increasing the polypeptide-to-DNA mass ratio to 1.0:1 (Fig.
5.8.b) the number of small spherical particles in the sample decreased and some 
aggregation became evident. Continued addition of increasing quantities of polymer 
(Fig. 5.8.c) resulted in significant aggregation with a distinct network of polymer 
evident between the particles. Some complexes also adopted a rod-like 
conformation. At higher magnifications these complexes exhibited a similar 
amorphous structure to that seen in Figure 5.I.e.
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Figure. 5.5. Effect of polymer-to-DNA ratio on the zeta potential of poly-L- 
lysine(214)-DNA complexes in terms of mass (Plate A) and theoretical charge (Plate 
B). Measurements were made as described in section 5.5.
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Figure 5.6. Representative ELS power spectrum for a positively charged 
polypeptide-DNA complex. The power spectrum was obtained for a complex 




Figure 5.7. Physical characterisation of poly-L-lysine(214)-DNA complexes. 
Condensates prepared at a polypeptide-to-DNA of 0.4:1 were examined at 




Figure 5.8. Influence of polypeptide concentration on complex morphology. 
Condensates were prepared at a polypeptide-to-DNA mass ratio of 0.4:1 (a), 1.0:1 (b) 
and 5.0:1 (c). Final magnification is 40K. [Bar (applies a-c ) = 200 nm].
127
5.11. Discussion.
5.11.1. Influence o f Polypeptide-to-DNA ratio on transfection efficiency.
The efficiency with which B16 cells are transformed using polypeptide-DNA 
delivery systems is a function of a number of variables. In the case of streptavidin- 
polylysine and histone HI complexes, a major influence was the ratio of donor DNA 
to polypeptide in the transfection mixture. Similar effects to those seen with 
streptavidin-polylysine and histone HI were also observed for complexes formed 
from a series of polylysine polymers of differing chain lengths. However, using 
these simpler systems, it was possible to examine the underlying physicochemical 
changes produced on varying the polypeptide-to-DNA ratio.
5.11.2. Gene transfer mediated by electrostatic interactions.
In accordance with previous experiments, which used streptavidin-polylysine and 
histone HI to facilitate gene delivery, the increase in p-galactosidase expression 
observed with the poly-L-lysine polymers was not gradual but was produced on 
achieving a specific DNA-to-polypeptide mass ratio. Calculations showed this ratio 
to be near or above the theoretical point of charge neutralisation suggesting the 
possibility that the non-specific association between polylysine-DNA complexes and 
the cell surface was the result of an electrostatic interaction. Zeta potential 
measurements made on complexes between poly-L-lysine (214) and pRSVlacZ 
showed the overall surface charge of particles within the system was a function of the 
polypeptide-to-DNA ratio. Similar observations have recently been made by 
Mumper et al, (1994) for complexes formed between polyamidoamine cascade 
polymers and plasmid DNA. Schreier et al, (1994) also showed that the addition of 
DOTMA/DOPE cationic liposomes to DNA results in changes in the zeta potential 
of the system; continued addition of liposomes produced a formulation with a net 
positive charge. For poly-L-lysine(214)-DNA complexes the transition from an 
anionic to a cationic system was produced at a polypeptide-to-DNA mass ratio
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between 0.2:1 and 0.4:1. Since it was also between these ratios that complexes 
started to function as effective delivery systems the uptake of DNA would appear to 
be charge-mediated. The mechanistic implication of these data is that a sufficient 
excess of polymer is required to neutralise the negatively charged DNA in a 
polylysine-DNA complex, so that interaction with the electronegative cell surface 
can occur. This is in addition to the requirement for charge neutralisation to induce 
DNA collapse. From the enzymatic stability studies the neutralisation of charge and 
DNA condensation is also implicated in the protection of the nucleic acids from 
degradation.
As non-specific gene transfer is charge-mediated, then it may be assumed that the 
highest level of gene expression would be achieved with formulations having the 
most positive zeta potential. However, as the zeta potential of complexes with a 
polypeptide-to-DNA mass ratio of 1.0:1 and greater is relatively constant, an 
indication that negatively charged binding sites on DNA are fully occupied, then 
using systems containing increasing amounts of polymer would not serve to increase 
charge-mediated interactions. Indeed, transfection of cells with poly-L-lysine(214)- 
DNA complexes was optimal at a mass ratio of 0.4:1. It is therefore possible that 
although complexes must be cationically charged to induce DNA uptake the 
magnitude of this charge is not important in determining gene transfer. 
Alternatively, at higher polypeptide-to-DNA ratios some competing factor may be 
reducing gene transfer.
5.11.3. Physical characterisation o f polylysine-DNA complexes.
There are relatively few structure-function studies involving the internalisation of 
polymer-DNA structures into eukaryotic cells. However, Wagner et al, (1991) 
advanced the theory that the biological activity of transferrin-poly-L-lysine-DNA 
complexes, targeted to the transferrin receptor in various cell lines, correlates to the 
formation of condensates of 80-100 nm in diameter. Examination of complexes
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formed between poly-L-lysine(214) and pRSVlacZ, at different polypeptide-to-DNA 
mass ratios, showed structures with distinctly different morphology. When the 
polypeptide-to-DNA mass ratio was increased complexes proceeded from a discreet 
to an aggregated state. Since charged pharmaceutical systems are generally stable 
(Washington, 1990) it is likely that this aggregation results from multi-point binding 
between particles during the process of DNA condensation. The diameter of 
particles prepared at a polypeptide-to-DNA mass ratio of 0.4:1, the optimum for 
biological activity, was significantly smaller than the size of the aggregates seen in 
systems prepared with higher quantities of polymer.
It therefore seemed likely that the reproducible diminution of delivery efficiency 
observed with carrier formulations with high polypeptide-to-DNA mass ratios was a 
result of the change between small spherical complexes and aggregated systems. 
Bond and Wold (1987) noted a similar change in the bioactivity of poly-L-omithine- 
DNA complexes but were unable to account for the phenomenon. The size and 
morphology of complexes therefore appears to significantly affect gene transfer 
efficiency and is determined by factors including the DNA-to-polypeptide ratio. 
However, as the size distribution of complexes within a system is polydisperse then 
the possibility arises that only a sub-set of the total particle population is active; 
smaller particles being capable of negotiating nuclear pores. The presence of some 
small particles in aggregated formulations may explain the low levels of gene 
expression detected in cells following transfection. This hypothesis is supported by 
Plank et al, (1994) who observed the slow formation of polylysine-DNA precipitates 
of up to 1 pM in diameter in a gene transfer system. Using density gradient 
centrifugation, precipitates and smaller complexes were isolated and used in a 
subsequent gene transfer experiment; the transfection efficiency with the soluble 
fraction was 20-fold higher than with the precipitate fraction. Although no direct 
experimental evidence is available it is possible that extensive cross linking in
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polymer-DNA systems could totally prevent gene transfer. This effect may explain 
the inability of the alanine-lysine graft co-polymers to facilitate gene transfer despite 
inducing DNA condensation.
5.11,4. Transfection efficiency as a function o f chain length.
Although the mass of polylysine polymer required to induce DNA condensation 
was previously shown to be independent of chain length (see section 2.7.) this 
property appeared to significantly influence the level of p-galactosidase expression 
following gene transfer. From these data, complexes formed with poly-L-lysine(127) 
were twice as efficient as those complexes produced with longer chain polymer 
molecules containing 214 and 859 lysine monomer units. As cross-linking has been 
shown to affect transfection efficiency then it is feasible that the increased gene 
expression seen with polylysine(127) resulted as complexes formed with this shorter 
polypeptide were less likely to aggregate. The very short chain length polymers, 
represented by polylysine(13), did not induce effective DNA condensation and were 
unable to facilitate gene transfer at any polypeptide-to-DNA ratio tested. Therefore, 
in optimising the length of the cationic carrier for gene transfer systems it would 
appear that a compromise must be achieved between DNA condensation and cross- 
linking.
5.12. Summary.
The data presented in this chapter shows that only positively charged polypeptide- 
DNA complexes are taken up by B 16 melanoma cells. The non-specific association 
between polylysine-DNA complexes and the cell surface was therefore on an 
electrostatic basis. However, the morphology of complexes also determines the 
efficiency of gene transfer; it is probable that smaller particles are more bioactive. In 
addition, it appears that the chain length of polypeptides used to form complexes 
affects the efficiency of gene transfer.
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Chapter 6
Strategies for targeting gene delivery to B16 melanoma cells.
Strategies which circumvent problems with non-specific gene transfer generally 
involve delivering DNA to cells by receptor-mediated endocytosis. The mechanism 
proposed in this study to achieve selective gene delivery to melanoma cells is to use 
a derivative of [Nle4,D-Phe7]a-MSH as a targeting agent. This peptide has a high 
affinity at the murine MCI receptor (Sawyer et al, 1980). Conjugation to the vector 
was by the polylysine-streptavidin-biotin link described in chapter 3. However, for 
efficient delivery of DNA by receptor-mediated endocytosis the conjugate must be 
rapidly and specifically taken up by the target cell; this requires a high affinity of the 
ligand for the receptor, high receptor density and a high rate of 
endocytosis/intemalisation. Consequently, the initial focus of the following 
experiments was to ensure Na-biotin-(Gly3)-[Nle4,D-Phe7]a-MSH retained the ability 
to specifically bind at the MCI receptor on conjugation to the outer coat of the 
vector. A second targeting strategy which utilises the binding of lectins to cell 
surface glycoconjugates was also tested. These molecules are overexpressed on 
neoplastic cells (Hynes, 1976; Nicolson, 1982).
6.1. Peptides.
Peptides were prepared in our laboratory using solid phase synthesis by Dr G.W.J. 
Olivier, and their preparation is therefore not described in detail. Lyophilised 
peptides were reconstituted with sterile 0.1 mM HC1 and stored at 4°C.
6.1.1. Biotinylation o f Na-(G\yf)-[Nle4,D-Phe7]a-MS¥L
Biotinylation of peptides was demonstrated by qualitative detection with avidin 
conjugated horseradish peroxidase (Sigma). Samples containing 1 mg/ml Na-biotin-
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(Gly3)-[Nle4,D-Phe7]a-MSH were added, dropwise, onto a nitrocellulose membrane 
(0.45 pM pore size). An equal mass of Na-(Gly3)-[Nle4,D-Phe7]a-MSH was blotted 
on the same membrane as a control. After air drying at ambient temperature, non­
specific binding was blocked using the method previously described for affinity 
blotting (section 3.8.2.). Following this, membranes were rinsed with TBS before 
incubating with avidin-HRP (2 pg/ml), for 60 minutes. Blots were developed as 
before; a positive purple colour reaction showed the test peptide had been 
biotinylated.
6.2. Radioiodination of a-MSH analogues.
Radioactive iodine was coupled at the Tyr2 position of the a-MSH analogues, 
[Nle4,D-Phe7]a-MSH and Na-biotin-(Gly3)-[Nle4,D-Phe7]a-MSH, by the oxidative 
chloramine T method described by Eberle and Hiibscher, (1979).
6.2.1. Column chromatography solutions.
1% v/vTFA.
50%, 60% and 80% v/v methanol +1% v/v TFA.
0.25 M sodium phosphate buffer, pH 7.4.
6.2.2. Iodination reaction reagents.
0.25% w/v BSA in 0.05 M phosphate buffer pH 7.4.
1 % w/v Polypep (Sigma) in 0.05 M phosphate buffer, pH 7.4.
0.1% w/v chloramine-T in distilled water (prepared immediately before use).
6.2.3. Preconditioning o f purification columns.
A C l8 reverse phase column packed with Spherisorb ODS (Anachem), was 
preconditioned by washing according to the following protocol:
3 x 1 ml 1% v/v TFA.
3 x 1 ml 80% v/v methanol/ 1%TFA.
1 x 1 ml 1% w/v Polypep solution (protein digest).
3 x 1 ml 1% v/v TFA.
133
6.2.4. Peptide iodination.
Prior to the iodination reaction, 20 pg [Nle4,D-Phe7]a-MSH or Na-biotin-(Gly3)- 
[Nle4,D-Phe7]a-MSH was diluted to 20 pi in 0.25 M phosphate buffer (pH 7.4). To 
the peptide solution 10 pi Na125I (nominally 37 Mbq activity) was added, and the 
oxidation reaction then initiated using 10 pi 0.1% w/v chloramine-T solution. After 
30 seconds the reaction was quenched with 0.6 ml 0.25% w/v BSA. To remove 
unreacted Na125I the reaction mixture was applied to a preconditioned ODS column 
which was then washed twice with phosphate buffer. The iodinated ligand was 
eluted by washing the column with 4 x 1 ml 50% v/v methanol/l%v/v TFA followed 
by 2 x 1 ml 60% Methanol/1% TFA. The eluate was retained for further purification 
by reverse phase HPLC.
6.2.5. Purification o f radiolabelled peptides.
Eluate from the iodination reaction contained a mixture of mono- and di-iodinated 
peptides necessitating further purification by HPLC. An exponential gradient of 
0.1% TFA in water and 0.1% TFA in 70% acetonitrile/30% water was used with 
fractions collected at one minute intervals from 25-40 minutes after injection. The 
mono-iodinated compound [125I-Tyr2,Nle4,D-Phe7]a-MSH, which was used as a 
radiotracer in competitive binding experiments, eluted 35 minutes after injection; 
with the di-iodinated peptide eluting approximately three minutes later. Na-biotin- 
(Gly3)-[125I-Tyr2,Nle4,D-Phe7]a-MSH was isolated using the same chromatographic 
conditions and was found to elute 36 minutes after injection. The di-iodinated 
peptide eluted after 39 minutes. Radioactivity in each fraction was quantified on a 
LKB 1277 Gammamaster gamma counter. Those fractions associated with the 
mono-iodinated peptide peak were pooled, their collective activity measured as 
counts per minute (cpm), and the radiotracer concentration determined as outlined in 
section 6.2.6.
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6.2.6. Calculation of radiotracer concentration.
The concentration of radiotracer was calculated from the measured radioactivity 
by the following method:
By definition, [125I-Tyr2,Nle4,D-Phe7]a-MSH contains 1 mole of 125I per mole of 
peptide.
1 matom 125I = 1 x 10"3 moles [l25I-Tyr2,Nle4,D-Phe7]a-MSH.
As carrier free Na125I (Amersham) has a specific activity of 80.5 x 1012 Bq/matom 
then 1 mole of [125I-Tyr2,Nle4,D-Phe7]a-MSH has an activity of 80.5 x 1015 Bq.
1 Bq = 1 decay per second or 60 decays per minute and the efficiency of the gamma 
counter = 70%.
1 mole [125I-Tyr2,Nle4,D-Phe7]a-MSH would register 80.5 x 1012 x 103 x 60 x 0.7 
cpm = 3.38 x 1018 cpm on the LKB 1277 Gammamaster gamma counter.
This relationship was also used to determine the concentration of Na-biotin-(Gly3)- 
[125I-T yr2,Nle4,D-Phe7] a-MSH.
6.3. Formation of streptavidin-peptide conjugates.
Prior to use streptavidin (Sigma) and FTTC-streptavidin (Sigma) were dissolved in 
PBS at a concentration of 3.3 pM and stored in 0.5 ml aliquots at 4°C. Immediately 
before use, N“-biotin-(Gly3 )-[Nle4,D-Phe7]a-MSH (1 mg/ml) was diluted in PBS to a 
concentration of 3.3 pM. For quantitative assessment of conjugate formation the 
peptide reaction solution was spiked with 5 pi of a 2.4 x 10'8M solution of Na- 
biotin-(Gly3)-[125I-Tyr2,Nle4,D-Phe7]a-MSH (molar ratio labelled : unlabelled 
peptide = 1 : 14,000). Conjugates were then prepared by adding 0.5 ml of peptide
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solution to an equal volume of streptavidin or HTC-streptavidin solution. The 
reaction mixture was then incubated with constant agitation at 4°C for 60 minutes.
6.3.1. Purification o f streptavidin-peptide conjugates.
Uncomplexed biotinylated peptide was removed from reaction mixtures using 
streptavidin coated magnetizable beads (Dynabeads M-280, Dynal). These beads are 
non-porous, uniform, supermagnetic polystyrene particles. Prior to use, beads were 
washed twice using 0.1% BSA/PBS in order to remove sodium azide and reduce 
non-specific binding. The beads were then resuspended at 10 mg/ml in 0.1% 
BS A/PBS. All manipulations were conducted under aseptic conditions using filter- 
sterilised solutions. Conjugate reaction mixtures were then added to 150 pi of bead 
suspension in a 1.8 ml screw capped microcentrifuge tube and the suspension 
incubated, with gentle agitation, at 4°C for 60 minutes. Following this, the tube was 
placed in a strong magnetic field (Magnetic Particle Concentrator; Dynal) for five 
minutes. During this time the magnetic beads with bound biotinylated peptide were 
attracted to the wall of the tube, forming a firm pellet. The supernatant containing 
the peptide-streptavidin complexes was then carefully removed using a pipette while 
the magnet remained in place.
6.3.2. Validation o f purification.
The purification procedure was validated using a reaction mixture spiked with the 
radiolabelled peptide Na-biotin-(Gly3 )-[125I-Tyr2,Nle4,D-Phe7]a-MSH. Conjugates 
were prepared as described in section 6.3.1. Following purification of the reaction 
mixture, the supernatant was aspirated and retained. The beads were then released 
from the magnet and washed with 2 x 1.0 ml aliquots of PBS. Magnetic separation 
was performed between each washing. Finally, the beads were resuspended in 0.5 ml 
PBS. Radioactivity remaining in the supernatant and on the beads was measured 
using a gamma counter. The proportion of 125I activity retained on the beads was 
expressed as a percentage of the input. The relationship between measured
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radioactivity (cpm) and the specific activity of Na125I was then used to calculate the 
total molar quantity of peptide retained on the beads or in the supernatant.
6.3.3. Specific binding o f  Na-biotin-(Gly3)-[Nle4,D-Phe7]a-MSH by streptavidin 
coated magnetic beads.
The total capacity of streptavidin coated magnetic beads to bind Na-biotin-(Gly3 )- 
[Nle4,D-Phe7]a-MSH was determined using the radiotracer described in section
6.2.5. Peptide solutions containing 1.65 nanomoles Na-biotin-(Gly3 )-[Nle4,D-Phe7]a 
-MSH spiked with the radiotracer were added to 150 pi of bead suspension (1.5 mg) 
and incubated for 60 minutes at 4°C. Radioactivity retained on the beads was then 
measured. The contribution of non-specific binding was determined by blocking 
specific binding sites by pre-incubating beads with a 1.0 ml volume of biotin solution 
(6 x 10"5 M) for 60 minutes at room temperature. The biotin solution was then 
removed, beads washed with PBS and pelleted by centrifugation at 13,000 rpm for 5 
seconds. Beads were resuspended in 150 pi PBS and used immediately.
6.3.4. 2-iminobiotin chromatography.
Formation of conjugates between streptavidin and Na-biotin-(Gly3 )-[Nle4,D-Phe7] 
a-MSH was confirmed using 2-iminobiotin affinity chromatography. A column was 
prepared from a 1 ml disposable plastic syringe and packed with a 2-iminobiotin 
modified 6% beaded agarose gel (Sigma) to give a settled volume of 0.25 ml. The 
gel matrix was supported by a porous PTFE disk inserted at the bottom of the syringe 
barrel. Purified FTTC-streptavidin-Na-biotin-(Gly3 )-[Nle4,D-Phe7]a-MSH conjugate 
was then applied to the column which had been previously been equilibrated with 10 
column volumes (2.5 ml) of binding buffer (50 mM sodium carbonate, 1 M sodium 
chloride). Conjugates used in this experiment contained the radiolabelled peptide Na 
-biotin-(Gly3)-[125I-Tyr2,Nle4,D-Phe7]a-MSH. The column was washed with 0.5 ml 
aliquots of phosphate buffered saline (pH 7.3) until background levels of 125I activity
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were observed in the collected fractions. Following this, the wash buffer was 
changed to 0.1 M acetic acid and 125I activity in the eluted fractions measured.
6.4. Binding of peptide-conjugates at the MCI receptor.
Competitive binding assays were carried out following a method adapted from 
Siegrist et al, (1988) as described by Erskine Grout (1993).
6.4.1. Binding medium.
RPMI 1640 medium containing 25 mM Hepes and 0.2% BSA was prepared 
immediately before use. Hepes solution containing BSA was prepared as a 10X 
concentrate in serum free RPMI 1640 and stored at -20°C until used.
6.4.2. Competition Binding.
B16 cells were detached from flasks, counted and seeded at a density of 5 x 105 
cells per well into 24 well plates and incubated for 15 hours under standard 
conditions. The medium was aspirated from the wells and the cells washed twice 
with ice-cold RPMI 1640 without additives and placed on ice to cool to 0-4°C. A 
fixed concentration of the radiotracer [125I-Tyr2,Nle4,D-Phe7]a-MSH, nominally 0.1 
nM, and serial dilutions of the conjugate or test peptide were added to the binding 
medium. Concentrations in the range of 1 xlO'6 to 1 x 10'12 M were used. 
Following this, 0.5 ml of the binding medium containing the test compound and the 
radiotracer was added into each well. After an 8 hour incubation at 0-4°C, unbound 
radiotracer was removed and the cells washed twice with RPMI 1640 medium 
without additives. The cells were then lysed with 1 M NaOH and the residual 
radioactivity counted.
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6.4.3. Analysis of binding data.
MINSQ non-linear least square regression analysis was used to calculate 
dissociation constants from the binding data employing the following equation:
cp„t e 0 .  * cpmw „,
[A]+Kdax ill
K . .db
with cpm(test) = cpm for sample point
cpm max = maximum bound (no competitor) 
cpm huh = minimum bound (excess competitor)
[A] = Concentration of radiotracer
[B] = Concentration of competitor
Kda = dissociation constant of [125I-Tyr2,Nle4,D-Phe7]a-MSH (0.48 nM)
Kdb = dissociation constant of competitor
6.5. FITC-Concanavalin A binding to B16 melanoma cells.
Labelling of unfixed B16 melanoma cells was carried out with concanavalin A 
which was derivatised with fluorescein-isothiocyanate (Sigma). Washing and 
labelling procedures were conducted at 4°C to avoid endocytic uptake of lectins. 
Cells were harvested from confluent cultures using 0.02% EDTA/PBS, washed twice 
with PBS, and resuspended at 1 x 106 cells/ml. To 0.5 ml of cell suspension an equal 
volume of labelling solution containing FTTC-Con A in PBS was added and the 
mixture incubated for 90 minutes with occasional agitation. FTTC-Con A was used 
at a final concentrations of 12.5 pg/ml. The specificity of lectin binding to the cells 
was established by incubating cells with FTTC-Con A in the presence of 0.1 M 
maltose. To eliminate the possibility of fluorescent changes resulting from
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differences in osmolarity, control samples were also prepared in the presence and 
absence of the specific inhibitory sugar. After incubation, cells were washed twice in 
ice cold PBS, pelleted by centrifugation, and resuspended in 1.0 ml of PBS. Cell 
fluorescence was analysed by flow cytometry.
6.6. Formation of binary complexes for gene targeting studies.
Prior to the construction of tertiary complexes containing ligands for gene 
targeting, binary complexes of plasmid DNA and streptavidin-poly-L-lysine were 
pre-formed. Complexes were prepared as follows; 6.0 pg pRSVlacZ in 250 pi HBS 
was mixed with an equal volume of HBS containing 2.6 pg streptavidin- 
polylysine(219) and incubated at room temperature for 30 minutes. The formulation 
chosen (Polypeptide:DNA;(pg:pg) = 0.43:1) ensured complete DNA complexation 
but minimised non-specific gene transfer.
6.6.1. Preparation o f vectors containing Na-biotin-(Gly3)-[Nle4,D-Phe7]a-MSYL
Vectors containing Na-biotin-(Gly3 )-[Nle4,D-Phe7]a-MSH were derived by 
varying the amount of biotinylated-peptide added to pre-formed binary complexes. 
A 1 mg/ml stock solution of Na-biotin-(Gly3)-[Nle4,D-Phe7]a-MSH was diluted to 2 
pg/ml in HBS and aliquots added to conjugate suspensions to give complexes. 
Peptide containing conjugates were incubated for a further 30 minutes before use. 
Complexes used in the experiments contained either 45 or 22.5 molecules per 
complex. The ratio of peptide ligand-to-streptavidin in the complexes was 1:1 and 
0.5:1 respectively. Hence, these complexes were designated as 1.0 X and 0.5 X 
conjugates.
6.6.2. Preparation o f vectors containing concanavatin A.
Targetable concanavalin A vectors were prepared from the binary complexes 
described in section 6.6. Biotinylated ConA (Sigma) was dissolved at a
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concentration of 20 nmoles/ml in filter sterilised HBS according to the 
manufacturer's instructions and aliquots added to conjugate suspensions to give 
between 4.5 and 45 ConA molecules per complex. These complexes were
designated as 0.1 X and 1.0 X conjugates respectively. Systems were treated as 
described in section 6.6.1.
RESULTS
6.7. Preparation of N“-biotin-(Gly3)-[12SI-Tyr2,Nle4,D-Phe7]a-MSH.
The conjugation of streptavidin and biotinylated peptides was followed using a 
radiotracer prepared by iodination of Na-biotin-(Gly3)-[Nle4,D-Phe7]a-MSH. The 
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Figure 6.1. Elution profile of mono- and di-iodinated Na-biotin-(Gly3)-[Nle4,D- 
Phe7]a-MSH from analytical scale HPLC. Na-biotin-(Gly3)-[125I-Tyr2,Nle4,D-Phe7] 
a-MSH (1) eluted at 36 minutes and Na-biotin-(Gly3)-[(125I)2-Tyr2,Nle4,D-Phe7]a- 
MSH (2) at 39 min.
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6.8. Confirmation of conjugate formation using 2-iminobiotin chromatography.
In preliminary experiments the peptides produced by solid phase synthesis were 
shown to be biotinylated by affinity blotting with avidin-HRP. However in order to 
validate the binding of these peptides to streptavidin, purified reaction mixtures were 
qualitatively analysed by 2-iminobiotin affinity chromatography. As can be seen 
from Figure 6.2., the radiolabelled peptide Na-biotin-(Gly3)-[125I-Tyr2,Nle4,D-Phe7]a 
-MSH, which had been incubated with FTTC-streptavidin, was extensively retained 
on the column. A small quantity of l25I activity was eluted on loading although 
washing the column with phosphate buffered saline (pH 7.3) rapidly reduced 
radioactivity in the collected fractions to background levels. Complexes containing 
the iodinated radiotracer were then released from the column by washing with low 
pH buffer (0.1 M acetic acid). The majority of applied 125I activity (60%) was found 
in these specifically eluted fractions.
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Figure 6.2. Elution of FTrC-streptavidin-Na-biotin-(Gly3)-[Nle4,D-Phe7]a-MSH 
complexes from a 2-iminobiotin affinity column. Complexes containing the 
radiotracer Na-biotin-(Gly3)-[125I-Tyr2,Nle4,D-Phe7]a-MSH were loaded on to the 
column at pH 11.0 and specifically eluted by application of 0.1 M acetic acid.
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6.9. Validation of purification.
The results presented in Table 6.1. show the capability of the streptavidin coated 
magnetic beads to specifically bind Na-biotin-(Gly3)-[Nle4,D-Phe7]a-MSH. 
Incubation of 1.5 mg of beads with peptide solution resulted in the retention of 46.5 
± 6.0% of the applied radioactivity. The contribution of non-specific effects to this 
total was assessed by blocking binding sites on the bead surface. Under these 
conditions 125I activity associated with the beads was reduced to 3.7 ± 0.5% of the 
applied dose. At the end of the 60 minute incubation period a concomitant increase 
in 125I activity remaining in the supernatant (83.7 ± 1.1%) was also demonstrated. 
Using these data it was calculated that each milligram of bead suspension binds a 
maximum 442 picomoles of Na-biotin-(Gly3)-[Nle4,D-Phe7]a-MSH. Conjugation of 
streptavidin and Na-biotin-(Gly3)-[Nle4,D-Phe7]a-MSH was followed by measuring 
the relative amounts of activity remaining in the reaction supernatant or bound onto 
the beads. The quantity of Na-biotin-(Gly3)-[Nle4,D-Phe7]a-MSH removed 
following purification of streptavidin-peptide reaction mixtures (58 ± 25 pmols; n=3) 
was significantly less than the calculated maximum capacity. The majority of the 
radiolabel (94.4 ± 1.4%;n=3) was held in solution indicating successful 
complexation. In an attempt to establish if any biotinylated peptide remained in 
solution at the end of the incubation period 125I activity was measured on the 
purification beads and on beads pre-incubated with biotin. The amount of peptide 
retained was not significantly different under each of the conditions (p > 0.05, t test 
unpaired). Similar results were obtained with FITC-streptavidin.
6.10. Binding at the MCI receptor.
Dissociation constants of Na-biotin-(Gly3)-[Nle4,D-Phe7]a-MSH and conjugates 
with streptavidin and FITC-streptavidin at the murine MCI receptor were estimated 
from the radioactivity associated with the cells as described in section 6.4. The 
means and standard deviations of three or more experiments were determined for 
each compound. Incubation of cells with [125I-Tyr2,Nle4,D-Phe7]a-MSH in the
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Table 6.1. Retention of Na-biotin-(Gly3)-[125I-Tyr2,Nle4,D-Phe7]a-MSH by 
streptavidin coated beads. Data is expressed as the percentage of input radioactivity 















FITC-Streptavidin-Na-biotin-(Gly3)-[Nle4,D-Phe7]a-MSH 91.8±0.4 5.4±0.4 97.2±0.1
Table 6.2. Retention of Na-biotin-(Gly3 )-[Nle4,D-Phe7]a-MSH by streptavidin 
coated beads. The total quantity of peptide retained was calculated using data 
derived using Na-biotin-(Gly3)-[125I-Tyr2,Nle4,D-Phe7]a-MSH (Table 6.1.). Data is 











Streptavidin-Na-biotin-(Gly3)-[Nle4,D-Phe7]a-MSH 1558±26 58±25 1616±6.9
FITC-Streptavidin-Na-biotin-(Gly3)-[Nle4,D-Phe7]a-MSH 1515±7 89±7 1604±2.0
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presence of increasing concentrations of Na-biotin-(Gly3)-[Nle4,D-Phe7]a-MSH and 
streptavidin or FITC-streptavidin peptide-conjugates showed a dose dependent and 
saturable displacement of radiotracer binding (Fig. 6.3.) The dissociation constants 
derived by linear least square regression from the competition binding curves are 
given in Table 6.3. Conjugation of Na-biotin-(Gly3)-[Nle4,D-Phe7]a-MSH with 
streptavidin or FITC-streptavidin produced species with significantly lower binding 
than the native peptide (p < 0.05, t test unpaired). The binding affinity of 
streptavidin-Na-biotin-(Gly3)-[Nle4,D-Phe7]a-MSH was 40-fold lower than the 
native peptide. Binding affinities of conjugates formed with streptavidin or FITC- 
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Figure 6.3. Binding activity of the biotinylated peptide and streptavidin/streptavidin- 
FITC peptide conjugates to the murine MCI receptor. Confluent monolayers of cells 
were incubated with [125I-Tyr2,Nle4,D-Phe7]a-MSH in the presence of increasing 
concentrations of native Na-biotin-(Gly3)-[Nle4,D-Phe7]a-MSH (A ), streptavidin- 
peptide complexes (•), or FITC-streptavidin-peptide complexes (■). After 8 hours at 
4°C binding was terminated and the remaining 125I activity measured. Data represent 
the mean ± SD for three replicate experiments.
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Table 6.3. Dissociation constants of Na-biotin-(Gly3)-[Nle4,D-Phe7]a-MSH and 
streptavidin-peptide complexes. Mean values of the three individual experiments are 
also shown.
Compound Binding (Kdb) Relative
Binding
Na-biotin-(Gly3)-[Nle4,D-Phe7]a-MSH
(1) 8.22 x 10‘10
(2) 1.53 x 10'9
(3) 3.38 x 10'9
Mean = 1.9 x 10'9 
S.D. = ± 1.3 x 10‘9
1.000
Streptavidin-Na-biotin-(Gly3)-[Nle4,D-Phe7]a-MSH
(1) 7.62 x 10*8
(2) 4.19 x 10"8
(3) 1.07 x 10‘7
Mean = 7.5 x 10‘8 
S.D. = ± 3.3 x 10*9
0.025
Streptavidin-FITC-Na-biotin-(Gly3)-[Nle4,D-Phe7]a-MSH
(1) 7.82 x lO'8
(2) 5.77 x lO'8
(3) 1.07 x 10'7
Mean = 8.1 x 10'8 
S.D. = ± 2.5 x 10'8
0.023
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6.11. Gene delivery to B16 cells using Na-biotin-(Gly3)-[Nle4,D-Phe7]a-MSH.
Experiments examining the possibility of delivering polylysine-pRSVlacZ 
conjugates via the MCI receptor utilised conjugates containing N“-biotin-(Gly3)- 
[Nle4,D-Phe7]a-MSH. B16 cells were incubated with complexes formulated to 
reduce charge-mediated uptake (Polypeptide:DNA;(jig:|ig) = 0.43:1) in the presence 
of 100 pM chloroquine for 4 hours. As controls, cells were incubated with HBS and 
the streptavidin-polylysine formulation optimised for non-specific gene transfer 
(Polypeptide:DNA;(pg:pg) = 0.63:1). The results presented in Figure 6.4. indicate 
significant p-galactosidase expression following delivery of pRSVlacZ complexed 
with streptavidin-polylysine at polypeptide-to-DNA mass ratios of 0.43:1 and 0.63:1. 
However, at the higher mass ratio the level of relative enzyme activity was 4-fold 
greater than with the 0.43:1 formulation. The inclusion of varying quantities of N“- 
biotin-(Gly3)-[Nle4,D-Phe7]a-MSH into complexes produced no significant increase 
in p-galactosidase activity compared to the control system (p > 0.05, t test unpaired). 
Indeed, with the 0.5 X conjugate a decrease in p-galactosidase expression was seen.
6.12. Binding of Concanavalin A to B16 melanoma cells.
Expression of concanavalin A binding sites on B16 cells was determined by flow 
cytometry. The frequency and fluorescence profiles of control and stained cells are 
presented in Figure 6.5. These results indicate that relative to the fluorescence 
histogram pattern of the control cell population (mean = 5.7), that of B16 cells 
incubated with FITC-Con A was displaced to the right (mean = 804.0). Fluorescence 
staining under these conditions was intense; a similar level of staining and degree of 
shift was also observed when cells were incubated with higher concentrations of 
FTTC-ConA (25 and 100 pg/ml). In order to demonstrate the specificity of binding, 
cells were incubated with FTTC-ConA in the presence of 0.1 M maltose. Under these 
conditions, displacement of the histogram pattern was not as great. The mean 
fluorescence intensity of this cell population (Mean = 147.1) was reduced to 18% of
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Figure 6.4. Gene transfer mediated by MSH-targeted molecular conjugates. B16 
melanoma cells were transfected with molecular conjugates contained variable 
. amounts of Na-biotin-(Gly3)-[Nle4,D-Phe7]a-MSH. The 1.0 X conjugates contained 
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Figure 6.5. Fluorescence distribution of B16 melanoma cells stained with FITC- 
ConA. Panel a, Control; Panel b, FITC-ConA (12.5 |ig/ml); Panel c, Control + 0.1 
M maltose; Panel d, FITC-ConA (12.5 jig/ml) + 0.1 M maltose. FLl=fluorescence 



























Figure 6.6. Gene transfer mediated by ConA-targeted molecular conjugates. B16 
melanoma cells were transfected with molecular conjugates containing variable 

















the value found following incubation of cells with FTTC-ConA alone. In each case, 
the fluorescence histogram pattern of stained cells was similar in shape to that of the 
background. Cultures incubated with 0.1 M maltose (mean = 5.7) were 
indistinguishable from experimental cultures (mean = 6.4).
6.13. Gene delivery to B16 melanoma cells mediated by Concanavalin A.
To test the feasibility of receptor mediated gene delivery to B16 cells via lectins, 
cells were incubated with poly-L-lysine-DNA-Con A complexes for 4 hours in the 
presence of 100 pM chloroquine. As controls, cells were also treated with blank 
medium (HBS), pRSVlacZ (6 pg) and pRSVlacZ in combination with Con A (200 
nanomoles/ml). The results, shown in Figure 6.6. indicate that neither DNA or 
DNA+Con A produced high levels of gene transfer. In each case reporter gene 
expression was not significantly different from background levels (p > 0.05, t test 
unpaired). However, incorporation of varying amounts of Con A into the complex 
formulation produced a significant increase in gene expression (p < 0.05, t test 
unpaired) at a ratio of biotinylated lectin to streptavidin of 1:1 (i.e. 45 pmol 
biotinylated ConA: 45 pmol streptavidin).
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6.14. Discussion.
Although, a-melanocyte stimulating hormone and its derivatives have been 
employed in targeting small molecule drugs (Varga and Asato, 1977; Lejeune and 
Ghanem, 1993) the majority of ligands covalently linked to polypeptide-DNA 
delivery systems have been globular proteins. It was therefore necessary to confirm 
that the proposed ligand, Na-biotin-(Gly3)-[Nle4,D-Phe7]a-MSH, retained the ability 
to bind at the MCI receptor after conjugation to the outer coat of the molecular 
vector. Evidence for binding following conjugation to streptavidin, was obtained 
from competitive binding assays. However, it was of concern that the efficiency 
with which the streptavidin-ligand complex formed was such that free peptide could 
remain in solution and influence any estimate of binding affinity.
6.14.1. Binding o f  Na-biotin-(Gly3)-[Nle4,D-Phe7]a-MSH and streptavidin.
Qualitative evidence for the specific binding of Na-biotin-(Gly3)-[Nle4,D-Phe7]a- 
MSH and streptavidin was determined using 2-iminobiotin affinity chromatography. 
This technique is- based on the work of Green, (1966), who showed that the 
iminobiotin-avidin dissociation constant was pH dependent and identified the free 
base of iminobiotin as the species that binds to avidin. These fundamental 
observations were applied by Hofmannn et al, (1980) to the chromatographic 
purification of streptavidin and by Fudem-Goldin and Orr, (1990) in the isolation of 
rhodamine-avidin conjugates. In order that the chromatographic behaviour of 
complexes containing Na-biotin-(Gly3)-[Nle4,D-Phe7]<x-MSH could be followed the 
radiolabelled tracer Na-biotin-(Gly3)-[125I-Tyr2,Nle4,D-Phe7]a-MSH was included 
into reaction mixtures. Application of a purified conjugate-peptide reaction mixture 
to the iminobiotin column, resulted in the retention of the majority of 125I activity. 
The small quantity of the label eluting on application of the reaction mixture could 
be attributed to complexes with no free biotin binding sites (i.e. tetramers). As the 
binding capacity of the column is specific for streptavidin then all retained 125I
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activity must be associated with the biotin-binding protein. Furthermore, the release 
of radiolabel from the column under conditions which increase the iminobiotin- 
streptavidin dissociation constant provides additional evidence that Na-biotin-(Gly3 )- 
[Nle4,D-Phe7]a-MSH was specifically retained through its link to streptavidin. In 
this regard, streptavidin effectively bridges between the biotinylated peptide ligand 
and iminobiotin residues on the column. This is possible as the protein consists of 
four homologous sub-units each containing a single biotin-binding site (Gitlin et al,
1988).
6.14.2. Purification o f reaction mixtures.
The streptavidin-coated magnetic beads used in this study were found to be 
capable of specifically binding up to 442 picomoles of peptide per milligram of bead 
suspension. Therefore, using the method described in section 6.3.3. it was possible 
to remove up to 40% of the peptide included in the reaction mixture. However, it is 
clear from the data presented in Table 6.2. that over the 60 minute incubation period 
the majority of biotinylated peptide was conjugated to streptavidin and therefore 
remained in solution. The exact amount of free biotinylated peptide removed on the 
beads proved difficult to measure but importantly the quantity of 125I activity 
retained from the reaction mixture was not significantly different to the level of non­
specific binding. These data were indicative of a high efficiency of conjugation and 
suggested that a maximum of 1.5% of the peptide remained free. This was probably 
a reflection of the ratio at which streptavidin and the peptide were combined. 
Although equimolar quantities of streptavidin and biotinylated peptide were mixed in 
the reaction mixture the ratio of peptide-biotin residues to biotin-binding sites was 1 
to 4. It is also noteworthy that these results show general agreement with the work of 
Chaiet and Wolf, (1964) who determined the biotin binding capacity of streptavidin 
using a microbiological assay. In this study when four molecules of biotin were 
combined with two molecules of streptavidin less than 1% of biotin remained free.
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Encouraged by these results the ability of streptavidin-peptide conjugates to bind to 
the murine MCI receptor was tested.
6.14.3. Binding o f streptavidin-peptide conjugates to the MCI receptor.
For targeting studies Na-biotin-(Gly3)-[Nle4,D-Phe7]a-MSH was used as an 
alternative to a-MSH as it exhibits higher affinity binding at the MCI receptor 
(Sawyer et al, 1980). The dissociation constant (Kdb) for Na-biotin-(Gly3)-[Nle4,D- 
Phe7]a-MSH (1.9 ± 1.3 nM) was similar to that estimated by Sahm et al, (1994) for 
[Nle4,D-Phe7]a-MSH (Kdb= 2.02 nM). Therefore, after modification of the N- 
terminus of [Nle4,D-Phe7]a-MSH, to provide a biotin residue for linking to 
streptavidin, the peptide retains a high binding affinity. Conjugation of Na-biotin- 
(Gly3)-[Nle4,D-Phe7]a-MSH to streptavidin and FITC-streptavidin produced species 
which retained the ability to displace [125I-Tyr2,Nle4,D-Phe7]a-MSH from the MCI 
receptor; this radioligand binds specifically to the cell surface receptor (Sahm, 1994). 
However, the binding affinities of streptavidin-Na-biotin-(Gly3)-[Nle4,D-Phe7]a- 
MSH (K<|b = 75 ± 3.3 nM) and FlTC-streptavidin-Na-biotin-(Gly3)-[Nle4,D-Phe7]a- 
MSH (Kdb = 81 ± 2.5 nM) were reduced compared to the native peptide. This 
decrease is thought to result from steric hindrance produced by conjugating the 2 
kDa peptide to a large protein of approximately 60 kDa. However, the binding 
affinity of the complex was sufficiently high to proceed with targeting experiments. 
Indeed, biotinylated peptides have been used in the localisation of other G-protein 
coupled receptors (Schvartz et al, 1991; Sakai et al, 1994).
6.14.4. Gene transfer mediated by Na-biotin-(Gly3)-[Nle4,D-Phe7]a-MSlL
Previous studies have shown transferrin containing molecular conjugate vectors to 
be capable of transfecting several cell types (Zenke et al, 1990; Lozier et al, 1994). 
B16 murine melanoma cells have been successfully transfected using this system 
(Wagner et al, 1994b). However, although transferrin receptors are overexpressed in
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specific disease states (Faulk et al, 1980) these receptors are also found in high 
numbers on the cells of healthy tissues. Therefore, Na-biotin-(Gly3)-[Nle4,D-Phe7]a- 
MSH was incorporated into complexes in an attempt deliver complexes through the 
MCI receptor and increase the specificity of gene transfer. The expression of this 
type of G-protein coupled receptor is confined to melanocyte derived cells. 
However, in transfection experiments no increase in delivery efficiency was 
produced on incorporating Na-biotin-(Gly3)-[Nle4,D-Phe7]<x-MSH into complexes. 
This was surprising as it had previously been demonstrated that conjugation of these 
ligands to streptavidin did not ablate interaction with the receptor. However, under 
the conditions described in these experiments it is possible that although the receptor 
is internalised (Adams et al, 1993) the paucity of receptors on each cell limits the 
efficiency of gene delivery. The B16 cells used in this laboratory express between 
5,000 to 25000 receptors/cell (Sahm, 1994). This is significantly lower than the 
density of transferrin receptors on the K-562 cell line used in studies with transferrin- 
polylysine conjugates; Wagner et al, (1994a) calculated that each cell K-562 cell 
presented 150,000-transferrin receptors. Furthermore, these workers have shown that 
the number of transferrin receptors significantly influences gene delivery efficiency 
(Cotten et al, 1990); up-regulation of transferrin receptors on K-562 cells with 
desferrioxamine increased gene transfer efficiency ten-fold. In addition, recent 
studies have shown uptake of transferrin-polycation-DNA complexes varied with the 
cell type. This was presumably a function of the receptor number (Plank et al, 1994; 
Curiel et al, 1994). In the case of the B16 melanoma cell line, incorporation of 
transferrin into polycation-DNA complexes produced only a 1.5-fold increase in 
luciferase gene expression.
6.14.5. Gene transfer mediated by concanavalin A.
Lectins are a group of proteinaceous molecules which are capable of recognising 
specific glycoconjugates on the surface of cells (Liener et al, 1986). The use of these
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agents in targeting complexes to neoplastic cells is based on observations that cell 
surface differences exist between the normal and malignant phenotypes. The 
transformation from normal cells is associated with changes in the amount and/or 
display of cell surface glycoconjugates (Irimura and Nicolson, 1984). Additionally, 
on binding to their receptors lectins become internalised so that agents conjugated to 
these ligands are able to penetrate the plasma membrane of cells (Roche et al, 1983). 
Concanavalin A, which shows binding specificity to a-D-glucose and a-D-mannose 
expressing carbohydrate chains, was chosen as the targeting agent in this study as it 
has been successfully used in the receptor mediated delivery of chimeric toxins 
(Gilliland et al, 1978) and cationic-polypeptide DNA vectors to neoplastic cells 
(Batra et al, 1994). This molecule was shown to bind glycoconjugates on the cell 
surface of B16 cells with a high degree of specificity.
The inclusion of Con A in polycation-DNA complexes did produced a statistically 
significant increase in the delivery of polylysine-DNA complexes to B16 melanoma 
cells. However, this increase in p-galactosidase expression was only two fold greater 
than seen with the native complex and was associated with some variability between 
samples. The results obtained in this study were similar to those described by Batra 
et al, (1994) for delivery of polycation-DNA conjugates to Lewis lung carcinoma 
cells. Additionally, we must consider that although it was possible to increase the 
efficiency of delivery using this strategy a significant proportion of uptake was 
mediated through the electrostatic interaction of complexes with cell surfaces. 
Furthermore, following transfection with Con A targeted systems P-galactosidase 
expression in B16 cells was no greater than the level of enzyme activity routinely 
produced by polycation-mediated non-specific gene delivery (ca. 600 milliunits/mg 
protein). Therefore, although lectins can mediate gene delivery, the levels of 
efficiency achieved may not be practically significant.
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6.15. Summary.
Targeting of polycation-DNA complexes would restrict the expression of 
therapeutic genes to neoplastic cells and reduce potential adverse effects from 
immuno- and gene directed enzyme prodrug therapy. In this study, two strategies 
were tested for the selective delivery of polycation-DNA complexes to melanoma 
cells; in each case biotinylated derivatives of the ligand were incorporated into 
streptavidin-polylysine conjugates. Complexes containing the peptide Na-biotin- 
(Gly3)-[Nle4,D-Phe7]a-MSH, found on melanocytes, failed to increase gene transfer 
efficiency. A less selective strategy which employed the lectin concanavalin A was 
more successful. However, the levels of p-galactosidase activity produced by this 
system were no greater than seen with the polycation-DNA complexes optimised for 





There are now more than 4500 human diseases which are classified as having a 
genetic origin (Mckusik, 1988). In the main, genetic disorders are relatively rare but 
it is now recognised that some of the most common illnesses such as cancers and 
cardiovascular disease have genetic components. These diseases are potential targets 
for gene therapies. However, in any treatment strategy the therapeutic gene must be 
introduced efficiently into the target tissue or cell. This makes the delivery system an 
active component of the therapy. On the basis of their potential for targeting and 
ability to encapsulate large sequences of foreign DNA, cationic polypeptides have 
emerged as promising non-viral technologies for gene transfer. However, if these 
systems are to form the basis of gene medicines, an understanding of the formulation 
factors controlling the efficiency of delivery and targeting is required.
The addition of cationic polypeptides to negatively charged DNA molecules is 
known to result in a rapid and spontaneous ionic interaction. Furthermore, the 
resultant charge neutralisation produces a thermodynamic state in which DNA 
molecules can condense into discrete structures. However, in order to produce 
pharmaceutically acceptable delivery systems it is necessary to better understand the 
factors affecting gene transfer. The most influential formulation factor appears to be 
the ratio of peptide cation-to-DNA phosphate in the system, which controls (1) the 
surface charge on complexes; (2) DNA condensation; and (3) complex morphology. 
Perhaps the most significant of these physicochemical properties is the electrostatic 
charge on complexes as it directly affects both non-specific and receptor-mediated 
gene transfer. In order to facilitate non-specific gene transfer the peptide 
cation/DNA phosphate ratio must be manipulated to produce complexes with a
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positive zeta potential. Under these conditions positively charged complexes, like 
other cationic macromolecules (Ryser, 1967), are taken up into cells by endocytosis. 
However, the ideal system for in vivo targeted gene delivery would be 
electrostatically neutral; under these conditions DNA would be condensed, protected 
from nuclease digestion, and non-specific uptake minimised. Systems of this type 
have proved difficult to prepare by the method used in this study; the direct addition 
of polypeptides to DNA. Therefore, in targeting delivery of DNA through a cell 
surface receptor ligand a component of total gene transfer was charge mediated. 
Moreover, where the receptor ligand chosen for targeting is inefficient (e.g. 
concanavalin A), the level of gene transfer with ligand-polylysine complexes may be 
lower than that observed with a non-ligand-polypeptide system. In this respect, it 
may be more appropriate to deliver foreign genes using a non-specific delivery 
system whilst restricting expression with cell specific promoters.
It is possible that improvements in gene transfer efficiency can be achieved by 
modifying the physical and chemical nature of the polypeptide carrier. For example, 
in this study a critical dependence of the gene transfer efficiency on the molecular 
weight of the carrier was established. In polylysine based systems it is possible to 
manufacture a two-fold increase in gene transfer efficiency by the relatively simple 
measure of reducing the molecular weight of the carrier from 28,000 to 16,300 Da. 
A change in the conformation of the complex leading to reduced cross-linking may 
provide one possible explanation for the higher level of gene expression observed 
with low molecular weight carriers.
Recent studies have also proposed the inclusion into delivery systems of peptide 
sequences that encode nuclear localisation signals . The object of this strategy is to 
increase the amount of transgenic DNA reaching the nucleus (Conary et al, 1995). In 
this respect it is possible that the high levels of transformation achieved with histone 
HI were the result of this protein carrying a nuclear localisation sequence.
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The modification of the polypeptide sequence is also likely to be important for the 
acceptance of polypeptide carriers for in vivo gene transfer. Poly-L-lysine, although a 
useful model, is likely to be restricted by its inherent cytotoxicity. The cationic 
nature of this molecule causes it to adsorb to electronegative regions of membranes, 
a process which results in morphological changes and changes in cell permeability to 
ions and macromolecules (Ryser and Hancock, 1965). As an alternative, co­
polymers containing neutral amino acid residues have been proposed as carriers. The 
substitution of lysine homopolymers with alanine produces branched co-polymers 
with reduced cytotoxicity and the ability to condense DNA. However, the results 
from transfection studies with these polymers were disappointing as genes delivered 
by this strategy were not expressed. More encouraging results have been observed 
with linear co-polymers of these amino acids (B. Thomas, personal communication). 
Since both linear and branched co-polymers of alanine and lysine induce DNA 
condensation, the differences in transfection activities are more likely to result from 
subtle changes in complex morphology or stability to nuclease enzymes.
In spite of the advantages offered by cationic polypeptide delivery systems the 
technique is still severely limited by the poor escape of endocytosed DNA from the 
endosome/lysosme trafficking pathway. Methods proposed to increase delivery 
efficiencies have included the co-intemalisation of inactivated adenoviral particles 
and virally-derived fusion peptides. However, such techniques remain at the 
experimental stage and their safety in vivo has not been established. An alternative 
approach is the possible development of hybrid vector systems containing both a 
polycationic moiety and a membrane fusion-promoting lipid. Notably, a series of 
lipospermines has been synthesised and shown to be active in vitro (Behr et al,
1989). A more flexible strategy would be the inclusion of membrane active lipids 
into systems partially condensed with a non-toxic polycation. DNA condensed with 
the polycation is expected to be highly stabilised. In this respect Gershon et al,
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(1993), in examining the conformation of the liposome-DNA complex have 
demonstrated the possibility of condensing DNA using simple mixtures of lipids and 
polycations. However, the gene transfer activity of such systems remains to be 
investigated.
Identification of some of the physicochemical factors affecting polycation 
mediated gene delivery represents a contribution to the rational design of non-viral 
gene delivery vectors. Moreover, it is envisaged that data obtained from model 
systems based on poly-L-lysine could be applied to increase the efficiency of less 
toxic second-generation cationic polypeptide carriers. In establishing the importance 
of physicochemical factors to the efficiency of gene transfer, their quantification and 
control is recognised as important to the development of cationic polypeptide-DNA 
complexes as gene medicines.
7.1. Further work.
At present, systematic efforts to show chemical structure activity relationships for 
cationic polypeptide carriers have been limited. Investigations of this type would 
constitute a major step towards the understanding of DNA complexation and the 
development of more efficient vector systems. On a more basic level, the methods 
used to prepare polypeptide-DNA complexes have been recognised as a potential 
cause of variations in gene transfer efficiency. The formation of complexes by a 
controlled annealing process, such as in salt gradient dialysis, may reduce problems 
of this kind. Further to the work presented in this study, more detailed knowledge of 
the correlation between the physicochemical properties of complexes and gene 
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Appendix 1: Media and Solutions
Where appropriate, media and solutions were sterilised by autoclaving for 15 
minutes at 15 lbs/sq. inch (121°C) on a liquid cycle.
Buffer A: 20 mM Hepes/IM NaCl, pH 7.9.
Buffer B: 20 mM Hepes/2M NaCl, pH 7.9.
Buffer PI: 100 pg/ml RNase A, 50 mM Tris-HCl, 10 mM EDTA, pH 8.0.
Buffer P2: 200 mM NaOH, 1% w/v SDS.
Buffer P3: 3.0 M Potassium acetate, pH 5.5.
Buffer QBT: 750 mM NaCl, 50 mM MOPS, 15% v/v ethanol, 0.15% v/v Triton X-100.
Buffer QC: 1.0 M NaCl, 50 mM MOPS, 15% v/v ethanol.
Buffer QF: 1.25 M NaCl, 50 mM Tris-HCl, 15% v/v ethanol.
DNA loading buffer: 50 mM EDTA, 0.2% SDS, 0.05% w/v bromophenol blue, 50% glycerol. 
Ethidium Bromide: 1 mg/ml in double distilled water.
Hepes Buffered Saline (HBS): 20 mM Hepes, 150 mM NaCl, pH 7.4.
Phosphate Buffered Saline (PBS): 137 mM NaCl, 2.7 mM KC1, 4.3 mM Na2H P04, 1.4 mM 
KH2P 0 4, pH 7.3.
LB medium (Luria-Bertani medium): (per litre) 10 g Bacto tryptone (Difco), 5 g Bacto yeast extract 
(Difco) and 10 g NaCl, adjusted to pH 7.0 with NaOH. LB plates were made from 1 litre of LB plus 
20 g agar (Difco).
RNAase A: 10 mg/ml pancreatic ribonuclease A (Sigma) in STE heated to 100°C for 5 minutes and 
allowed to cool to room temperature.
SM salts (2X): 20 mM Hepes, 275 mM NaCl, 5.4 mM KC1, 8.6 mM Na2HP04, 2.8 mM KH2P 0 4, pH 
7.3.
SOC medium: 2% Bacto-tryptone (Difco), 0.5% Bacto yeast extract (Difco), 10 mM NaCl, 2.5 mM 
KC1, lOmM MgCl2, 1 mM MgS04, 20 mM glucose.
STE: 10 mM Tris-HCl, 15 mM NaCl, pH 7.5.
TAE (10X): (per litre) 48.4 g Tris-base, 11.4 ml glacial acetic acid, 20 ml 0.5 M EDTA, pH 8.0.
TBS: 0.9% w/v NaCl in 10 mM Tris-HCl, pH 7.4.
TBS-Tween: 0.15% w/v Tween 20 in TBS.
TE: lOmM Tris-HCl, 1 mM EDTA, pH 8.0.
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Appendix 2: Molecular Weight Markers.
For agarose gel electrophoresis, markers consisted of Hind IH-cut lambda DNA 
(Sigma) or EcoRl/Hind IE-cut lambda DNA (Northumbria Biologicals). The digests 
consist of DNA fragments of the following sizes (Base pairs):
Hind Ill-cut X DNA EcoRl/Hind in -cu t X DNA
1: 23130 5: 2322 1: 21226 8: 1584
2: 9416 6: 2027 2: 5148 9: 1375
3: 6557 7: 625 3: 4973 10: 947
4: 4268 8: 125 4: 4268 11: 831
5: 3530 12: 564
6: 2027 13: 125
7: 1904
For SDS-PAGE pre-stained markers (Bio-Rad) consisted of;
Protein Molecular Weight
Phosphorylase B 106 kDa
Bovine serum albumin 80 kDa
Ovalbumin 49.5 kDa
Carbonic anhydrase 32.5 kDa
Soybean trypsin inhibitor 27.5 kDa
Lysozyme 18.5 kDa
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Appendix 3: Calibration curves for quantitative assays.
A3.1. UV assay for streptavidin.
Serial dilutions were prepared from a 1 mg/ml solution of streptavidin and the 
following concentrations produced in HBS (pH 7.4): 0.1, 0.2, 0.3, 0.4 and 0.5 mg/ml. 
These gave a linear Beer-Lambert plot for absorbance at 280 nm (Fig. A3.1.) with 
the following linear regression analysis:
Slope = 1.29 ml.mg'1 Intercept = -8 x 10'3 r = 0.9978
A3.2. Ninhydrin assay for primary amines.
A series of sample solutions were prepared by dilution of a 0.2 mg/ml stock 
solution of poly-L-lysine*HBr(219) with HBS. Samples were produced which 
contained poly-L-lysine equivalent to 0.5, 1.0, 1.5, 2.0, 2.5, and 3.5 x 10'7 moles of 
amine in 1.0 ml total volume. Analysis was performed as described in section 3.7.2. 
A linear Beer-Lambert plot for absorbance at 570 nm was determined (Fig. A3.2.) 
with the following linear regression analysis.
Slope = 1.1 x 10"1 pmol'1 Intercept = 2.1 x 10'3 r = 0.9982
A3.3. Spectrophotometric analysis of p-galactosidase activity in cell extracts.
A series of sample solutions were produced in 0.1 M sodium phosphate buffer 
from a commercial stock solution (1.06 units/ml). The samples, which contained p- 
galactosidase equivalent to 0, 2, 4, 6, 8, 10 and 12 milliunits of activity, were then 
. assayed by the method described in section 4.2.2. A linear Beer-Lambert plot for 
absorbance at 420 nm was obtained (Fig. A3.3.) with the following linear regression 
analysis:
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Figure. A3.1. Absorbance at 280nm (•) versus streptavidin concentration.
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Figure. A3.2. Ninhydrin colour absorbance at 570nm (•) versus quantity of amine. 
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Figure A3.3. Absorbance at 420 nm versus p-galactosidase activity. Increasing 
quantities of P-galactosidase (milliunits activity) were incubated with assay reagent 
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Figure A3.4. Standard curve for DC protein assay (Bio-Rad). Calibration was 
performed using bovine serum albumin.
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A3.4. Assay for soluble protein content of cell extracts.
A standard curve for soluble protein content was determined using BSA (Sigma). 
From a 2 mg/ml stock solution of BSA 0.1 ml samples were prepared in 0.1M 
sodium phosphate buffer (pH 7.4) containing 0, 25, 50, and 75 fig of protein. 
Assayed by the method described in section 4.2.3. this gave a linear relationship 
between absorbance at 750 nm and protein content in the original sample (Fig. 
A3.4.). Above 100 pg protein a deviation from linearity was observed. The 
following linear regression analysis was obtained.
Slope = 3.8 x 10'3 pg'1 Intercept = -3.5 x 10'3 r = 0.999
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